Investigation of the role of T cells in airway inflammation using novel murine models of disease by Hutchison, Sharon
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Sharon Hutchison
©Sharon Hutchison, April 2007
Ii*i
INVESTIGATION OF THE ROLE OF T CELLS 
IN AIRWAY INFLAMMATION USING NOVEL 
MURINE MODELS OF DISEASE I
Thesis submitted to the 
University of Glasgow for the degree of 
Doctor of Philosophy
Ir
Containing work carried out in the 
Division of Immunology, Infection and Inflammation, 
Faculty of Medicine,
University of Glasgow,
G lI  6NT
■
ProQuest Number: 10391290
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391290
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
[GLASGOW 
UNIVEilSITYl 
LUBRARV:
SUMMARY
Asthma is a highly prevalent disease characterised by variable airflow obstruction, bronchial 
hyperresponsiveness and airways inflammation. Studies over the last 20 years have 
established that an immunological response centred on Th2 lymphocytes and their mediators 
is critical to the development of the disease, although other elements including structural 
cells are thought to contribute to the final outcome. In this thesis animal models have been 
developed to investigate the role of inflammation in the development and progression of 
allergic airways disease. As CD4^ T cells have been suggested as a possible therapeutic 
target in asthma, techniques were employed that allowed the identification and quantification 
of antigen-specific T cells in different anatomically relevant compartments including, 
draining and peripheral lymph nodes, lungs and bronchoalveolar lavage fluid, providing 
novel information on the role of T cells in these models. This information produced has 
important implications for future development of therapeutic agents targeting T cells.
To investigate the role of antigen-specific T cells in airways inflammation, an adoptive 
transfer model was established. The aim of the model was to allow tracking of antigen- 
specific T cells as well as inducing airway eosinophilia in conjunction with IgE production 
and associated Th2 cytokines. Our investigations revealed that a single immunisation with 
OVA followed by 1-3 intranasal antigen airway challenges did not induce BAL eosinophilia 
although identification of Ag-specific T cells was possible in the lymph nodes and the lung. 
However, it was found that a more aggressive regime of three immunisations and one 
airways challenge was required to induce lung eosinophilia and associated pathology (long 
model). Manipulation of the single immunisation, single airway challenge with the addition
S'
of LPS to antigen in the airways challenge resulted in lung eosinophilia and pathology (short 
model) as seen in the three prime, one challenge model, demonstrating that different models 
can be adapted to produce the same outcome. It was found that when antigen-specific T cells 
were compared between the two models where pathology or no pathology was see, resulted 
in different expression of certain cytokines, costimulatory molecules and chemokine 
receptors. When no pathology was present, it was found that IFNy was upregulated in both 
models. In the long model when pathology was present, IL-5 expression was upregulated, 
and in contrast IL-13 was upregulated in the short model when pathology was induced, with 
CCR3 upregulated in both models. This data demonstrates that although similar endpoints 
were observed the route by which the response was initiated differs.
To determine the site of T cell division in airway inflammation, antigen-specific T cells were 
tracked in different compartments throughout the course of disease and their expression of 
proliferating cell nuclear antigen (PCNA) was measured as an indication of their recent 
division. When T cell division was quantified by LSC in the long model it was found that 
there was an early wave of T cell division seen in the lung, followed by similar in the 
draining lymph node. Subsequently, another wave of anti gen-specific T cell division was 
seen in the lung tissue. The early T cell division may have been caused by uptake and 
presentation of antigen by resident dendritic cells, which have been shown to be present in 
the lung. The location of these dendritic cells allows them to have direct contact with 
incoming antigens. It is known that there is a dendritic cell network situated immediately 
above and beneath the basement membrane of the upper and lower airways enabling these 
cells to sample the epithelium for inhaled antigens. It has also been shown in experimental
The effect of the anti-inflammatory agent etanercept (anti-TNFa) was studied in the airways 
models. It was shown that TN Fa blockade during either the induction or effector phases 
caused no reduction in pathology associated with the disease. However, blockade during the
A
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models of respiratory infection that a population of memory T cells are established in the 
lung parenchyma and the lung airways. Airway resident memory cells contribute 
significantly to recall responses by providing immediate effector activity at the site of 
antigen entry, showing that there is local antigen presentation in the lung. This data gives an 
insight into the location and timing of T cell division and activation and may enable more 
accurate therapeutic intervention in airways inflammation.
:£i:;;
Toll-like receptors (TLRs) are a critical part of innate immunity allowing recognition of 
conserved molecular patterns on microbial products. Both epidemiological and laboratory 
investigations have shown a complex relationship between TLR ligands and allergic airways 
inflammation with some studies demonstrating a protective effect and others showing 
disease exacerbation. In this thesis I investigated the role of LPS and Pam3CSK4 (BLP) in 
the above mentioned murine models of airways inflammation. Given locally, LPS or BLP 
resulted in an increased antigen-driven eosinophilic inflammation in the airways, which was 
accompanied by increased antigen-specific T cell numbers in the airways. When given 
systemically, LPS or BLP was shown to reduce airways inflammation, although no effect on 
antigen-specific T cells was observed. The results emphasise the many underlying factors 
involved in the immune response, and give an insight into the role exogenous factors may 
play in mediating the immune response.
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induction phase prevented lymph node hypertrophy. When T N Fa blockade was 
administered throughout the induction and effector phases of disease, lymph node 
hypertrophy and lung pathology were reduced, although the reduction in BAL eosinophilia 
was not significant. This was associated with a reduction in BAL IL-5 production, showing 
that anti-TNFa treatment is needed throughout the course of the disease to reduce 
inflammation. When anti-TNFa treatment was administered in a more acute short model of 
airways inflammation, the result was more pronounced, showing a reduction in BAL 
eosinophilia, pathology, lymph node hypertrophy, BAL IL-5 production and IgE production. 
When L-selectin expression was assessed on antigen-specific T cells it was found that the 
draining lymph nodes and the lung tissue had increased expression in both anti-TNFa and 
control mice. These data suggest that although anti-TNFa treatment affects the 
accumulation of T cells in draining lymph nodes, it does not mediate its effects via the 
expression of L-selectin. Thus anti-TNFa may be useful in severe and acute asthma.
These data have contributed to our understanding of how inflammatory and immunological 
processes combine to result in eosinophilic airways inflammation and highlight the 
multifactorial nature of asthma. The findings concerning the role and location of T cells in 
allergic airways inflammation provide useful novel insights into underlying immune 
pathologic pathways. This has important implications for future development of therapeutic 
agents targeting T cells.
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CHAPTER 1 - INTRODUCTION
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1.1 Introduction
1.1.1 The burden of lung disease
Allergic diseases such as asthma, rhinitis, eczema and those associated with food are
The profile of both infectious and non-infectious lung diseases in developing countries over
'ÎÎ
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reaching epidemic proportions in developed and developing countries [1]. The prevalence of
asthma alone has almost doubled over the past twenty years, affecting approximately 300 
million people worldwide and an estimated 400 million by 2025 [2]. The rapid increase in 
asthma has been attributed to aspects common in western culture, including outdoor and 
indoor pollution, childhood immunizations, and cleaner living conditions, although no single
cause has been identified [2, 3].
■'-3^
3
the past century reflects prevailing sociopolitical and economic forces. The lung, perhaps 
more than any other organ system is influenced by poverty, occupation and personal habits.
?These influences are seen in the association between tuberculosis and pneumoconiosis first described in miners, the increasing prevalence of asthma and smoking-related chronic 
obstructive pulmonary disease, and the current dual epidemics of tuberculosis and infections 
associated with the human immunodeficiency virus (HIV). The global prediction for
developing countries is that by the year 2020 respiratory diseases (including infections) will
'iaccount for a large majority of deaths and a considerable burden of disability adjusted life
years. The Lung Health Survey 2002 performed in Cape Town provides disease prevalence
and has identified complex interactions between causative factors and disease. Consistent 
and biologically plausible associations between smoking and susceptibility to tuberculosis 
and pneumonia in HIV-infected patients have been reported.
25
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In 2001, the British Thoracic Society published the report ‘The Burden of Lung Disease’ 
which collates for the first time, statistics detailing the size of the problem of respiratory 
diseases in the United Kingdom [4]. Figures in this report showed that one in four deaths in 
the UK can be attributed to respiratory disease, and that more people in the UK die from 
respiratory illness than from coronary heart disease or cancer. Significant morbidity was also 
commented upon: 7% of adults reported long-term respiratory symptoms or illnesses and in 
children the most commonly-reported long-term illnesses are those of the respiratory system. 
This pattern is repeated on a global basis with respiratory infections, malignancies and 
airways disorders all featuring in the ten leading causes of mortality worldwide and 
conditions such as chronic obstructive pulmonary disease (COPD) are predicted to increase 
as a cause of death by 2030 [5]. Reports such as these indicate that respiratory diseases pose 
one of the major challenges for health strategists, clinicians and researchers alike on both a 
national and global scale.
1.1.2 The burden of asthma
Asthma mortality is relatively low compared to other respiratory diseases, however 
awareness has increased over recent years, and it is now recognised that morbidity created 
by this condition is extremely high. There are an estimated 15 million disability-adjusted 
life years (DALYs) lost to asthma every year [6] suggesting considerable unmet clinical 
need. The current high prevalence of asthma is not easily explained by our current 
understanding of the underlying pathophysiology, a fact highlighted by the Global Initiative 
for Asthma (GINA) [7], which has identified investigation into the causation of asthma as a 
key area for research.
26
1.2 Innate and adaptive immunity
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1.1.3 Trends in asthma
Is has become apparent that not only is asthma common [6], but its prevalence has increased 
steadily throughout the latter part of the last century by rates of up to 5% per year [8, 9]. The 
reasons behind this trend are not clear and increased diagnosis and over-reporting of 
symptoms do not account for the size of the increase [10]. Some evidence suggests that it 
may be associated with a concurrent increase in atopy [9], an increase that some researchers 
have attributed to reduced exposure to microbial insults in industrialised nations -  the so- 
called ‘Hygiene Hypothesis’ [11] which will be discussed in more detail later. Recent 
reports would suggest that the rising prevalence of asthma may now be slowing [12] and just 
as it was unclear what caused the steady increase of the past few decades, it is unclear now
why it may be reaching a plateau. This only serves to underline our need to understand more
' ■;
fully both the causes of asthma and the factors that exacerbate or relieve it.
To understand the mechanisms involved in any disease, including asthma, it is necessary 
first to understand the working of the immune response itself. I will give a brief overview 
introducing the basics of the immune response, to give a better understanding of how 
diseases are initiated and controlled.
II
The immune response of mammals can be divided into two parts: innate and adaptive 
immunity. The innate immune response provides a non-specific defence against infection, 
which is rapid (within a few minutes), and has no immunological memory. The innate 
system protects against pathogens. This defence extends from physical barriers (for example
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skin and epithelia) to the recruitment of inflammatory cells (such as macrophages, mast 
cells, eosinophils, neutrophils, and dendritic cells (DCs)). Thereafter, the immune system 
produces a more specific response mediated by T and B lymphocytes. These lymphocytes 
efficiently eradicate pathogens, and provide immunological memory, which confers 
increased protection against re-infection. The innate and adaptive immune systems are not 
mutually exclusive, with many cells of the innate system also participating in the effector 
mechanism of the adaptive response. A number of cells of both the innate and adaptive 
immune system have been implicated in the pathogenesis of asthma.
1.2.1 Innate defences
The innate immune system is evolutionarily the most ancient of an organism’s defences
'
against pathogens and includes physical barriers, antimicrobial agents and cells. Although 
the adaptive immune system specialises in generating receptors recognising a wide variety of 
foreign proteins in the form of T cell receptors or immunoglobulin, the innate response also 
has its own means of detecting invading pathogens. As there is no mechanism for generating 
receptor diversity in the way that T and B cells can do, conserved (and therefore usually 
biologically essential) motifs on the pathogen, termed pathogen-associated molecular 
patterns (or PAMPs), are recognised [13]. The corresponding receptors are pattern
■Î'recognition receptors (PRRs) and include mannose-binding lectin and the scavenger 
receptors. PRRs may sense molecular structures present in pathogens or endogenous danger 
signals which indicate profound cellular damage. Various families of PRRs exist, which are 
either expressed on the cell surface, reside in extracellular compartments or may be released 
as secreted molecules in the extracellular space. The intracellular NOD-like receptor (NLR)
28
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family seem to play a pivotal role in the recognition of intracellular PAMPs [570], NOD-like 
receptors are cytosolic proteins that contain a central nucleotide-binding oligomerization
domain (NACHT), an N-terminal effector-binding domain and C-terminal leucine-rich 
repeats (LRRs). NOD-like receptors have been implicated as ancient cellular sentinels 
mediating protective immune responses against intracellular pathogens. Recent studies have 
described the genetic association of polymorphisms in NOD-like receptor genes with 
complex chronic inflammatory barrier diseases, such as Crohn’s disease and asthma and with 
rare auto-inflammatory syndromes including familial cold urticaria, M uckle-W ells
.syndrome and Blau syndrome [571].
si
Another family of PRRs, which has received considerable interest, is the Toll-like receptors
(TLRs). These receptors bind a wide variety of microbial products, but are particularly
noteworthy because of their ability to influence the developing adaptive immune response. 
This link between innate and acquired immune responses suggests a mechanism by which 
agents such as pollution, cigarette smoke and microbial products could affect immunological
processes such as those found in asthma.
■
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1.2.1.1 TLRs
3Toll was first discovered when Drosophila fruitfly embryos deficient in Toll displayed 
aberrant ventral-dorsal development, and diminished protection against fungal infection [14- 
16]. Subsequent work revealed the presence of a family of mammalian homologues to Toll,
termed TLRs [17, 18], which recognize pathogens, or pathogen-derived products (see table 
1.1). TLR activation triggers both the early innate and adaptive immune responses.
TLRs recognize PAMPs displayed by various microbial components including gram-positive 
and -negative bacteria [19-23]; DNA and RNA viruses [24-26]; fungi [27] and parasites and 
protozoa [28-31]. TLRs are type 1 transmembrane receptors that possess an extracellular 
leucine-rich repeat domain and cytoplasmic domain homologous with that of the interleukin 
1 receptor (ILIR) family [17, 32]. Upon stimulation, TLRs and IL IR  interact with the 
adapter molecule, myeloid differentiation factor-88 (MyD88), recruiting the ILlR-associated 
kinase (IRAK), leading to the activation of the transcription factor nuclear factor-KB (NFkB) 
and inflammatory gene transcription [33]. All TLRs characterised so far, except TLR3, 
signal through the adaptor protein MyD88. However some TLRs also appear to signal 
through a MyD88-independent pathway under specific conditions.
TLR2 recognizes a wide variety of PAMPs from bacteria, yeast, fungi, and parasites, and is 
thought to act as a receptor by forming heterodimers with TLRl or TLR6 [34, 35]. TLR2/6 
heterodimer binds gram positive cell wall components, such as peptidoglycan, and 
mycoplasmal lipopeptides that are diacylated, whereas TLR2/1 heterodimers recognises 
bacterial lipopeptides that are triacylated [34-37]. TLR4 functions as a homodimer or homo­
oligomers and detects lipopolysaccharide (LPS), a major cell wall component of gram 
negative bacteria [17, 23]. Recognition of LPS also requires the association of LPS-binding 
protein (LBP) [38], CD14 [39] and MD2 [40]. MyD88-dependent and MyDSS-independent 
pathways both mediate TLR4 signalling [41, 42].
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TLR Exogenous Ligand
TLRl M ycobacterial lipoprotein, triacylated lipopeptides
TLR2 LPS, zymosan, peptidoglycan, lipoproteins, lipotechoic 
acid, glycosylphosphatidylinositol (GPI)-anchor 
proteins, Pam 3Cys-Ser-Lys4
TLR3 Poly (I:C) (viral ds RNA)
TLR4 LPS, respiratory syncytial virus protein F
TLR5 Flagellin
TLR6 M y c o p la sm a tic  lip o p ro te in s , l ip o te c h o ic  ac id , 
peptidoglycan
TLR7 ss RNA (virus), resiquimoid, im iquinoid
TLR8 Resiquimoid, imiquinoid
TLR9 CpG DNA, dsDNA (virus), ISS
TLRIO Unknown
T L R ll Uropathogenic bacterial antigens, profilin (T. gondii)
î
i
Table 1.1: Toll-Iike recep tors and their exogenous receptors.
1.2.1.2 TLRs and the immune system
TLRs are involved in both innate and adaptive immunity. Initial recognition of the highly 
conserved PAMPs on pathogens by the innate immune cells causes release of chemokines, 
recruitment of cells to sites of inflammation, triggering of phagocytosis with degradation and 
presentation of pathogen-derived peptides. TLRs are highly expressed on antigen presenting 
cells (APCs), which upon activation release inflammatory cytokines and express co­
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stimulatory molecules. TLRs are able to activate the innate system and they also initiate the 
development of antigen-specific adaptive immune responses.
Pathogen recognition by TLRs induce the expression of selectins, chemokines and 
chemokine receptors that regulate cell migration to sites of inflammation [43]. Innate cells 
such as neutrophils, natural killer (NK) cells, mast cells, eosinophils, DCs, macrophages, 
endothelial and epithelial cells express a variety of TLRs which, upon binding of ligands, 
will generate pro-inflammatory signals and cytokines that will result in microbial killing [20, 
37, 44-48]. In the absence of TLRs, particularly TLR2/TLR4 or MyD88, macrophages show 
impaired bacterial killing compared with wild type cells [48], suggesting that TLRs are 
important in the initial recognition, cell migration, phagocytosis, and clearance of pathogens 
by the innate system.
DCs express a large number of TLRs, however the precise pattern of TLR on different 
subsets of DCs is unknown. Human myeloid DCs express all 11 TLRs except TLR4 and 
TLR9 and can recognize bacterial, fungal and viral pathogens [49-52]. Plasmacytoid DCs 
(pDCs) express TLR7 and TLR9, whereas C D llc+  human myeloid DCs (mDCs) express 
T L R l, TLR2, TLR3, TLR5, TLR6, and TLR8 [49-52]. Mouse DC TLRs are more 
heterogeneous than human, with most TLRs expressed on most DC subsets [53, 54].
TLRs initiate adaptive immunity mainly through DCs. These immature cells capture 
microbial antigens in the peripheral tissues, mature, process the antigen into peptides, and 
then migrate to draining lymph nodes to present processed peptide to T cells. The activation
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■of TLRs results in downregulation of inflammatory chemokine receptors (such as CCR6)
TLRs may also be involved in determining the T helper 1 (Thl)/ T helper 2 (Th2) balance 
[60]. The density of antigenic peptide presented, the degree of co-stimulation, and the 
amount and nature of cytokines and inflammatory mediators produced by DCs at the site of 
inflammation have all been shown to influence T cell differentiation [61].
1.2.2 Adaptive Immunity
Adaptive immunity is capable of recognising and selectively eliminating specific foreign 
microbes and molecules (e.g. foreign antigens). Unlike innate immune responses, adaptive 
immune responses are not the same in all members of the species but are reactions to 
specific antigenic challenges. The four main characteristics of the adaptive immune 
response are: antigenic specificity, diversity, immunologic memory and self/nonself 
recognition [62].
Antigen specificity permits the immune response to distinguish among antigens. The 
immune system can recognise billions of unique structures on foreign antigens, generating
33
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and upregulation of receptors for lymphoid chemokines (such as CCR7), which stimulates a :.DC migration to lymphoid tissue [55, 56]. TLR activation also increases the expression of
,CCR2, CCR5, and CCR7 on DCs; enhances the production of IL-12, tumour necrosis factor 
a  (TNF-a) and IL-6 by DCs; and up-regulates co-stimulatory molecules such as CD40,
CD80 (B7-1), CD86 (B7-2) and major histocompatibility (MHC) class II [55-59]. These 
changes allow DCs to mature and present antigenic peptides to T cells more effectively.
1
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huge diversity. Once the immune system has recognised and responded to an antigen, it
exhibits immunological memory, causing a second encounter with the same antigen to be
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heightened [63]. This means that there is life-long immunity to most infectious agents after 
the initial encounter. The adaptive immune response only responds to foreign antigens, 
making a distinction between self and nonself, reducing inappropriate responses.
An effective immune response involves two major groups of cells: lymphocytes and antigen 
presenting cells. Because lymphocytes produce and display antigen-binding cell-surface 
receptors, they mediate the defining immunological attributes of specificity, diversity, 
memory, and self/nonself recognition. There are two main types of lymphocytes: B
lymphocytes and T lymphocytes. As the main focus of this thesis concerns T cells I will 
briefly discuss B lymphocytes and elaborate more on T lymphocytes. I3;3:4
1.2.2.1 B lymphocytes
"I
B lymphocytes mature in the bone marrow and upon leaving express an antigen-binding
■ :
receptor on its membrane, which is a membrane-bound antibody molecule. When a naïve B 
cell first encounters the matching antigen for its membrane-bound antibody, the binding 
causes the cell to proliferate. The progeny differentiate into memory B cells and effector B 
cells called plasma cells [64]. Memory B cells have a longer life span than naïve cells and 
express membrane-bound antibody as their parent did. Plasma cells produce antibody as a 
form that can be secreted, although they only survive for a few days, secreting large amounts 
of the antibody in this time. These antibodies are the major effector molecules of humoral 
immunity.
surfaces.
1.2.2.2 T lymphocytes
C P4+T cells are probably the most important helper cells involved in the immune response.
They are responsible for many effector functions as well as activating other aspects of the 
immune response, including B lymphocytes, CD8^ T cells, macrophages, DCs and many 
others [65]. CD4^T cells are present in high numbers in secondary lymphoid organs (lymph
.nodes, spleen) and also in the bloodstream, comprising about 60-70% of the T cell 
population. Mature CD4^ T cells are characterised by CD3 expression, and T cell 
receptor (TCR). CD4^T cells are crucial in most immune responses including autoimmune 
diseases, chronic inflammatory diseases and hypersensitivity diseases. Five to ten percent of 
T cells in the body express receptors composed of y and ô chains, which are structurally 
similar to the a(3 TCR but have different specificities. The yà TCR may recognise a variety
of protein and non-protein antigens. T cells expressing yÔ TCRs are abundant in epithelia, 
suggesting that these T cells recognise microbes commonly encountered at epithelial
1.2.2.3 T cell activation
Activation of T cells occurs when a professional APC displays the appropriate set of ligands 
to a naïve T cell. This process is well regulated and has restrictions on the type and location 
of cells that can present antigen with MHCII, as well as the requisite sets of co-stimulatory 
molecules, before the T cell can be fully activated (See Figure 1.1). To be recognised by a 
CD4^ T cell, antigen must be ingested by an APC, degraded into peptides and presented on 
the surface of the APC, by newly synthesised MHCII molecules (reviewed in [66]) and
IV
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finally recognised by a T cell antigen receptor. The TCRs recognise fragments of antigens 
bound to molecules of the MHC on the surface of an APC. The peptide binding proteins are 
of two types, MHCI and MHCII, which stimulate cytotoxic T cells (CTLs) and helper T cells 
respectively. Intracellular antigens bind to MHC I molecules and are recognised by CTLs, 
which become activated and can directly kill a target cell. Extracellular antigens, are 
presented by MHC I molecules to helper T cells, which once activated, have immune 
regulatory functions. The APC must also display a number of accessory molecules, which 
trigger specific receptors on the T cell to provide co-stimulation via the TCR. These co­
stimulatory signals are necessary because the TCR cannot initiate intracellular signalling on 
its own, as it does not undergo conformational changes after binding antigen and has short 
cytoplasmic regions. CD4 is a 55kDa single chain molecule, made up of four Ig superfamily 
domains, which bind to the domain of the MHCII molecule. The binding of CD4 
stabilises the binding of the T cell to the APC and initiates tyrosine kinase mediated 
signalling via the TCR. This allows the first step in TCR-mediated signalling, allowing the 
activation of the CD3^ chain by bringing together the CD4 and CD3-TCR complex.
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Tcell APC
ICOS B7.h
CD40L CD40
Class II MHC^ peptideTCR
CTLA-4 CD80/CD86(B7.1/B7.2)
OX40L0X40
ICAM-1LFA-1
Figure 1.1: T cell and APC co-stimulatory molecules
Major surface molecules of CD4^ cells involved in activation of these cells and the 
molecules on APCs recognised by the receptors are shown. Abbreviations: Inducible co­
stimulatory molecule (ICOS), cytotoxic T lymphocyte associated protein 4 (CTLA-4); 
lymphocyte function associated antigen-1 (LFA-I), intercellular adhesion molecule-1 
(ICAM-1 ).Many of the co-stimulatory molecules belong to the CD28 or TNF/TNF receptor 
families. CD28 is present on mature CD4  ^T cells and binds to CD80 and CD86 on APCs. 
CD28 is important for CD4"^  T cell activation, and is essential for clonal expansion, effector 
T cell differentiation, germinal centre formation and memory cell generation (671. CD28 co­
stimulation prolongs TCR signalling, causing an increase in IL-2 production and improved 
CD4^  T cell survival (68 j. Inducible co-stimulatory molecule (ICOS) is highly homologous 
to CD28, but is expressed after CD28-mediated activation of CD4^  T cells. ICOS binds to
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B7RP1 on B cells and promotes the differentiation of effector T cells after clonal expansion 
[69].
Of the TNF family of receptors, CD40 ligand (CD40L) is most important in T cell 
activation. CD40L is expressed on activated T cells and binds CD40 on APCs. It is 
important in T cell help for B cell differentiation and the production of IL-12 and interferon 
(IFN)y in T hl cell differentiation. CD40L expression requires the activation of T cell via 
CD28 and TCR.
There are many other molecules involved in co-stimulation of T cells, including 0X40, 
which binds OX40L on DCs. Many adhesion molecules also act as accessory factors during 
T cell-APC interaction, such as intracellular adhesion molecule (ICAM) 3 and its ligand DC- 
SIGN, leukocyte function antigen 1 (LFA-1) and its ligand ICAM-1, which form organised 
binding complexes and aid the focus of TCR on correct MHCII complexes. These 
interactions also enhance signalling within the T cell.
1.2.2.4 Dendritic Cells and CD4+ T cell priming
DCs are a sparsely distributed, migratory group of bone-marrow derived leukocytes that are 
specialised for the uptake, transport, processing and presentation of antigens to T cells [70- 
72]. As immature cells, DCs continuously circle the peripheral tissues, sampling the 
environment for antigens. Once they encounter a danger signal, which may be a microbial 
product or tissue damage, migration of the DCs to lymph nodes is initiated. The antigen is 
then processed and presented on the APC as described above. DCs also upregulate co­
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stimulatory molecules required for effective interaction with T cells. The most important 
chemokine involved in DC migration is CCR7, which binds the chemokines E D ll ligand 
chemokine (ELC/CCL19) and secondary lymphoid tissue chemokine (SLC/CCL21) which 
are produced in lymphoid organs, and are responsible for recruiting both DCs and naïve T 
cells to this site [73]. Once in the lymph nodes, mature DCs can efficiently trigger an 
immune response by T cells with a receptor that is specific for the foreign peptide MHC 
complexes on the DC surface [74]. Quiescent DCs do not express CCR7, however they have 
receptors for chemokines produced by tissue cells such as CCR6, and chemokines produced 
during inflammation (CCRl, CCR2, CCR5).
DCs interact with other cells as well as T cells, including B cells and NK cells and may also 
remain in peripheral tissues as inflammatory mediators, instead of migrating to lymph nodes 
[74]. These different roles for DCs has led to the identification of different subsets of cells 
(Table 1.2), based on their origin, tissue distribution, differentiation status and function [75]. 
The relationship between the DC subsets remains unclear, however they are thought to have 
distinct effects on CD4T cells, by stimulating T hl or Th2 responses or T cell tolerance.
Phenotype Subtype Location
CD4 CDS'" 
CD205'" CD lib-
Lymphoid Spleen, Thymus, 
Mesenteric LN, Skin draining LN
CD4+ CDS 
CD205 CDllb+
Myeloid Spleen,
Mesenteric LN, Skin draining LN
CD4 CDS 
CD205- CDllb+
Myeloid Spleen,
Mesenteric LN, Skin draining LN
CD4 CDS 
CD205^ CDllb+
Myeloid Spleen,
Mesenteric LN, Skin draining LN
CD4 CDS'" 
CD205'" CDllb+
Langerhans Spleen,
Mesenteric LN, Skin draining LN
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Table 1.2: DC subsets
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1.2.2.5 Differentiation
A number of models have been proposed to explain how naïve T cells differentiate into Thl 
or Th2 cells [80, 81]. Many factors influence the generation of T hl or Th2 cells. The 
cytokines IL-12 and lL-4 acting through STAT4 and STAT6 respectively are thought to play 
a major role in the outcome (reviewed in [76, 77]). It has been proposed that certain 
transcription factors are important in the gene-expression programmes of Thl and Th2 cells 
(Figure 1.2). T-box transcription factor (T-bet) has been shown to have a central role in Thl 
development [82, 83], and GATA-3 seems to be crucial to induce Th2 cell differentiation
40
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After engagement of the TCR by the appropriate MHC complex as described above, clonal 
expansion of T helper cells is triggered, followed by rapid programmed differentiation [76, 
77]. Naïve T helper cells can differentiate into at least two functional classes of cell during 
an immune response: Thl cells, which secrete IFNy, and Th2 cells, which secrete IL-4 [78]. 
T hl cells are responsible for cell-mediated immunity, whereas Th2 cells are responsible for 
extracellular immunity. Both Th subsets have been implicated in pathological responses.
For example, T hl cells can mediate organ-specific autoimmunity and Th2 cells have been 
implicated in the pathogenesis of asthma and allergy [79].
■
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[84, 85] (See Figure 1.2). IL-25 (IL-17E), a distinct member of the IE-17 cytokine family,
plays important roles in evoking T helper type 2 (Th2) cell-mediated inflammation that
.features the infiltrations of eosinophils and Th2 memory cells [572]. Recent studies have
shown that DCs activated by thymic stromal lymphopoietin (TSLP) are able to prime naïve 
CD4^ T cells to differentiate into Th2 cells that produce high amounts of TNFa but no IL-10
[86]. It was found that TSLP-induced OX40L on DCs was required for triggering naïve
second proposed mechanism, de novo differentiation of Th-17 cells in the absence of IL-23 
has been demonstrated by treatment of naïve CD4 cells with TGF-(31 and IL-6, an effect
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CD4^ T cells to produce IL-4, IL-5 and IL-13. It was also shown that OX40L promoted 
TN Fa but inhibited ILIO production in developing Th2 cells, could not polarise Th2 cells in 
the presence of IL-12 and exacerbated IL-12-induced T hl cell inflammation by promoting 
TN Fa and inhibiting IL-10 [86]. IL-33 is a cytokine belonging to the IL-1 supeifamily. IL- 
33 induces helper T cells to produce type 2 cytokines. IL-33 mediates its biological effects 
by interacting with the receptors ST-2 and lL-1 Receptor Accessory Protein, activating 
intracellular molecules in the NF-kB and MAP kinase signalling pathways that drive 
production of type 2 cytokines from polarized Th2 cells [573]. As well as transcription 
factors that are specific to Th subsets, recent studies have shown that some phenotypic 
markers are associated with each subset [87]. T hl cells have been shown to preferentially 
express the ligands for P and E selectin and facilitate the differential migration of these cells 
into inflammatory sites such as inflamed joints or sensitised skin [88]. CCR3, an eotaxin 
receptor, mediates the migration of Th2 cells, eosinophils and basophils to tissues 
undergoing allergic reactions, and is not expressed on Thl cells [89].
IL-17-producing CD4^ T cells (Th-17 cells) have been identified as a unique subset of Th 
cells that develops along a pathway that is distinct from the Thl and Th2 cell differentiation 
pathways. One proposed mechanism is IL-23-dependent, but independent of STAT-1, T-bet,
STAT4, and STAT6. The hallmark effector molecules of Thl and Th2 cells, e.g., IFN-y and 
IL-4, have each been found to negatively regulate the generation of these Th-17 cells. By a
■I!
heightened by IL-P and TNF-a.
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Figure 1.2: Factors involved in T cell differentiation.
1.3 Asthma Pathophysiology
1.3.1 Airway hyperresponsiveness
Airway hyperresponsiveness (AHR) is a characteristic feature of asthma and refers to the 
ability of airways to narrow after exposure to constrictor agonists |90 |. Airway 
responsiveness is measured using inhalation challenges with airway constrictor agonists, 
such as anticholinergics, in both clinical and research laboratories. The severity of AHR 
correlates with the severity of asthma and the amount of treatment needed to control the 
symptoms (91, 92 j. The degree of AHR is also associated with other features of asthma
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including variation in peak flow rates, the improvement in (forced expiratory volume) FEVj 
after inhalation of bronchodilators, and the degree of airway constriction caused by exercise 
[90].
Many different factors contribute to AHR found in asthmatic patients, and numerous 
inflammatory processes are thought to be important. Eosinophils are thought to play a major 
role in the airways by producing changes in airways tissue, including epithelial damage, 
thickening of the basement membrane and release of mediators that cause bronchial smooth 
muscle contraction [90]. Many of these processes are involved in interacting to produce 
these different responses and different mechanisms are involved in different components of 
AHR. Although bronchial wall eosinophilic infiltration is a prominent feature of asthma it is 
not solely responsible for AHR, since corticosteroid treatment reduces eosinophils but does 
not prevent AHR. However, the changing levels of eosinophilia may affect the changes in 
AHR. Many clinical studies have shown that in allergen induced asthma varying degrees of 
antigen exposure with increased eosinophils also increase AHR in asthmatics [93, 94].
1.3.2 Remodelling
As well as the function of lungs being altered in asthmatics, the structure of the airway is 
also changed. The term remodelling has been used to describe the deposition of new matrix 
in the airway walls and is associated with proliferation and activation of myofibroblasts [95]. 
It has been shown in severe asthmatics that epithelial injury and impaired repair led to the 
release of profibrogenic growth factors that act on mesenchymal cells to convert them to
43
myofibroblasts, which show increased ability to synthesize extracellular matrix (ECM) and 
produce mitogens and differentiation factors for smooth muscle cells [96]. The thickening 
of the airway wall, which has been shown in patients with varying degrees of asthma, may 
be one of the main differences between healthy individuals and asthmatic patients [97]. In 
fatal cases of asthma wall thickening has been shown to be greater compared to patients with 
mild or non asthmatic patients [98].
An increase in airway smooth muscle (ASM) involving both hyperplasia and hypertrophy 
are important in AHR [99][[100]. Several studies in patients that have died from severe 
asthma have revealed an increase in the muscle mass in the airway wall compared to normal 
controls [lOI] [102]. These studies have examined lung tissue, which have shown that there 
are changes in airway morphology and structure but also entails changes in cell-cell 
interactions and changes in the regulation of cells [103]. The changes in structure include an 
increase in matrix deposition, which is caused by increased mucus secretion by 
mesenchymal cells and an imbalance in matrix degrading enzymes and inhibitors of 
proteases [104] (see figure 1.3). ASM plays an important role in promoting and mediating 
airway remodelling. However, the physiologic consequences of airway remodelling remain 
unclear. In vitro studies of ASM have shown that they are able to promote airway 
inflammation through the secretion of cytokines and chemokines and alter its phenotype in 
response to growth factors, but these responses are still to be proven in vivo.
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Figure 1.3: The pathophysiology of asthma. Several inflammatory cells are recruited 
and/or activated in the airways, releasing a variety of inflammatory mediators that have 
acute effects on the airways, such as bronchoconstriction, mucus hypersecretion, and also 
structural changes including fibrosis and hyperplasia.
Details of the pathological changes found in the asthmatic lung have been obtained from 
bronchial biopsies of patients and post-mortem examinations of subjects who have died from 
asthma. Such studies have shown that an inflammatory infiltrate consisting of T 
lymphocytes, eosinophils and mast cells is typical and that these changes may be seen in 
non-allergic (‘intrinsic’) as well as allergic asthma, suggesting common mechanisms of
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disease. T cells appear to be predominantly of a Th2 phenotype [105-107], which will be 
explored later.
Other characteristic changes are found in the epithelium and airway wall. Epithelial damage
Mast cells (MCs) are resident in all normal tissues, where they are believed to play an
and shedding is common and may correlate with severity of AHR although some studies 
suggest that these findings may be a sampling artefact. Goblet cell hyperplasia is presumed
'
to contribute to mucus hypersecretion and thereby to airflow obstruction in asthma, and has 
been shown to be present in both mild asthmatics and fatal cases [96, 108]. Further airway 
narrowing is caused by thickening of the airway wall, much of which can be attributable to
an increase in smooth muscle mass.
I
important role in tissue homeostasis, wound healing, and host defence, particularly bacterial 
infection [109]. Chronic mast cell activation contributes to the pathophysiology of many
diverse diseases through the synthesis and release of numerous proinflammatory mediators 
and cytokines, the pattern of which varies depending on the stimulus [110].
■ ■
Mast cells secrete histamine, prostaglandin (PG) D2, and leukotriene (LT) C4, which are 
capable of inducing bronchoconstriction, mucus secretion, and mucosal oedema, all features
.of asthma. This is evident during experimental allergen challenge, in which blockade of 
these mediators attenuates the early decrease in lung function [111]. However, mast cells 
also synthesize and secrete a large number of cytokines (including lL-4, lL-5 TNF, and IL- 
13), which regulate both immunoglobulin (Ig) E synthesis and the development of 
eosinophilic inflammation, and several profibrogenic cytokines, including transforming
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growth factor (TGF) p and basic fibroblast growth factor [109, 111]. The serine proteases 
tryptase, chymase, and carboxy-peptidase are major secretory products of human mast cells 
that can interact with various cell types via protease-activated receptors (PARs) and by other
asthma exhibit features of chronic ongoing activation. Although most of these studies have 
been performed in atopic individuals, similar evidence has been obtained to support a role
47
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processes to alter their behaviour. Importantly, bronchial mucosal mast cells in subjects with
■Ï
for ongoing mast cell secretory activity in both nonatopic and occupational asthma [111].■ -i.
It is generally accepted that the disordered airway physiology and airway wall remodelling 
characteristic of asthma are consequences of the inflammatory process, but there are 
examples where this relationship is weak. This is most evident in patients with eosinophilic 
bronchitis (EB), a condition that accounts for about 15% of cases of cough referred to 
respiratory specialists. It is characterized by corticosteroid responsive cough and the 
presence of a sputum eosinophilia occurring in the absence of variable airflow obstruction or 
AHR [112]. However, despite differing functional effects on the airways, the 
immunopathology of asthma and EB is virtually identical [113, 114]. Thus, in 
bronchoalveolar lavage (BAL), induced sputum, and airway biopsies, the extent of T-cell
1
and eosinophil infiltration and activation, mucosal mast cell numbers, IL-4 and IL-5 
cytokine expression, epithelial integrity, subbasement membrane collagen deposition, and 
mediator concentrations including histamine and PGDg are almost identical. This suggests 
that many of the immunopathological features previously attributed to causing asthma may 
not be fundamental to the development of airflow obstruction and AHR.
::s:.
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and eosinophils as facilitators and effectors respectively, and the evidence for these
al published papers describing that CD4 lymphocytes in vitro could be polarised into two
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These findings illustrate the concept that both immunological inflammatory processes and 
changes involving structural tissues such as smooth muscle and epithelium, contribute to 
asthma pathophysiology. The inflammatory changes strongly implicate cells such as T cells
: 
.processes shall be considered in more detail.
1.3.3 Inflammation and asthma
.It had been known for decades that asthma is an inflammatory disease of the airways 1115] 
and is characterised by repeated episodes of airway obstruction and wheezing. Inhalation of 
allergens causes airway inflammation and increased airway responsiveness, which are both 
important in characteristics of clinical asthma [116]. After allergen inhalation there is a 
temporary influx of neutrophils [117] followed by a substantial accumulation of eosinophils 
and basophils [118]. The eosinophilia after allergen inhalation corresponds to levels seen in 
clinical asthma and is also persistent, which suggests the increased production and 
importance of these cells. The presence of eosinophils after exposure to allergen has been
■;s
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known for nearly 100 years. However, it was only recently thought that inflammation was 
the cause of asthma. Studies carried out in the early 1980’s using fibre optic bronchoscopy 
allowed evaluation of asthmatic patients, which showed that even when patients were 
asymptomatic, airway inflammation was still present. Also in the early 1980’s Mosmann et
subsets known as Thl and Th2 cells. Subsequent studies showed that Th2 cells were present 
in the airways of asthmatics [105]. Because Th2 cytokines induce eosinophilia, IgE I
I
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production, mucus production, and mast cells and are associated with other allergic diseases, 
they are thought to be involved in the pathophysiology of asthma.
1.4 T cells in asthma
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There are several factors that interact to cause airways hyperresponsiveness, and these can 
be considered in two broad categories: immunological mechanisms and the accompanying 
inflammatory changes, and non-immunological mechanisms (which comprise mainly the
Ï
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structural elements of the airways, as discussed above). The immunological mechanisms 
have been extensively studied over the past twenty years both in human subjects and animal 
models and current opinion favours a system whereby inflammation dominated by a Th2 
pattern of cells and cytokines [2] is key to the development of AHR.
1.4.1 Th2 cells in asthma
In both allergic and intrinsic asthma, the inflammatory response is associated with the 
recruitment of activated CD4^T lymphocytes expressing a Th2 cytokine profile [119, 120] 
and an influx of eosinophils. The interleukins, IL-4, IL-5, IL-9 and IL-I3, expressed by 
activated Th2 cells which are the dominant cell type in bronchoscopic biopsies and
bronchoalveolar lavage samples obtained from patients with asthma, are thought to play a
central role in the pathophysiology of asthma [105]. In murine models, T cells have also
.been shown to play a crucial role: transfer of primed, polarised Th2 cells into naïve 
recipients reproduces features of allergic airways inflammation following antigen challenge 
[121-123]. Similaily, such features are reduced or abolished if T cells are absent [124, 125].
j
Asthma is characterised histologically by a predominance of Th2 lymphocytes [126]. 
Bronchial biopsies taken from atopic and non-atopic asthmatics show elevated expression of 
transcription factors GATA-3, and STAT-6 [127]. It was demonstrated that STAT-6 and IL- 
4 receptor alpha were both necessary for the development of murine airways inflammation 
[128, 129]. It has also been shown that the cytokine IL-13 receptor heterodimer utilises the 
IL-4 receptor alpha chain, and STAT-6 pathway. In murine models STAT-6 and GATA-3 
deficiency or inhibition leads to suppression of airway eosinophilia and AHR. Conversely, 
the transcription factor T-bet, which is associated with Thl cell development, is decreased in 
the airways of asthmatic patients compared to healthy controls and its deletion in mice leads 
to the development of asthma-like features [130].
Of the cytokines thought to be important in asthma, IL-4, IL-5 and IL-13 have been studied 
in greatest detail. In allergic patients IL-4 has been shown to be present in the serum and in
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Exactly how Th2 cells contribute to an asthmatic phenotype has not yet been fully elucidated 
but several studies have advanced our knowledge in this area and the roles of individual Th2 
cytokines such as IL-4, IL-5 and IL-13 in inducing specific features of asthma, either 
directly or via other cells or cytokines are becoming clearer.
# 
I1.4.2 Th2 cytokines
Multiple cytokines play a critical role in orchestrating and perpetuating inflammation in 
asthma (figure 1.4) and have been implicated in the pathophysiology of asthma (See table 
1.3).
the BAL. Peripheral blood and mononuclear cells from atopic asthmatics show increased
have shown increased IL-4 levels [114, 132]. In a study where nebulised IL-4 was given to
s
IL-4 production in response to dust mite allergen [131] and BAL samples from asthmatics
patients with mild asthma, a significant increase in AHR associated with elevated sputum 
eosinophil numbers was seen [133].
In asthma IL-4 stimulates mucus-producing cells and eotaxin and other inflammatory cells 
from fibroblasts, suggesting that IL-4 is involved in airway remodelling. IL-4 upregulates 
expression of vascular cell adhesion molecule (VCAM) -1 on vascular endothelium to direct 
the migration of T lymphocytes, monocytes, basophils and eosinophils to the inflammatory 
site [134]. By increasing the expression of eotaxin, IL-4 inhibits eosinophil apoptosis and 
promotes eosinophil chemotaxis and activation [135]. IL-4 is essential in the development 
of allergic inflammation, as it is able to drive the differentiation of ThO lymphocytes to Th2 
cells [80]. This feature is unique to IL-4 and is not shared by IL13, which has many 
commonalities with IL-4. IL-4 is also capable of preventing T lymphocyte apoptosis 
ensuring that activation and proliferation of the T lymphocytes is maintained.
-
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Cytokine Effects in asthm a
IL-1 Induces AHR
Induction of eosinophils, T cell and epithelial activation 
Growth factor for Th2 cells
IL-2 Stimulates growth and differentiation of T cells 
Induction of eosinophilia
ÏL-3 Stimulates induction of eosinophilia and mast cells
IL-4 Stimulates eosinophil growth 
Promotes development of Th2 cells and IgG synthesis 
Inhibits development of T hl cells
IL-5 Enhances production, maturation and activation of eosinophils 
Promotes development of Th2 cells 
Induces AHR
IL-6 Activation of T cells 
Inhibits IL-1 release 
Induces IgE production
IL-9 Stimulates proliferation of activated T cells 
Enhances production of IgE
IL-10 Decreases eosinophil survival, AHR 
Inhibits macrophage activation
IL-13 Activates eosinophils 
Induces production of IgE
IL-15 Stimulates growth and differentiation of T cells
IL-16 Induces eosinophil migration 
Stimulates growth and chemotaxis of T cells
IL-17 Co-stimulation of T cell proliferation 
Activates epithelia, endothelial cells and fibrosis
IL-18 Inhibits IL-4 dependent release of IgE 
Causes release of IFNy from Thl cells
IL-21 Increases TNFa production
IL-23 Induces proliferation of memory T cells 
Causes IFNy secretion from T cells
11,-25 Induces IL-4, IL-5, IL-13 and eotaxin production in the lung 
Induces AHR, IgE production and eosinophils
IL-27 Enhances Th2 cytokine release
TNFa Activates epithelium, endothelium, APCs and macrophages
Induces AHR
IFNy Decreases eosinophilia after antigen challenge 
Inhibits Th2 cells and IgE release 
Induces AHR
Table 1.3: Cytokines involved in asthm a
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There have been many animal studies conducted that further strengthen the role of IL-4 in 
allergic inflammation [136-139]. When IL-4 is neutralised with anti-IL-4 antibodies in mice 
the development of allergen specific IgE is inhibited and eosinophilic inflammation and 
airway reactivity is reduced. The use of antigen (ovalbumin) specific induced airway models 
has given significant insight into the functions of IL-4 and many other cytokines. Using 
these models IL-4 has been shown to be essential for the development of ovalbumin-induced 
eosinophil influx into the airways, IgE production and an increase in airway responsiveness 
[122]. Transfer of IL-4 knock-out (KO) Th2 cells reduced airways eosinophilia and mucus 
hypersecretion but not AHR suggesting that IL-4 has a role in the inflammatory aspects of 
asthma but not AHR. More recent evidence suggests that IL-4-mediated effects on 
eosinophilia may act through suppressing the actions of IFN-y allowing recruitment of 
eosinophils from the lung interstitium into the airways.
Most studies have proven a role for IL-4 in inflammation rather than AHR. However, a 
study by Corry and co-workers showed that neutralisation of IL-4 during antigen 
sensitisation led to decreased AHR but not eosinophils [137]. Another study demonstrated a 
similar decrease in airway responses after blocking of the IL-4 receptor [128] but this may 
be because IL-4 and IL-13 share the IL-4Ra receptor component. Thus IL-4 appears to be 
important in establishing a Tli2 response, including IgE production [140] and subsequent 
inflammation, although effects on AHR may be indirect or attributable to IL-13. Despite 
these findings in murine models, anti-IL-4 monoclonal antibody, while demonstrating some 
benefit in patients with severe asthma [141, 142], has so far failed to establish itself in 
clinical practice.
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of asthma [153] and when IL-5 production was abolished, either in KO mice or by using 
neutralising antibodies, there was a corresponding decrease in BAL eosinophilia and AHR
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Despite its homology to IL-4 and sharing the IL-4Ra, IL-13 appears to have a more 
fundamental role in manifesting the effector features of asthma, particularly AHR [143]. IL- 
13 is a pleiotropic Th2 cytokine, thought of as a central mediator of asthma. Many studies 
have demonstrated that administration or overexpression of IL-13 leads to eosinophilia, 
mucus hypersecretion and AHR and that the neutralisation or knocking out of IL-13 leads to 
ablation of these key features of asthma. IL-13 appears to be important in both chronic 
airways inflammation and airway remodelling, although its neutralisation in established 
disease was ineffective [144]. An increasing number of pathways have been described for 
IL-13. Studies have shown that it can act directly on epithelial cells to induce mucus 
production via STAT-6 [145, 146] but can also induce some of its effects on eosinophil 
recruitment and AHR via both IL-5/eotaxin-dependent and -independent mechanisms. It has 
also been shown to have effects on DC maturation [148] implying an immunoregulatory 
role.
Eosinophils are one of the key effector cells in the pathogenesis of allergic inflammation.
IL-5 is the key cytokine in the production, differentiation, maturation and activation of 
eosinophils [149, 150]. In human asthmatics, IL-5 has been isolated from BAL and serum 
[151, 152] and inhalation of IL-5 leads to eosinophilia and increased AHR. In mice.
.overexpression of IL-5 leads to eosinophilic pathological changes in the lung characteristic
g
I
[154, 155].
3
However, the role of eosinophils in asthma remains controversial. It is still unclear whether 
eosinophils cause any damage in asthma or whether they are just an indicator of the
inflammatory process. They may also be part of the protective response against the
inflammation. When anti-IL-5 antibody treatment was tried in human clinical trials, there 
was no improvement in AHR despite an effect on sputum eosinophilia [156]. This suggests 
that eosinophils may not be causative in asthma although it should be noted that the 
clearance of eosinophils from the bronchial mucosa by anti-IL-5 was incomplete [157].
Furthermore, in a transgenic mouse overexpressing IL-5 there was a decrease in AHR which
33was abolished by anti-IL-5 antibodies [158]
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Figure 1.4: Th2 -type cytokine activity in allergic asthma. Upon recognition of the 
antigen and activation by APCs, naive T cells differentiate into Th2 cells, a process that is 
promoted by IL-4. Activated Th2 cells stimulate B cells to produce IgE antibodies in 
response to IL-4, and to a lower extent to IL-13 or IL-9. IgE binds the high affinity IgE 
receptor at the surface of mast cells, the proliferation and differentiation of which is 
promoted by IL-9. After contact with antigen, mast cells release the contents of their 
granules, including histamine, which will induce a bronchospasm, together with newly 
synthesised prostaglandins and leukotrienes (PGD2 and LTC4). Mast cells also release 
chemotactic factors that contribute to the recruitment of inflammatory cells, particularly 
eosinophils, whose proliferation and differentiation from bone marrow progenitors is 
promoted by IL-5 and IL-9. Finally, epithelial cells upregulate their production of mucus and 
chemokines in response to Th2 cytokines such as IL-4, IL-13, and IL-9 1159|.
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1.4.3 Thl cells in asthma
From the evidence presented above, it seems it is still generally believed that Th2 cells 
predominantly drive asthma. However, recent data suggests a role for Thl cells in driving
an increase of IFNy in the BAL. However, such treatment augmented noneosinophilic airway 
inflammation. T hl cells reduced the expression of eotaxin mRNA and augmented RANTES,
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asthma. Thl and Th2 cells are thought to have counter-regulatory properties, highlighting 
the importance of maintaining a balance between the two. [78]. Cytokines from T hl 
lymphocytes were originally thought to be protective of asthma by skewing the immune
response from a Th2 towards a T hl profile [160]. Furthermore, it was shown that antigen-
induced IFNy production was reduced in peripheral blood lymphocytes of asthmatics [161], 
and that IFNy and Tbet-1 were critical for attenuating airways eosinophilia in murine models
.
of asthma [162, 163]. However, it has since been demonstrated that IFNy is produced by
,f'S
BAL T cells [164] and may enhance airways inflammation [165]. In an adoptive murine 
transfer model of asthma, it was shown that T hl cells did not reduce airways inflammation,
but actually enhanced established disease through the activation and recruitment of 
neutrophils into the airways [121, 166, 167]. Randolph et al showed that adoptive transfer of 
either T h l or Th2 cells followed by antigen challenge was not sufficient to result in 
eosinophilic airways inflammation whereas co-transfer of T hl and Tli2 cells together was 
[167]. Furthermore, introduction of a viral infection, typically-viewed as a Thl-dominant
inflammatory event, was also able to facilitate eosinophilic inflammation by Th2 cells [168]. 
The transfer of T hl clones in a murine model of asthma induced attenuation of the 
eosinophilic airway inflammation, airway responsiveness, goblet cell hyperplasia and 
peribronchial fibrosis. These effects are accompanied by an inhibition of Th2 cytokines and s
I
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indicating that the adoptive transfer of T hl clones in asthma model mice diminishes the 
pathophysiology of asthma but augments noneosinophilic airway inflammation [574]. These 
results suggest that Thl cells may be able to attenuate an asthmatic phenotype in murine 
models through changes in chemokine and cytokine expression and their subsequent effects 
on the immune response.
Although Th2 responses seem to dominate asthmatic responses, the evidence presented 
above suggests that Thl responses may not completely oppose the response as originally 
thought.
1.4.4 T regulatory cells
As well as mediating the immune response, it is now clear that subset(s) of T cells may also 
act to regulate immunity. Although the concept of ‘suppressor’ T cells was largely 
discredited for many years, the rebranded regulatory T cell (Treg) has been intensively 
studied in the last decade. Several classifications of Tregs have been proposed, but three 
main subtypes have been best characterised. ‘Naturally-occurring’ CD4^CD25^ T cells, 
which comprise approximately 5% of all T cells, have been shown to suppress the 
proliferation and activation of CD25 T cells in an antigen-independent, cell contact- 
dependent manner [169, 170] and their absence leads to the development of a variety of 
autoimmune diseases in mice [169, 171]. Their existence in humans has now been 
demonstrated [172, 173] and the transcription factor foxp3 has been shown to be critical in 
their development and function [174-176]. T rl cells and Th3 cells differ from CD4^CD25^ T 
cells in that they differentiate in the periphery from CD25' T cells after antigen stimulation.
58
1.5 Other Cells in asthma 
1.5.1 Eosinophils
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%These Tregs appear to function in a cell contact-independent manner through cytokines such 
as IL-10 and TGF-|3 respectively [177-179].
Although mainly studied in relation to autoimmune disease, a role for Tregs in immune 
dysregulation in asthma is gradually being established. CD4^CD25^ T cells are able to 
suppress allergic airways inflammation in murine models [180-182]. The mechanism may be 
dependent on IL-10 production [180] and although in vitro studies of CD4"^CD25^ T cells 
suggest that their suppressive properties are not cytokine-mediated [169], this can be 
explained by the finding that IL-10 may be induced by Tregs but produced by alveolar 
macrophages thereby inhibiting the inflammation [181]. Other experiments have similarly 
demonstrated protective effects of cells with a phenotype similar to T rl cells in experimental 
asthma models [183, 184]. Interestingly, recent studies have shown that corticosteroid 
resistant asthma patients may have a defect in IL-10 production from their T cells and that
this may be reversed by vitamin D3 treatment [185]. These findings support the hypothesis
:that Tregs may be an important determinant of the outcome of the asthmatic process.
I
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The presence of increased numbers of activated eosinophils is a main characteristic of 
asthma and is thought to be central in the pathogenesis of the disease. However, the exact 
role of eosinophils remains unclear. Airway eosinophilia requires both IL-5 and STAT-6
signalling and it has been shown that CD4 T cells provide signals that promote eosinophil
mobilisation, activation and recruitment the respiratory tract. Eosinophils contain many
s
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toxic pro-inflammatory mediators, including granule proteins (major basic protein and 
eosinophil cationic protein) [186], reactive oxygen species [187], lipid mediators [188] and 
cytokines, all of which could contribute to airways inflammation. Several pieces of evidence
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link these cells to asthma: the presence of eosinophils in the airways of asthmatic patients
has been recognised for many years [189] and studies have also shown that the degree of 
eosinophils present in the airways of asthmatics correlates with the severity of the disease 
[190, 191]. Reduction of AHR by treatment with corticosteroids is associated with a 
decreased level of eosinophilia in the airways [192],
f
Animal models have not resolved the issue of the importance of eosinophils in asthma. Most 
murine models of asthma use eosinophil infiltration in the lung tissue or BAL as indicators 
of pathology and correlate this with AHR, but several studies have failed to show this
icorrelation [137, 193-195]. AHR has been shown to be either dependent or independent of 
eosinophils in two different eosinophil-deficient mouse strains [196, 197]. However, the
majority of studies are in favour of eosinophils playing an important role in allergic airways
inflammation. A study using eosinophil-deficient mice showed that direct intratracheal 
instillation of eosinophils into the airways restores AHR, perhaps proving a causative link 
between eosinophils and asthma [198]. Eosinophils can produce both Thl and Th2 cytokines
-[199] and may be able to present antigen to T cells [200, 201] implying a potential 
immunomodulatory role. They have also been implicated in the development of airway 
remodelling [197].
1.5.2 Mast cells
r
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MCs have been considered to be one of the main effector ceils in asthma. These tissue- 
resident cells are found in the airway submucosa of both healthy subjects and those with 
asthma but are present in increased numbers in the airway smooth muscle of asthmatic 
patients [113]. Crosslinking of FceRl-bound IgE with multivalent antigens initiates the 
activation of mast cells by promoting the aggregation of FcsRl [202]. The cell activation 
results in mast cell degranulation, with the secretion of preformed mediators, the de novo 
synthesis of pro-inflammatory lipid mediators and the synthesis and secretion of chemokines 
and cytokines [203, 204]. MCs may act as effector cells of the early asthmatic response via 
the release of these inflammatory mediators and granule contents. This concept is supported 
by increased degranulation of MCs from asthmatic airways [205, 206].
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Data regarding the role of MCs in airways inflammation has been inconclusive and depends 
on the experimental protocol used [207, 208]. This may be due to the fact that several 
mechanisms interact to produce the features of asthma and that different experimental 
protocols may emphasise these different mechanisms. Nevertheless, the paradigm of an IgE- 
mediated, MC-dependent early response in asthma is supported by murine models 
demonstrating that the IgE receptor FceRI on MCs is important in the airway response [209, 
210] and that activation of MCs using anti-IgE antibody enhances AHR [211]. More 
recently, the concept that MCs could also play a significant role in the late response and 
persistence of asthma, has been supported by findings that mast cells may influence the 
adaptive immune response by production of Th2-type cytokines [114, 212] and chemokines 
[213] and in numerous other ways [214].
1'I
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Mast cells are clearly important in the pathogenesis of asthma but it is still unknown exactly 
how they contribute to the disease outcome. Their role in the immediate response is 
reasonably well understood, but their influence in ongoing asthmatic disease requires further 
investigation. These cells provide an interesting link between the innate and adaptive 
immune response and may be important in gaining an understanding of how innate responses 
to microbial products, such as lipopolysaccharide, can impact upon the development and 
persistence of asthma.
1.5.3 B cells and IgE
The ability of B cells to produce IgE means that they may be of importance in asthma 
pathophysiology. It is probable that their function is in some way regulated by CD4^ T cells 
and Th2 cytokines have been shown to be important although not crucial for IgE production 
[140, 215].
IgE has become recognised as a major factor in atopic disease, in particular in allergic 
asthma where the severity of disease correlates with serum IgE titres [216, 217]. The 
majority of IgE is bound to the surface of mast cells and basophils by the high affinity IgE 
receptor FceRI. This converts FceRI to an antigen-specific receptor, whose activation leads 
to mast cell or basophil degranulation and subsequent downstream events associated with the 
Type I hypersensitivity reaction [209, 210].
The central feature in anaphylactic and immediate hypersensitivity reactions is IgE- 
dependent activation of mast cells and basophils leading to the release of histamine and other 
inflammatory mediators, such as prostaglandins and leukotrienes. Furthermore, upon
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Although IgE is important in the pathophysiology of asthma, it may not be crucial. AHR and
reduction in airway inflammatory cells by anti-IgE treatment was not associated with any 
change in AHR [223]. Thus, manipulation of IgE is an important addition to the therapeutic 
armamentarium against asthma, but may not cover all the elements conspiring to create an 
asthmatic phenotype.
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activation through IgE receptors, mast cells and basophils produce cytokines, such as IL-4 
and IL-5, which are potentially important in the recruitment of eosinophils, thus causing 
chronic allergic inflammation. Second, IgE bound to receptors on antigen-presenting cells, 
such as CD23 on B cells and to high-affinity IgE receptors (FcRI) on Langerhans' cells and 
monocytes can enhance antigen internalization and presentation to T cells, resulting in 
continuous activation of the immune system [575].
The importance of IgE in asthma led to the development of targeted therapy in the form of a 
monoclonal antibody (mAb) against anti-IgE, omalizumab (Xolair®) [218]. Omalizumab 
blocks the IgE high affinity receptor, and downregulates DC FceRI expression [219]. 
Clinical trials of omalizumab showed improvement in asthma symptoms and steroid usage in
asthmatic patients accompanied by a reduction in total IgE levels [220-222]. This study and 
others have shown that these effects may be due to a reduction in IgE-mediated activation of 
FceRI-expressing cells, suppression of sputum and airway wall eosinophilia, reduction in 
FceRL cells, and a reduction in T and B cells in bronchial biopsies [223].
eosinophilic inflammation can still occur in the absence of IgE [224] and in one trial, marked
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1.5.4 Dendritic Cells
DCs are the most effective APCs, and have been shown to be necessary for disease 
development in murine models of asthma [225] as previously discussed. They can be 
identified in both the lung parenchyma and airway compartments [226] and as professional 
APCs they are responsible for the antigen-specific activation, proliferation and functional 
polarisation of T cells [227]. The importance of DCs in allergic airways models has been 
demonstrated by the transfer of Ag-primed DCs into naïve mice leading to an asthma-type 
phenotype after allergen challenge [228]. Furthermore the absence of DCs results in ablation 
of these features [225].
Transgenic and inducible knockout murine models have been developed to specifically study 
the role of DCs in pulmonary allergic responses. These studies have determined that airway 
DCs take up inhaled antigen and migrate to the draining lymph node (DLN) [226, 229], a 
process which increases in both speed and numbers of cells when the DCs are activated 
[230]. Whether an encounter with an aeroallergen results in sensitisation and airway 
inflammation, or tolerance depends on the phenotypic class [231] and maturation status 
[232] of the DC. The traditional model of DC-T cell interactions places antigen-preseiitation 
in the DLN, but recent evidence suggests that this may also occur in the airway itself [233] 
and that DCs are important during the secondary response to antigen, not just during 
sensitisation [234]. Nevertheless, dendritic cells are clearly important in the pathogenesis of 
asthma, probably in both the sensitisation and effector phases of the disease.
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these unanswered questions using an adoptive transfer model of allergic airways 
inflammation.
Inhibition of chemokine receptor signalling in T cells by pertussis toxin reduced allergic 
airways inflammation in a murine model [242] and in another study, use of STAT6-deficient 
mice resulted in reduced expression of C C L ll, CCL17 and CCL22 (ligands for CCR3 and
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1.5.5 Cell trafficking in asthma
It is also important to consider the trafficking of cells between tissues and organs when 
considering the mechanisms involved in allergic airways inflammation. Effector T cells are 
necessary and sufficient to provide the Th2 cytokines needed to induce both histological 
changes and induce AHR [235]. Although many murine models have been employed to 
elucidate the mechanisms involved in asthma, none have determined when and where these
T cell interactions occur. It is still unclear whether initial interactions occur in the lung itself 
or in the lymph nodes, and where T cells migrate after antigen challenge. The ability to
track T cells of known antigen specificity in different compartments important in airway
. ■
inflammation could help to resolve these questions. This thesis aims to elucidate some of
Several stages in leukocyte migration have been studied but it is the role of chemokines and 
their receptors, particularly in the trafficking of lymphocytes, that has been studied most in 
regards to asthma [236]. Th2 cells preferentially express the chemokine receptors CRTh2, 
CCR3, CCR4 and CCR8 [237-239], whereas Thl-related chemokine receptors include 
CCR5 and CXCR3 [239, 240]. This has been corroborated in asthmatic patients who have 
been shown to express increased levels of these chemokines receptors [119, 241] and 
suggest that such molecules may be potential therapeutic targets in asthma.
1
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CCR4) associated with decreased eosinophilic inflammation [243]. In one study of CCR3- 
deficient mice, BAL eosinophilia was markedly reduced as was AHR, although T cells were
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not [244], and another showed reduced BAL eosinophils but increased tracheal mast cells 
.and no reduction in AHR [245]. These results reflect the fact that CCR3 is expressed not 
only on Tli2 cells but also several other cell types associated with asthma including 
eosinophils [246], mast cells [247] and basophils [248], and also emphasises that elements 
contributing to eosinophilic airways inflammation and AHR are not exclusive.
Deficiency in, or neutralisation of, CCR4 has not had any effect in experimental allergic 
airways inflammation although targeting CCR4 ligands (CCL17 and CCL22) does reduce 
both airways inflammation and hyperresponsiveness suggesting either differences in the 
effects of blocking the ligand over the receptor, or that additional receptors for CCL17 and 
CCL22 are contributing [250]. It has been shown in the airways that CCR3 is expressed
early, whereas CCR4 appears to be upreguiated with repeated or chronic antigen exposure
[251]. Thus chemokines and their receptors appear to be temporally regulated with
consequent implications for therapeutic intervention. Other studies have shown that CCR8 is 
.not critical for the development of airways inflammation but that blocking chemokines 
associated with lymphocyte recirculation or memory does result in reduced eosinophilia and 
A HR.
These results and others suggest that chemokines and their receptors do play an intrinsic role
in the pathophysiology of allergic airways inflammation, but that there are additional factors
influencing the migration of leukocytes. Gaining an in-depth understanding of these factors 
.and how they function will increase the prospect of being able to target leukocyte trafficking 
as a potential therapy for asthma.
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1.6 Animal models
1.6.1 Humans or animals?
The use of human patients to study diseases is restricted in its nature, in that most procedures 
need to be of limited invasiveness, ranging from exhaled breath condensate to bronchial 
biopsies. It is also difficult or impossible to obtain important tissues to study, such as lymph 
nodes or lungs, as they cannot be removed from live patients. It may be hard to determine 
the stage of disease progression patients are in, giving only a limited view of the ongoing 
disease processes. Consequently, intervention in the disease process and measurement of the 
outcome is largely limited to clinical trials, which are both costly and time-consuming. 
Using patients does not allow the generation of knock-outs, identification of antigen-specific 
lymphocytes, or transgenic studies possible, which have been useful when studying animal 
models of disease. Both practical and ethical constraints need to be taken into consideration 
where human subjects are concerned. Furthermore, the genetic diversity of human subjects is 
vast making these studies more challenging. Despite these drawbacks, human studies have 
been fundamental in elucidating the mechanisms involved in asthma, and used in 
conjunction with animal models have given greater insight into the immune response 
involved in asthma.
1.6.2 Advantages of Animal models
Much of our understanding of the response to allergens and the mechanisms involved in 
airways inflammation and allergic disease comes from the use of animal models, especially 
mice, rats and guinea pigs. These investigations have given an insight not only into the
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immunologie mechanisms underlying allergy, but have also allowed evaluation of potential
therapeutic agents. A major advantage of using animal models is that small rodents can be 
.bred cheaply and quickly, and in-breeding eliminates the genetic diversity encountered in 
human subjects. However, this may be considered a disadvantage, as humans are genetically
diverse, thus suggesting that the disease model may not be directly comparable. 
Manipulation of the murine genome allows the development of transgenic and knockout 
strains to investigate the role of specific gene products. Using animal models also allows 
many tissues that are unobtainable in humans, to be analysed. It is possible to image in vivo 
in murine models allowing interactions to be studied in intact animals, providing valuable t 
information that may not have been discovered in vitro.
I
I
The mouse model has become readily available and easy to adapt because of the emergence 
of monoclonal antibodies that are specific for murine proteins, and the availability of 
knockout and transgenic mice. Mice are currently the only species in which this technology
■
is readily available. Also, the lack of selective non-peptide antagonists to many cytokine, 
chemokine and growth factor receptors has made the models very appealing [252]. Murine
;models of airway inflammation are deemed to be useful as many of the features of clinical 
disease found in humans are also characteristic in the mouse models. It has been shown that
mice undergo early and late asthmatic responses [253], and show serum specific IgE, 
recruitment of lymphocytes and eosinophils and airway hyperresponsiveness when exposed
:
to allergens such as Der p i [254], which are relevant to humans. Murine models have also
been used to measure different aspects of airway remodelling, and it has been found that 
many of the cytokines, chemokines, growth related peptides and their receptors that are
expressed in the human disease are also expressed in the murine equivalent of the 
inflammatory murine models. This shows that findings in animal models can be translated 
to human clinical settings.
Importantly, many of the drugs that have been used in human studies of asthma are able to 
attenuate responses in the murine models. Glucocorticoids have been shown to inhibit the 
recruitment of eosinophils and inhibit AHR after antigen challenge in a chronic murine 
model [255]. Furthermore, pz-^drenoreceptor agonists provide bronchoprotection against 
antigen challenge [253]. It is also possible that novel anti-inflammatory agents can be tested 
in these models as they can be modulated by current therapeutic modalities. As has already 
been shown in some studies, not all positive results discovered through the use of murine 
models will prove effective at clinical trial level [154, 256]. However, these studies will still 
add further understanding of the disease pathophysiology.
1.6.3 Disadvantages of animal models
Despite the many benefits of animal models described above, there are also arguments
against using animal models to study diseases. Due to the complexity of asthma it may not
be possible to have a single animal model that can replicate all aspects of the human disease.
It is also not clear how much the anatomy and physiology of animals differs from that of
humans, requiring caution when interpreting results. For example, the mouse has fewer
divisions of the bronchial tree and fewer mucus-secreting glands in the respiratory 
.epithelium than humans [257]. Furthermore, although eosinophil degranulation has been 
shown to occur in asthmatic patients, there has been some doubt over whether this occurs in
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animals.
1.7 Asthma Therapies
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murine models of allergic airways inflammation |258, 259], although more recent studies 
would appear to suggest that it does [260].
In human studies of asthma, relevant biomarkers of therapeutics would be changes in 
pulmonary function tests, symptom scores or medication use, not all of which can be 
measured in animals and the assessment of the former has been the subject of much debate 
over recent years [261-264]. Many studies have also shown that animal studies can produce 
conflicting results when applied to humans. This has been found in conditions such as septic 
shock where clinical trials of anti-TNF drugs failed to show benefit [265] despite promising 
results in animal studies [266]. In asthma, although IL-5 neutralisation in animal models 
proved effective at reducing airway inflammation and AHR [154, 256], clinical trials of anti- 
IL-5 antibody have proved disappointing [156].
The ethical justification for the use of animals in research converges with the scientific and 
in some respects depends on it. It is based upon the view that increasing the knowledge base 
makes it possible to develop therapies that mitigate pain and suffering caused by illness and 
trauma, and thereby responds to the moral imperative to do good. It assumes that research 
can be carried out with no or minimal discomfort or distress to the animal research subjects, 
and that any pain and suffering experienced is compensated for by the alleviation of human
pain and suffering caused by disease and injury. Although animal and human studies
sometimes contradict each other, many valuable lessons have been gained from the use of
'i
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Drugs Mechanism of action
2^ adrenoreceptor agonists Bronchodilation by inhibiting 
contraction/inducing relaxation of smooth 
muscle
Anti-cholinergic agents Bronchodilation by blocking muscarinic 
receptors in smooth muscle
Anti-IgE monoclonal antibody Reduces free IgE levels and so inhibits 
mast cell/basophil/eosinophil activities
Corticosteroids Numerous effects on inflammatory 
mediators
Theophylline Principally a bronchodilator, but several 
other actions also proposed
Cromones Prevents release of histamine and other 
mediators from mast cells
Leukotriene antagonists Blocks action of leukotriene mediators
There are two main types of drugs that asthmatic patients use: ‘relievers’ and preventers’ 
[267]. Patients use relievers when they are symptomatic and preventers are used to keep the 
disease quiescent. These categorisations also help to determine where potential therapies 
should be targeted, either at the end-effector mechanism s such as airways 
hyperresponsiveness to achieve bronchodilation and symptom relief or at underlying 
processej? such as airways inflammation or airway remodelling to try and prevent symptoms 
developing (See table 1.4).
Table 1.4: Current asthma therapies and their mechanisms.
Of these agents, only (32-agonists and corticosteroids can be truly classified as described 
above (as reliever and preventer respectively) with the other drugs having a mixture of 
effects on AHR and/or inflammation. The principal side effect of (32-agonists is tremor,
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Much interest has centred recently on ‘biologic’ therapies i.e. drug treatments 
mechanistically designed to target a specific biological mediator of a disease, usually as a 
monoclonal antibody. The theoretical advantages of such agents would be the inhibition of a 
specific pathway resulting in the desired therapeutic effect with minimal side-effects.
72
1:
'caused by direct stimulation of p2-adrenergic receptors in skeletal muscle [268]. After many
years of research these (Sj-agonists and corticosteroids are still the conventional asthma
treatments, with treatments aimed at novel targets so far failing to make any real difference
to the clinical management of asthma [269]. These therapies are mainly used for mild
disease, where the inflammatory response of AHR, and variable airflow obstruction are
highly responsive to corticosteroids, making these drugs the first choice [95]. In severe and
persisting asthma inhaled corticosteroids are only partially effective and patients often 
.require intermittent or continuous oral corticosteroids. Although there are a range of other 
treatments for these patients, including cytotoxic agents and nebulised bronchodilators, they 
have variable benefits and have many side effects [270]. Thus, severe corticosteroid- 
refractory asthma represents a major unmet clinical need. An ideal therapy for asthma 
would have the anti-inflammatory disease-modifying properties of a preventer but without 
the damaging side effects of drugs such as steroids.
5
Biologic therapies grew out of observations that the cytokine TNFa appeared to have an 
apical role in an ‘inflammatory cascade’ of cytokines in rheumatoid arthritis (RA). Anti-TNF 
treatments such as etanercept and infliximab proved successful in clinical trials and are now 
established in rheumatoid arthritis [273-275] and other biologic agents for a growing range 
of conditions are in development [276]. Recently, anti-TNF therapy has shown beneficial 
effects in severe asthmatics [277]. The main side effects of anti-TNFa therapies are
i
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infections, and although rare, they can be severe and sometimes fatal-opportunistic 
infections and tuberculosis have been observed in some cases [278]. Anti-IgE mAb therapy 
has established a place for itself in the clinical management of asthma [220-222]. However, 
antibodies to IL-5, CD4 and C D lla  have so far failed to show any convincing benefit [141,
142, 156, 157, 279].
li.
To be able to develop these drugs, we must continue to refine our understanding of the 
underlying mechanisms of asthma such as airway inflammation and remodelling. It is also 
important to understand where cells are interacting, and what with, during disease to be able 
to specifically target drugs efficiently, thereby reducing any possible side effects. 
Understanding how these mechanisms work, what exacerbates them and what improves
them, should lead to the identification of new therapeutic targets.
I
1.7.1 TNFa
.7
T N F a  was first identified as a factor causing necrosis of tumours in mice [280]. It was 
subsequently identified as a major proinflammatory agent in conditions such as septic shock 
[281, 282] and is now recognised as the prototype member of the TNF family of ligands
,:.a(including lymphotoxins alpha and beta. Fas ligand, CD40 ligand and OX-40 ligand) binding 
to a corresponding family of receptors, the TNF-receptor family [283, 284]. TNF forms a 
homotrimer [285], and exists as a 26 kDa membrane-bound protein that may be cleaved by 
TNF-a converting enzyme (TACE) to form the 17 kDa soluble moiety [286]. Two receptors 
for TNFa are described [283]. TNFRl (p55) is widely-expressed, contains the cytoplasmic
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death domain found in several members of the TNFa receptor family and mediates many of 
the proinflammatory actions of TN Fa [287, 288]. TNFR2 (p75) does not contain the death 
domain and its actions are less clear, although it also binds lymphotoxins and has been 
shown to mediate thymocyte proliferation in response to TN Fa and apoptosis of mature 
activated T lymphocytes [283, 289].
ITN Fa is a potent pleiotropic cytokine with broad proinflammatory and immunoregulatory 1
Iactivities, and is produced by many cell types including monocytes, macrophages, 
lymphocytes, neutrophils, eosinophils, and mast cells [290]. It functions as a chemoattractant
■ iv -for neutrophils and monocytes, increases micro vascular permeability, and activates T cells,
;
eosinophils, and mast cells [291, 292]. Moreover, TN Fa induces endothelial adhesion 
molecules and thus may initiate the recruitment of circulatory inflammatory cells into the 
tissue [292, 293]. TN Fa mediates direct effects on target tissue cells e.g. kératinocytes, 
synovial fibroblasts, or osteoclast precursors, all of which may further promote a role in 
target tissue pathology.
The pro “inflammatory role of TNFa is best described in rheumatoid arthritis. RA synovial 
membrane contains numerous cytokines including TNFa that may be released upon culture
Î
in vitro. Neutralisation of the latter suppresses IL-6 and IL-1 secretion, in turn suggesting an 
apical hierarchical role for TN Fa [271, 272, 294]. Over-expression of TNFa in transgenic
'Îmice leads to spontaneous erosive polyarthritis [295]. Administration of anti-TNFa 
antibodies in transgenic arthritis models and in DBA/1 mice with collagen-induced arthritis 
(CIA) reduced joint inflammation and destruction [295] suggesting that TNFa played a key
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role in these disease processes and that neutralising TNFa activity in humans could lead to
275, 296-299], Thus approximately 40% of patients respond with at least 50% improvement 
in disease activity, with some achieving remarkable responses that are sustained over time 
and associated with prevention of articular damage assessed radiographically [283-286].
that remain.
1.7,2 Anti-TNFa in asthma
an improvement in clinical disease. Subsequent clinical trials revealed that anti-TNFa 
therapy is beneficial in RA although only a proportion of patients respond to treatment [273-
s
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Considerable residual unmet clinical need is reflected in those partial and non-responders
In the lung, TNFa is synthesised and stored mainly in mast cells and alveolar macrophages
.1;[300]. It functions as a chemoattractant for neutrophils and monocytes, increases 
microvascular permeability, and activates T cells, eosinophils, and mast cells. It has been 
shown that there is increased expression of TNFa in the airway of asthmatic patients 
compared to normal subjects [300, 301]. Mast cells are unique in being the only tissue- 
resident cells with granules containing preformed TNFa and consequently during the early 
stages of inflammation or infection they may be the sole source of this cytokine, and exert 
their biological effects by releasing preformed and de novo synthesised mediators such as 
histamine, proteases, leukotrienes, prostaglandins, and cytokines on cell activation [302]. 
T N F a  is able to stimulate the production of IL8, RANTES and GM-CSF by airway 
epithelial cells, which increases the expression of adhesion molecules such as ICAM-I and
i
VCAM-l, which are involved in the recruitment of inflammatory cells to the airways [303].
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1.8 Infection and asthma
IThis is also important for the recruitment of eosinophils to the airways. TN Fa is also
thought to be involved in airway remodelling through its effects on fibroblasts and by 
.inducing eosinophils to release matrix metalloprotease 9 [304],
A recent study by McLachlan and colleagues has emphasised the link between mast cells, 
TN Fa and the regulation of inflammation and immunity [305]. They showed in a murine 
model that injection of E. coli into the footpad led to hypertrophy of the popliteal (draining) 
lymph node attributable to influx of T and B lymphocytes, and was associated with mast cell 
degranulation in the footpad. Mast cell deficient mice (W/W'') mice showed significantly 
reduced lymph node swelling which was reversed by reconstitution of the mice with wild- 
type mast cells, but not with TNFa-deficien t mast cells. Lymph nodes are a central 
immunological site of the adaptive immune response and are important for the interaction of 
T cells and APCs and further induction of the immune response.
Many patients presenting with exacerbations of asthma also have a respiratory tract infection
(RTI). This has been highlighted in studies showing that between 37-44% of adult patients
with acute asthma have evidence of RTI [306, 307]. How infections influence the
.development and exacerbation of asthma requires further study if we are to provide effective 
.management for patients with asthma. In particular it is essential that the cellular and 
molecular basis for these interactions are elucidated in order to manipulate them. Three ways
'
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1.8,2 Bacterial infections and asthma
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in which infection can interact with asthma can be considered: viral infections, bacterial 
infections and how microbial products may affect the asthmatic process.
I'
1.8.1 Viral infections and asthma
Up to 85% exacerbations of asthma in children and up to 44% in adults may be associated 
with viral infections [307, 308] suggesting that viral RTI may be a major trigger of acute 
asthma. Studies of experimental rhinovirus infection have shown that there is increased 
histamine release, eosinophilic infiltration and AHR in the lungs of atopic asthmatics 
compared to healthy subjects [309-311]. Studies of patients with exacerbations of asthma
have shown that viral infection, exposure to allergen and sensitisation to allergen appear to
have a synergistic effect in triggering an acute attack [312]. Whether viruses can affect the
susceptibility of an individual to develop asthma is less clear and studies on respiratory 
syncytial virus (RSV) have shown that RSV bronchiolitis in infancy can increase the risk of
developing atopy and asthma later in childhood [313] but that this risk may have normalised 
by age thirteen [314]. This difference in effect depending on whether the infection takes 
place before the onset of asthma or atopy, or after the disease has become established may 
help to explain the differences between clinical studies showing correlation between RTIs
■
and infection and epidemiological data suggesting a protective effect on a population of 
exposure to infection.
5
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The studies demonstrating a link between RTI and exacerbations of asthma detected mostly 
viruses, although some evidence implicating bacterial infection is available [306], Most 
studies however, only provide circumstantial rather than causative evidence. For example, 
patients undergoing an exacerbation of asthma were found to have a higher rate of 
colonisation with Branhamella catarrhalis (now renamed Moraxella catarrhalis) than
control subjects, although there was a similarly high rate in stable asthmatics [315]. Another 
study implicated chronic sinusitis in difficult to manage asthma [316]. Although sinusitis has 
been associated with worsening of airway inflammation [317] it is not known whether or not 
this is due to the bacterial pathogens that are commonly implicated in sinusitis such as
' I
Streptococcus pneumoniae and Haemophilus influenzae. More convincing is evidence that 
‘atypical’ organisms such as Chlamydia pneumoniae and Mycoplasma pneumoniae are 
associated with exacerbation of asthma [318-320] with some studies suggesting that 
treatment of these organisms may improve asthma control [321]. Although it seems likely 
that bacterial infection adversely affects asthma, evidence to support this is not as 
comprehensive as that for viruses, warranting further study in this area.
1.9 Microbial products and asthma
IAllergic diseases are typically characterized by predominance of Th2 cytokines, such as IL-4 
and lL-5, which promote IgE production and eosinophilia [322]. However, the process by 
which microbes and their products, such as endotoxin, influence expression of this 
phenotype remains unknown. Some propose that early exposures result in a skewing of T- 
cell differentiation toward the Thl phenotype and away from Th2 [323]. Evidence for this
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mutual exclusivity comes from laboratory studies, which show that T hl cytokines, such as 
inteiferon-y, are capable of suppressing IL-4 and IL-5 production [324], and observational 
studies, which show that house dust endotoxin levels are positively associated with 
inteiferon-y production by CD4+ T cells but not lL-4, IL-5, or IL-13 [325]. However, the 
incidence of both Th2 diseases, such as asthma, allergic rhinitis, and atopic dermatitis, and 
T hl diseases, such as type 1 diabetes mellitus, multiple sclerosis, and Crohn’s disease, has 
increased, suggesting a more general loss of T-cell suppression [326]. It has been proposed 
that the lack of intense infections in industrialised countries owing to improved hygiene,
vaccination and use of antibiotics may alter the immune system such that it responds 
inappropriately to innocuous substances [327]. The “hygiene hypothesis” [11] has been 
given an immunological framework in which the balance between Thl and Th2 immune 
responses is pivotal [328]. It has been postulated that limited exposure to bacterial and viral 
pathogens during early childhood results in an insufficient stimulation of Thl cells, which in 
turn cannot couterbalance the expansion of Th2 cells and results in a predisposition to 
allergy [329]. Although endotoxin exposure can result in IL-12 production and the
.
subsequent expression of inteiferon-y [330], a T hl cytokine, TLR-4 signalling has also been 
shown to be important for optimal Th2 development [331].
z
A recent study used explanted nasal mucosa from 22 children and 17 adults and stimulated 
with allergen and/or LPS [332], In mucosa taken from children with atopy, stimulation with 
both allergen and LPS abrogated Th2 cytokine expression and increased Thl cytokine 
production when compared with allergen stimulation alone. However, Th2 cytokine 
expression was restored when these cells were also incubated with neutralizing antibody
'•i-
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against IL-10, IL-12, or inteiferon-y, suggesting that the effect of LPS was mediated in part 
through the production of these cytokines. Stimulation of cells with both allergen and LPS 
also resulted in an increase in the number of T-cells expressing TLR-4 receptors, an increase 
in the number of TLR-4—positive cells that contain IL-10, and an increase in the number of 
cells that express both CD4 and CD25 when compared with allergen stimulation alone. The 
effect of LPS stimulation on IL-10 transcription and TLR-4 expression appeared diminished 
in adults when compared with children. Together these findings suggest that LPS may down- 
regulate allergic response through T hl skewing and/or the expansion of regulatory T cells, 
but that these effects are most prominent in children, whose developing immune system is 
still susceptible.
To date, two cross-sectional studies suggest that in situations of high environmental 
endotoxin exposure, functional mutations in the TLR-4 gene may protect against bronchial
reactivity [326] and atopy. The protective effect of TLR-4 function mutations on airway 
responsiveness may reflect reduced localized inflammation in the lung. However, the 
mechanism by which high endotoxin exposure and TLR-4 functional mutations may interact 
to lower the risk of atopy has yet to be established.
■S;3
I %1.10 Objectives
The introduction discusses the current understanding regarding the pathophysiology of 
asthma. A great deal of research has provided the basis for the current understanding of a 
Th2-mediated inflammatory disease of the airways, with increasing evidence suggesting that
■Î
underlying irregularities in the structural elements of the airways may be of importance. A 
great deal of this information has been gained from using animal models. However, it has 
been shown that this can be conflicting with clinical studies and also confusing due to the 
variability in models, strains and conditions. Many questions remain unanswered in fully 
understanding then mechanisms underlying airway inflammation, including how asthma 
therapies really work and how external factors influence disease outcome. The objectives of
I. To establish and characterise a murine model of allergic airways inflammation
3 . To investigate the impact of microbial products, specifically LPS, on allergic
this thesis are therefore:
■ il.
■S
Adoptive transfer of transgenic T cells allows antigen-specific cells to be identified in .A' 
different cellular compartments. Employing this system, the precise locations can be 
tracked ex-vivo in a murine model of allergic airways inflammation, providing novel Iinformation on the interactions of anti gen-specific T cells in the airways response.
S
2. To investigate the effects of TNF blockade on mechanisms of airway 
inflammation
3The effects of inhibiting TNF activity in these models will be examined and the results
■‘pcompared with findings in emerging clinical trials of anti-TNF therapies in asthma.
f
airways inflammation
I
s.
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Using the model established above, the effect of exogenous inflammation on airways 
inflammation will be examined and characterised.
4. To elucidate where and when T cell interactions take place in allergic airways 
inflammation
Tracking CD4^ T cells will help to define the behaviour of antigen-specific lymphocytes in 
vivo and aim to clarify important issues involving the location of effector and memory T cell 
populations in allergic airways inflammation.
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CHAPTER 2 - MATERIALS AND METHODS
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2.1 Animals
2.1.1 Animals
Wild-type BALB/c and C57BL/6 mice were purchased from Harlan Olac (Bicester, Oxon,
UK). D O ll.lO  mice are homozygous for the chicken ovalbumin (OVA) peptideg^.ggç/I-A'^- 
specific D O ll.lO  TCR transgenes (detected using the clonotypic mAh KJ1.26) on the 
BALB/c background [333], and were bred in-house by Biological Services, University of 
Glasgow.
3
.12.1.2 Animal welfare
All mice were housed in pathogen-free conditions in facilities run by Biological Services, 
University of Glasgow and University of Strathclyde in accordance with United Kingdom 
Home Office regulations under the Animals (Scientific Procedures) Act 1986. Severe 
immuno compromised) SCID mice were housed in micro-isolator cages with filtered air and 
were fed sterilised feed. All procedures were carried out under Project Licence Number 
60/3046.
I
2.2 Preparation of cell suspensions for adoptive transfer
Peripheral lymph nodes, mesenteric lymph nodes, and spleens from D O ll.lO  BALB/c mice 
were pooled and forced through Nitex (Cadisch Precision Meshes, London, U.K.) using a 
syringe plunger. The suspensions were washed in sterile RPMI 1640 (Invitrogen Life
Technologies, Paisley, U.K.). Cells were washed by adding 1 ml of FACS buffer (See table
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2.3) before the suspensions were centrifuged at 450xg for 5 min and the supernatant 
discarded. The percentage of KJ1.26^CD4^ D O ll.lO  T cells in these preparations was 
determined by flow cytometric analysis as described below. Cell suspensions containing 3 x 
10® Tg T cells in 200 pt\ were injected i.v. into age-matched BALB/c recipients.
-
2,3 Adoptive transfer model of allergic airways inflammation
T cell receptor Transgenic (Tg) Ag-specific T cells were adoptively transferred into recipient 
mice before induction of airways inflammation [334]. In these experiments 3x10® transgenic 
cells were adoptively transferred into naïve BALB/c recipients before immunisation with 
lOOpg OVA (chicken OVA, fraction V was obtained from Sigma-Aldrich) in a 1% alum 
suspension (Brenntag Biosectar, Frederikssund, Denmark) by i.p. injection on up to three 
occasions a week apart, followed by an intranasal challenge of 50fig OVA from 1 to 3 times. 'i■"'P:
The mice were culled on subsequent days. Samples collected included BAL fluid for 
cytospin and flow cytometry analysis of BAL cells and enzyme linked immunosorbant assay 
(ELISA) analysis of cytokines; serum for immunoglobulin assays; draining lymph nodes ,
(DLN: mediastinal) and peripheral lymph nodes (PLN: axillary, brachial, inguinal, cervical) 
for flow cytometry analysis for Ag-specific Tg cells, immunoflourescence (IF)-staining for 
Ag-specific cells and ex vivo cell culture with Ag-restimulation; and lungs for IF-staining for 
Ag-specific cells and histological analysis.
2.4 CFSE-labelling of cells
In some experim ents, T cells were labelled with the green-fluorescen t dye 
carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen Ltd, formerly Molecular *
Probes). Single cell suspensions were prepared as below and washed in HBSS (Invitrogen 
Life Technologies, Paisley, U.K) before being resuspended in a suitable volume to give a 
concentration of 5x10^ cells/ml. 0.5p.l/ml lOmM CFSE was added before incubation at 37°C 
for 10 minutes. The cells were then diluted in at least lOx volume complete RPMI (cRPMI)
(see table 2.3) before centrifugation at 400xg for 5 minutes at 4°C and resuspended in a 
medium and volume appropriate for subsequent use.
I
2.5 Intranasal dosing
Mice were anaesthetised by intraperitoneal injection of 250|ul avertin (1:1 w/v solution of 
2,2,2-tribromoethanol in tert-amyl alcohol (Sigma Aldrich, UK). 30fxl of reagent was then 
administered to the nostril using a 200p.1 pipette. Mice recovered from the anaesthesia in a 
warmed environment before being returned to standard housing conditions.
2.6 Intratracheal dosing
Mice were anaesthetised as for intranasal (i.n.) dosing. Once unconscious, the mouse was 
positioned vertically by their upper incisors on a custom-made support (Institute of 
Biological and Life Sciences (IBLS) Workshop, University of Glasgow). This allowed direct 
and atraumatic access to the trachea via the mouth using a blunt-tipped 25G needle (needles
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purchased from Becton Dickinson (BD), Franklin Lakes, USA) and blunted by the IBLS 
Workshop). The reagent was then administered via the needle using a 1ml syringe. Mice 
were allowed to recover from the anaesthesia in a warmed environment before being 
returned to standard housing.
2.6.1 Intranasal vs Intratracheal
Intranasal administration of antigen to the airways has been criticised for the inconsistency 
of the dose of antigen given due to the variability in anaesthesia and also the effect of 
antigen on the nasal mucosa. However, this technique is easier to administer than 
intratracheal dosing, which is a favoured method of antigen administration and is more 
invasive. When intratracheal and intranasal administration was compared in this airway 
model, no significant differences were seen in the level of eosinophilia induced (data not 
shown). Intranasal immunisation has also been proven to cause a response in the lower 
airway, suggesting that its administration is effective [335]. Another method employed to 
administer antigen to the airways is nébulisation. This method allows the dosing of several 
mice at one time, without the need for anaesthetic and multiple doses are safe. However, 
there are also disadvantages to this protocol. Specialised equipment is needed and although 
a measured dose of antigen is given to each chamber, there is no guarantee that each mouse 
will inhale an equal amount. As nébulisation is administered in the air, there is a chance that 
antigen may be present on the fur and ingested by mice during grooming, leading to 
induction of oral tolerance [336, 337]. Despite the advantages and disadvantages of all three 
methods, different research groups all still routinely use them, and have all been shown to 
induce allergic inflammation of the lungs. Our studies have chosen to use intranasal antigen
87
i g
administration; due to ease of delivery and using intratracheal dosing saw no significant
advantage.
2.7 TLR ligands
TLR4 ligand LPS (E. coli 055:B5, Sigma Aldrich, UK) or TLR2 ligand Pam3CSK4 (BLP)
2.10 Bronchoalveolar lavage
Bronchoalveolar lavage was performed following termination by cardiac puncture. The 
trachea was exposed and a horizontal incision made between the cartilage rings. The trachea
Ï
(EMC Microcollections GmBH, Germany) was given intranasally or intraperitoneally at 
varying doses.
2.8 Etanercept
Etanercept (Wyeth Pharmaceuticals, Taplow, UK) a TNFRII-human FC fusion protein, was 
given at a dose of i.p. (50pg/0.5mg/kg) or s.c. (25pg/0.5mg/kg) injection. Control animals 
were given human IgG (Sigma Aldrich, UK) by the same route.
2.9 Cardiac puncture
Following an overdose of anaesthetic (500p,l avertin i.p.) the heart was exposed and blood 
was withdrawn using a 23G needle and 1ml syringe inserted into the right ventricle. This 
method of anaesthetic overdose followed by exsanguination conformed to a Schedule 1
termination according to the Animals (Scientific Procedures) Act 1986.
was then cannulated using polythene tubing (0.58mm internal diameter, 0.78mm outer 
diameter, Portex-Smiths Medical, Hythe, UK) over a 23G needle attached to a 1ml syringe. 
The needle was held in place using forceps while a 0.8ml aliquot of PBS (Invitrogen Life 
Technologies, Paisley, U.K) was injected and the lungs could be seen to inflate. After 10s 
the lavage fluid was withdrawn using the same syringe and collected in a 1.5ml 
microcentrifuge tube. This was repeated with a second 0.8ml aliquot, which was pooled with 
the first. Samples were stored on ice until processing.
2.11 Harvesting of lymphoid organs
Peripheral lymph nodes comprised inguinal, popliteal, axillary and brachial lymph nodes 
(LNs). Cervical, mesenteric and para-aortic lymph nodes were also included if maximal cell 
numbers were required. Draining lymph nodes refer to thoracic lymph nodes. In experiments 
where LNs were weighed or were required for immunohistochemistry (IHC) or 
immunofluorescent staining the same node site was sampled on each occasion (left inguinal 
LN for PLN and central mediastinal LN for DLN). For IHC and IF, nodes were snap frozen 
in liquid nitrogen in OCT embedding medium (Bayer, Newbury, UK) before being stored at 
-70°C. For cellular processing, LNs and spleens were collected into incomplete RPMI 
(iRPMI).
2.12 Lung samples
After opening the thoracic cage, the lungs were carefully separated from surrounding tissue 
by blunt dissection and removed en bloc with the heart. For histological analysis, lungs were 
inflated with 1ml 10% neutral buffered formalin (NBF) via the trachea, which was then tied
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the cavity was manipulated for 15 seconds to allow adequate mixing and mobilisation of 
cells before aspiration using the same syringe. Generally 4-5ml of fluid was recovered. The 
volume of peritoneal lavage fluid obtained was recorded and the sample was kept on ice
Blood was collected into 1.5ml microcentrifuge tubes and allowed to clot at room 
temperature for 2-3 hours. Clotted samples were then centrifuged at 18400xg for 30 minutes 
at 4°C. Serum was carefully aspirated from the samples and collected in 0.5ml 
microcentrifuge tubes and stored at
2.15 Preparation of blood cells for flow cytometry
Blood was initially collected into heparinised capillary tubes before being expelled into 5 ml 
round-bottom polystyrene test tubes (FACS tubes, BD) by flushing with 1ml FACS buffer. 
Cells were washed by centrifugation at 400g for 5 minutes, resuspended in 1ml FACS buffer
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3I:off with thread. The lungs were immersed in NBF for at least 72 hours before processing. 
For IHC or IF, lungs were inflated with 1ml 50% OCT in PBS and immersed in OCT in an 
aluminium foil mould before freezing at -20°C with final storage at -70°C.
2.13 Peritoneal lavage
Mice were killed by cervical dislocation and the peritoneum exposed. 5ml of ice-cold PBS 
was injected into the peritoneal cavity using a 23G needle and 5ml syringe. The fluid within
until further processing.
■"I;| l
2.14 Serum samples
I
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and centrifuged again as above. The cell pellet was incubated in 200|xl Fc block (anti- 
CD 16/32 hybridoma supernatant from Clone 2.4G2) for 10 minutes at 4°C before staining. 
Samples were subjected to red cell lysis by incubation in FACS Lysing Solution (BD) for 10 
minutes at room temperature and then washed in 1ml FACS buffer as above. Cell pellets 
were resuspended in 200-1000|il FACSFlow (BD) and filtered through 100|im nylon 
monofilament gauze (Cadisch Precision Meshes Ltd., London) before analysis using a 
FACSCalibur flow cytometer (BD). Data was analysed using either Cellquest (BD) or 
FlowJo (Tree Star Inc, Ashland, USA). An aliquot of cells could be removed after the red 
cell lysis stage for cytospin analysis if required.
2.16 Lymphoid organs
Lymph node or spleen cells were dispersed by crushing under lOOxm nylon gauze using the 
end of a syringe plunger in iRPMI. Cells were washed twice in l-25ml iRPMI according to 
the number of organs used by centrifugation at 400xg for 5 minutes at 4°C, then resuspended 
in an appropriate volume of either incomplete or complete RPMI. If red cell lysis was 
required it was performed before the final wash by resuspending spleen cell pellets in 2ml 
Red Cell Lysis buffer for 1 minute at room temperature before addition of lOx volume 
iRPMI. The number of viable cells was determined using a Neubauer haemocytometer 
(Weber Scientific International Ltd, Teddington, UK) diluted in 0.1% w/v trypan blue.
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2.17 Cell culture
2.18 Cytospin preparations
. .' ' a
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Cells derived from lymphoid organs were routinely cultured in complete RPMI at 37°C in a 
humidified atmosphere enriched with 5% CO^. Cells were cultured at a concentration of
1x10® cells/ml in 2ml/well. Response to antigen stimulation was performed by adding sterile 
OVA to a final concentration of Img/ml to cultures with control cultures supplemented with 
medium alone. For measurement of cytokine production, cultures were performed in 24 well 
plates and supernatants harvested after 96 hours and stored for further analysis. Remaining 
cells could be collected at this stage for FACS analysis by washing the wells with 1ml 
iRPMI or FACS buffer. For assessment of the proliferative response, cultures were
performed in triplicate in round-bottom 96 well plates (2x10® cells in 200|il per well) and
assayed at 72 hours. For the last 8 hours of culture, cells were pulsed with ICi/well tritiated
(pH]-labelled) thymidine (West of Scotland Radionuclide Dispensary, Glasgow, UK) before 
being harvested onto glass fibre filter mats (PerkinElmer LAS (UK) Ltd., UK) using a 
Wallac 1295-004 96 Well Harvester (PerkinElmer) and [3"]-thymidine incorporation 
measured using a Wallac 1205 Betaplate Liquid Scintillation Counter (PerkinElmer).
Cytospin preparations were used to perform differential cell counts from BAL samples,
peritoneal washes and blood cells. For BAL samples, the volume of sample was first 
estimated by weighing the sample against an empty 1.5ml microcentrifuge tube. The cells 
were then centrifuged at 400g for 5 minutes at 4°C and the supernatant removed and stored 
at -20° C for later analysis. Cell pellets were resuspended in 1ml PBS and the cells counted, 
allowing the calculation of total cells per ml of BAL fluid. 5x10"  ^cells were then spun onto
i
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glass slides using a Shandon CytospinS (ThermoShandon, Runcorn, UK) at 350rpm for 6 
minutes. The slides were allowed to air-dry for 10 minutes before being fixed in methanol at 
room temperature for 10 minutes. Fixed cytospin slides were stained with Rapi-Diff II (a
10 minutes at 4°C. l |i l  each of phycoerythrin (PE)-labelied anti-CD4 mAh and biotin-
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.rapid Romanowsky stain) and then had coverslips affixed using DPX mountant (BDH
Laboratory Supplies, Poole, UK). Differential cell counts were performed by counting at
least 400 cells by light microscopy in consecutive high power fields (xlOOO magnification),
.identifying different cell types by staining and morphological characteristics. Experimental 
conditions were blinded to the observer during counting. Peritoneal lavage and blood 
samples were treated in a similar fashion.
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2.19 Flow cytometry
ILymphoid cells were analysed for the presence of D O ll.lO  Tg T cells by staining for 
surface expression of CD4 and the Tg TCR [338]. Single cell suspensions were prepared 
from lymphoid organs as described above, resuspended in 200|l1 F c block and incubated for
. Ï
-Ilabelled KJ1 -26 mAb (recognising the transgenic TCR) or appropriately-labelled isotype 
controls (all antibodies from BD Pharmingen unless otherwise stated) was added to each 
sample which was then incubated for 20 minutes at 4°C. Cells were washed by addition of 
1ml FACS buffer followed by centrifugation at 400g for 5 minutes at 4°C. The cell pellets 
were resuspended in 50pl FACS buffer with l\x\ streptavidin-conjugated fluorescein (Vector 
Laboratories Inc, Burlingame CA, USA) and incubated for a further 10 minutes at 4°C. The 
cells were washed FACS buffer as above and resuspended in 1ml FACSflow. I
1
In some experiments, the expression of memory markers was examined using antibodies 
against CD45RB and CD62L labelled with the appropriate fluorochromes. In these cases, the 
staining procedure was the same with the appropriate antibodies or isotype controls added 
after the addition of Fc block. In experiments where CFSE labelled cells were transferred, 
three-colour analysis was performed using appropriate flourochromes and isotype controls. 
Analysis was performed using Cellquest or FlowJo software. Antibodies used for flow 
cytometry are summarised in Table 2.1.
Antigen Isotype Supplier (Clone) Label
CD4 Rat IgG2a BD (RM4-5) PE, PerCP,APC
CD45RB Rat IgG2a BD (16A) FITC
CD62L Rat IgG2a BD (MEL-14) PE
OVA-TCR Mouse IgG2a (KJl-26) Biotin
Sterptavidin-PE N/A BD PE
Streptavidin-FITC N/A Vector Laboratories FITC
Streptavidin-APC N/A BD APC
Table 2.1: Flow cytometry reagents
2.20 Lung histology
Lung specimens collected in 10% neutral buffered formalin were transferred into 70%, 90% 
and 100% ethanol successively to dehydrate. After embedding in paraffin wax, sections were 
cut at a thickness of 6p,m and mounted on microscope slides. Sections were stained with
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(Table 3.1). Ail sections were scored by the same observer who was blinded to experimental 
conditions at the time of counting.
2.21 Immunofluorescence staining for KJl-26^ T cells, proliferating cell 
nuclear antigen (PCNA) and B220
haematoxylin and eosin (H&E). For allergic airways inflammation experiments the degree of 
inflammation was assessed on lung sections using the scoring system discussed in Chapter 3
Î
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KJl-26^ (OVA-specific) T cells were identified on tissue sections using tyramide signal 
amplification (TSATM) [339]. 6pm  sections from lung or lymph node samples frozen in 
OCT were cut using a cryostat (ThermoShandon) and mounted onto SuperFrost slides
(BHD, Poole, UK) before being allowed to air-dry and stored at -20°C until further 
processing. Slides were brought to room temperature and fixed in acetone and the sections 
outlined with a wax pen to allow addition of solutions without cross contamination. The 
remainder of the staining process was carried out in a humidified darkened chamber.
■Sections were rehydrated in PBS for 10 minutes before incubating in 0.1% azide/2% H^O  ^
for 45 minutes, changing the solution three times. After washing in PBS, endogenous biotin 
was blocked by sequential 15 minute incubations with Avidin then Biotin solutions (Avidin- 
Biotin blocking kit from Vector Laboratories), each followed by washes in TNT buffer. The 
primary antibody, biotinylated KJl-26, was diluted 1:250 in 1% blocking reagent (BR, from
■
TSATM Biotin system, Perkin Elmer Life Sciences, Boston, USA) and added to sections 
which were incubated for 40 minutes. Control sections were incubated with 1% blocking 
reagent (BR) only. Sections were washed three times in TNT buffer between the remainder 
of the steps. Streptavidin-horseradish peroxidise (HRP, from TSATM kit, Invitrogen Ltd)
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Streptavidin-AF647 (Molecular Probes) diluted 1:500 in BR was added to KJ1.26 stained
these cells within anatomical regions within the section [340]. A computer-controlled 
microscope stage allows the precise localisation and quantification of cells identified by their 
fluorescence following laser excitation. By setting a threshold intensity of KJl-26 staining, 
KJ1-26+ T cells can be identified and enumerated within a tissue section or within pre­
defined regions within the section.
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was diluted 1:100 in 1% BR and added to sections which were incubated for 30 minutes. 
Sections were then incubated in biotinylated tyramide diluted 1:50 in amplification diluent 
(both from TSATM kit) for 10 minutes. Sections were washed three times in TNT buffer.
I
sections for 30min, then sections were washed three times in TNT buffer. Anti-PCNA
■(Santa Cruz,UK) diluted 1:250 in BR (isotype rabbit-IgG, BD) was added to sections and IIincubated for 30 minutes, then sections were washed three times in TNT buffer. Then anti­
rabbit IgG-HRP (BD) diluted 1:500 in BR and B220-FITC (BD) diluted l:250was added to
-
slides and incubate for 30 minutes. Sections were washed three times in TNT buffer.
1Finally, the fluorochrome Pacific tyramide blue (Invitrogen Ltd) was added, diluted 1:100 in 
amplification buffer (from TSATM kit) was incubated for 30 minutes before being washed 
three times in TNT. The slides were left to dry briefly and mounted in Vectashield (Vector 
Laboratories) with a glass coverlsip and sealed with nailvarnish.
s
Sections were imaged using a Laser Scanning Cytometer equipped with Argon, Helium-
:Neon and Ultraviolet lasers (Compucyte, Cambridge, USA) and data analysed using the
-
WinCyte software (Improvision, Coventry, UK). Laser scanning cytometry combines the 
identification of fluorescently-labelled cells in tissue sections with the ability to quantify
1  fci
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2.22 Immunohistochemistry staining for KJl-26^ cells
Lung and LN sections were cut, mounted and fixed as for IF staining then stained as 
previously described [338]. Briefly, sections were rehydrated in PBS with 2% goat serum 
(GS) for 15 minutes before incubating for 30 minutes with biotinylated K Jl-26 (diluted 
1:500 in 2% GS or 2% GS alone for control sections). Sections were washed three times in 
PBS before addition of ABC-AP solution (all IHC reagents from Vector Laboratories unless 
otherwise stated) for 30 minutes. After washing, BCIP/NBT was added and sections 
incubated for 45 minutes or until blue staining was evident.
If staining for B220 was required, sections were washed in PBS before biotinylated anti- 
B220 antibody was added (1:400 in 2% GS, or just GS for control sections). Sections were 
washed in PBS after 30 minutes before addition of ABC-HRP and further incubation for 30 
minutes. DAB substrate was added for 10 minutes followed by DAB enhancing solution if 
brown staining was not evident. Slides were washed in water, then dehydrated by sequential 
washes in 75%, 95% and 100% ethanol followed by Histoclear (BS&S Ltd, Edinburgh, UK) 
before mounting with glass coverslips using Vectormount and sealing with nail varnish.
2.23 Enzyme-linked immunosorbent assay (ELISA)
2.23.1 Cytokine analysis
Immulon 4 HBX plates (ThermoShandon) were coated with capture antibody in ELISA 
coating buffer (details of antibodies in Table 2.2) and incubated overnight. Plates were
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washed with ELISA wash buffer before incubating in 200^il/weII ELISA blocking buffer for 
37°^ for I hour. After washing, standards at known concentrations and samples were added 
in duplicate and incubated for 1.5-2 hours. Samples were BAL supernatants, serum or 
culture supernatants; standards were diluted in a suitable medium to match the sample. The 
plates were washed again and detection (biotinylated) antibodies added and incubated for a 
further 1-1.5 hours. Streptavidin-HRP conjugate (Extravidin, Sigma) was then added after 
further washes and incubated for 30 minutes before washing and addition of TMB substrate 
(KPL, Gaithersburg, USA) for up to 30 minutes or until sufficient blue colour had 
developed. Optical density was then read on an MRX II microplate reader (Dynex 
Technologies, Worthing, UK) at 630nm or at 405nm if the reaction was stopped by addition 
of an equal volume of Stop solution (KPL). A standard curve was generated from the 
standard data allowing the calculation of cytokine concentrations in samples.
2.23.2 Multiplex analysis of cytokines
In some experiments, cytokines were analysed by multiplex analysis. This system uses 
biotinylated detection antibodies for the desired analytes conjugated to beads of defined 
spectral properties. These beads can be used in a solid phase sandwich immunoassay 
whereby analytes within a sample bind to the beads via the detection antibody. Addition of 
the streptavidin-conjugated fluorescent protein R-phycoerythrin (RPE) means that laser 
excitation of the beads within the detection instrument allows identification of analyte- 
specific beads with the fluorescence intensity of each bead being proportional to the amount 
of analyte in the sample. The advantage of this system is that several analytes can be
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analysed in a small volume of sample by using a combination of beads thus saving time and 
sample volume.
Biosource Multiplex kits LMC0002 (Thl/Th2 6-plex), LMC0003 (Inflammatory 4-plex), 
LMC0I31 (IL-13) and LMC0006 (Cytokine 20-plex) were used according to the 
manufacturer’s instructions. All reagents and buffers were sourced from the kits. Briefly, the 
supplied 96 well filter plate was pre-wetted with Working Wash solution before aspiration of 
well contents using vacuum apparatus. If more than one kit was being used, beads were 
premixed. Otherwise beads were resuspended and 25^1 bead mixture added per well and 
washed twice by the addition and aspiration of Working Wash solution from the wells. 
50pl/well Incubation Buffer was added followed by lOOpl/well standard or 50jil Assay 
Diluent plus 50fil sample. Plates were covered in aluminium foil and incubated on shaking 
apparatus at room temperature for 2 hours. The wells were then washed twice and 
lOOp-l/well biotinylated detection antibody added and incubated for I hour as above. 
Following two more washes, lOOp-l/well Steptavidin-RPE was added and incubated for 30 
minutes as above. The wells were washed three final times before resuspending the beads in 
IOO|il/well Working Wash solution and acquiring data on a Luminex lOOTM. Data was 
analysed using Luminex software and provided standard curves and sample data for each 
analyte.
2.23.3 Immunoglobulins
OVA-specific immunoglobulins were analysed from serum samples by first coating 
Immulon 4 HBX plates with IOp.g/ml OVA in OptEIA coating buffer and incubating 
overnight at 4°C. Plates were washed in ELISA wash buffer and incubated with ELISA
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blocking buffer for 1 hour at 37°^ before being washed again. Serum samples were diluted to
■
1:50 (IgE and IgG2a) or 1:500 (IgG l) or a suitable dilution determined by previous 
experiments and added to plates with serial dilutions down the plate. Test serum from naïve 
mice was included to allow comparison between plates. After incubation for 2 hours, plates
were washed and detection antibodies added (Table 2.2) and incubated for 1 hour. Plates
were washed again and streptavidin-HRP conjugate added and incubated for 30 minutes. For
OVA-specific IgE, streptavidin-HRP conjugate was added at the same time as the detection
antibody for a total incubation of 1.5 hours. After washing, TMB substrate was added for 30
minutes or until sufficient blue colour had developed. Optical densities were read on a 
,microplate reader at 630nm or 405nm if the reaction was stopped with Stop solution. 
Plotting OD against sample dilution created dilution curves for each sample allowing 
comparison between samples at an appropriate dilution.
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Analyte Supplier Capture(pg/ml) Detection(pg/ml)
Murine
IL-4 BD 2 2
IL-5 BD 4 4
IL-13 R&D 4 4
IFN-y BD 2 I
TNF BD (OptEIA kit) Kit Kit
IgE BD N/A 2
IgGl BD N/A 0.5
IgG2a BD N/A 0.5
Table 2.2: ELISA reagents
2.24 RNA Extraction
RNA extraction was carried out according to the Qiagen RNeasy Kit protocol. Briefly, cells 
stored at -80°^ in RLT buffer were thawed and the sample was homogenised by passing 
through a 25 gauge needle on a 1ml sterile (RNase free) syringe. 350pl 70% ethanol was 
added and pipetted to mix. Up to 700^1 sample was added to an RNeasy mini column with 
2mnl collection tube and centrifuged for 15 seconds at 8000g. The flowthrough is discarded. 
350jil buffer RWI is added to the column and centrifuged as before discarding the 
flowthrough. 80pl Dnase solution (lOpl Dnase, 70^1 RDD buffer) is added to the column 
and incubated for 15 minutes at room temperature. Then 350pl buffer RWI is added to the
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column and centrifuged as above, discarding the flowthrough and the collection tube. The
column is transferred to a new collection tube and 500|xl buffer RPE is added to the column 
and centrifuged as above discarding the flowthrough. Another 500pl buffer RPE is added to 
column and centrifuged for 2 minutes at 8000g then transferred to a new collection tube. 
The column is centrifuged at 8000g for 1 minute then transferred to a new collection tube. 
30pl RNase free water is added and centrifuged for 1 minute at 8000g, the step is repeated. 
The RNA levels were measured using a spectrophotometer then the sample is then stored at - 
20°C until needed.
2.25 Production of complementary DNA (cDNA)
cDNA synthesis was carried out according to Invitrogen Superscript III Reverse 
Transcriptase kit. Complementary DNA (cDNA) was produced from the total RNA sample 
by adding 2 p,g of RNA, I pi random primers, I pi dNTPS and the appropriate amount of 
Dnase/Rnase free water (Sigma) to give a final volume of I3pl to a Dnase/Rnase free thermo 
tube (Abgene, Surrey, UK). The resulting suspension was mixed and spun for 1 min at 
I2,000rpm on a bench top microfuge. The solution was then heated to 65°C for 5 minutes
■
then incubated on ice for at least 1 minute. Samples were centrifuged briefly, then the 
following was added: 4pl 5X First Strand Buffer, Ipl O.IM DTT, Ipl RNase OUT, and Ipl 
Superscript III RT. Samples were mixed by pipetting. The following cycle was used to 
make cDNA: 25*<2 for 5 minutes, 50°C for 60 minutes and 70°C for 5 minutes. The samples 
were then stored at -20°C until required.
2.26 Quantitative Real Time PCR
Quantitative real time PCR was carried out using a Statagene Mx™ machine and analysed 
using MxPro™ 3000 QPCR software. Primers for genes were designed using the following 
conditions: Tm: 58°C to 61°C, not bigger difference than 2°C in the primer pair, primer 
lengths of 19-24 base pairs, Guanine cytosine (GC) contents: 45-55%, PCR amplicon 
lengths: 100-200 base pairs. Reactions were set up containing 5pi cDNA, 5pM forward and 
reverse primers, lOpM probe (Invitrogen), master mix (Brilliant® SYBR® Green QPCR 
master mix), and H^ O make each reaction to 25pl. Solution was plated into 96 well plates. 
Plates were capped and centrifuged. The plate was then placed in the thermal block of the 
M x3000P®  system. The assay was run using the SYBR green module in the MxPro 
analysis software. The assay was run for 35 cycles then analysed accordingly.
2.27 Statistics
Results are expressed as mean ± standard error of the mean (SEM). To test significance 
Student’s unpaired t test was performed. A value of p < 0.05 was regarded as significant.
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2.28 Buffers
Buffer Constituents
Phosphate buffered saline 8g NaCl, 1.16g Na^HPG ,^ 0.2g KCl, 0.2g KH2PO4 in I litre
(PBS) distilled water, pH 74
FACS buffer 2% ECS, 0.05% sodium azide in PBS
ELISA Coating buffer O.IM NaHCOs pH 8.4
ELISA Wash buffer 0.05% Tween-20 in PBS pH 74
ELISA Blocking buffer 10% ECS in PBS
OptEIA Coating Buffer 8.4g NaHCOs, 3.56g N^COs in 1 litre distilled water, pH 9.4
TNT wash buffer 10ml 0. IM Trizma base, 10ml 0.15M NaCl, 50pl Tween-20, 
80ml distilled water
TNB buffer 5ml O.IM Trizma base, 5ml 0.15M NaCl, 
50pl Blocking Reagent (TSA^ "^  kit)
Binding buffer lOmM Hepes/NaOH, 140mM NaCl, 2.5mM CaCh, pH 7.4
Incomplete RPMI RPMI-1640 medium
Complete RPMI RPMI-1640 medium, 10% ECS, 2mM L-glutamine, 
lOOIU/ml penicillin, lOOpg/ml streptomycin
Table 2.3: Buffers
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C H A PT E R  3CHARACTERISATION OF M URINE
MODELS OF ALLERGIC AIRWAYS INFLAMMATION
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3.1 Introduction
The most commonly employed animal model of asthma is the murine allergic airways 
inflammation model [341]. In this model the mouse is sensitised by systemic vaccination 
with antigen, followed by an airways antigen challenge. This protocol induces inflammation 
with associated eosinophilia, IgE production and airways hyperresponsiveness. This model 
was set up to emulate the immunological sequelae of asthma, allowing the underlying 
immunological and physiological mechanisms to be studied, and potential therapeutic 
interventions and their outcomes investigated.
Over the years, many variations of the airways model have been established. However, no 
particular system has been established as standard. Therefore many different mouse strains 
and immunisation and challenge protocols have been used to study airways inflammation 
(reviewed in [342]). There is also a great deal of variation in the readouts employed as 
measurement of disease. These range from bronchoalveolar lavage cell measurements, 
cytokine and antibody production and controversial AHR readings [261-264]. Thus 
although animal models are regularly used, these factors should be considered when 
comparison between different studies are made. It is therefore important that researchers are 
consistent with their models and subsequent readouts.
The use of animal models has given a wealth of information about many mechanisms 
.involved in the inflammatory process of asthma including cytokines, chemokines, 
transcription factors and much more [343-347]. The D O ll.lO  system is well-established in 
studies of T cell interactions [339, 348] and has also been used in models of experimental
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asthma although in most cases the transgenic cells were used principally to investigate the 
different effects of transferring T hl or Tli2 cells rather than to examine compartment- 
specific contributions by these cells [194, 242, 349, 350]. Where Ag-specific T cells have 
been tracked into different tissues following transfer, some studies have identified but not 
enumerated the transgenic T cells [121]. The remainder of studies have almost exclusively 
used T cells which have been polarised and activated in vitro to either a T hl or Tli2 
phenotype before transfer [168, 195, 251, 351-354].
However, not as much attention has been given to when and where the interaction between 
these and other cells take place. This may be in part due to their low precursor frequency, 
making them hard to detect [355]. To comprehend how a disease works, it is important to 
know if antigen-specific T cells play a role in the disease, and therefore could be targeted as 
a therapy. Furthermore, an unanswered question is the location of activation and 
maintenance of naïve and memory T cells specific for the eliciting antigen. It is still 
unknown where antigen presentation takes place, whether it is in the draining lymph node or 
the lung itself. The use of antigen-specific T cells will enable us to gain a clearer 
understanding of these problems, and be able to design and target therapeutics specifically 
and rationally.
The use of the D O II.IO  system in this study enables us to track T cells of a known 
specificity in vivo in a model of airways inflammation. The aim of this model was to allow 
tracking of Ag-specific T cells as well as inducing airway eosinophilia in conjunction with 
IgE production and associated Th2 cytokines. Our investigations revealed that a single
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immunisation with OVA followed by 1-3 intranasal antigen airway challenges did not
I
induce BAL eosinophilia although identification of Ag-specific T cells was possible in the 
lymph nodes and the lung. However, it was found that a more aggressive regime of three 
immunisations and one airways challenge was required to induce lung eosinophilia and 
associated pathology. Manipulation of the single immunisation, single airway challenge 
model with the addition of LPS to antigen in the airways challenge resulted in lung 
eosinophilia and pathology as found in the three prime, one challenge model. It was found 
that when antigen-specific T cells were compared between the long and short models the 
expression of cytokines, co-stimulatory molecules and adhesion molecules examined 
differed between the two disease models, suggesting that although similar endpoints were 
observed the route by which the response was initiated differs.
modified to include three OVA airway challenges instead of one, to determine if this was
3.2 Results
To establish a robust murine model of airways inflammation in which lung eosinophilia and 
associated pathology were induced and antigen-specific T cells could be tracked, an adoptive 
transfer model was established and optimised. The aim was to induce a relatively low level 
of eosinophilia so as to allow future investigation of interventions that may exacerbate or 
ameliorate the inflammation. Initial experiments carried out using a single systemic prime 
with OVA/alum followed by a single OVA airway challenge (Figure 3.1 A). This protocol 
did not result in eosinophilia (Figure 3.1 B), although it was possible to identify antigen- 
specific T cells in the draining lymph nodes of the lungs (Figure 3.1 D). As the single prime 
of antigen and single challenge of antigen did not induce lung eosinophilia, the protocol was
-:i
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rigorous enough to induce a response. However, this more aggressive approach did not 
result in lung eosinophilia (Figure 3.1 C).
lungs were scored over 10 consecutive fields at x200 magnification. In order to be included,
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3.2,1 Assessment of lung inflammation
An important readout in the assessment of the airway model is the level of lung 
inflammation present. The assessment of BAL eosinophilia from cytospins is a useful 
readout but does not give a complete overview of the whole situation. It is important to see 
what is happening in an intact lung. For this reason a histological scoring system of lung 
sections, to be used in conjunction with other readouts, was developed.
Histological examination of lung sections for inflammation show that changes in pathology 
can be heterogeneous andthat some areas may show inflammation, whereas another area on 
the same section may show no changes. This can be seen in figure 3.2 where two views 
from the same slide tell a different story. Figure 3.2 A shows perivascular and 
peribronchiolar eosinophilic inflammatory infiltrates, and figure 3.2 B shows no 
inflammation. This is representative of human conditions, where it is rare that the whole 
lung is involved and inflammation is likely to be patchy.
I4.i
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Because of the differences seen in the same lung sections, an objective scoring system was 
needed to allow fair and reproducible scoring of sections. A system previously optimised by 
Professor Sarah Howie, (University of Edinburgh) was adopted to overcome this problem 
[356]. The scoring system is shown in Table 3.1. Briefly, H&E stained sections of whole
l |
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each field had to contain a complete transection of at least one bronchiole less than half a 
field width in diameter, a blood vessel and an alveolar airway. Inflammatory cell infiltrate, 
i.e. the number of immune cells present, was evaluated around the blood vessel walls 
(perivascular compartment), the bronchiolar epithelium and the peri-bronchiolar alveolar 
tissue. Inflammation was also scored on the basis of increased alveolar wall thickness. 
Figure 3.3 shows these criteria in an inflamed lung section.
Area scored ‘ 1 2 3 4
Perivascular compartment^ No infiltration < 20 cells 21-100 cells >100 cells
Bronchiolar epithelium No infiltration <5 cells 6-10 cells >10 cells
Peribronchiolar alveolar 
tissue^
No infiltration <20 cells 21-100 cells >100 cells
Alveolar walls'^ No infiltration 2-3 cells 4-5 cells > 5 cells
 ^Each field is viewed at x200 magnification and must contain a complete transaction of at 
least one bronchiole less than half the field in diameter, a blood vessel and an alveolar 
airway, in an area of well-inflated tissue.
 ^Cells around blood vessel walls
 ^ Sub-bronchiolar tissue: beneath the basement membrane and smooth muscle, not 
immediately adjacent to a blood vessel.
Focal expansion of alveolar wall by that number of cells.
Table 3.1: Lung inflammation scores
3.2.2 Increasing the number of OVA immunisations produces BAL eosinophilia
As increasing the number of airway challenges did not lead to BAL eosinophilia, a model 
was set up with three OVA/alura immunisations and one OVA airway challenge (Figure 3.4 
A). When BAL fluid was analysed for cell infiltrates it was found that this protocol induced 
significant BAL eosinophilia (Figure 3.4 B), which was accompanied by an increase in lung 
inflammation (Figure 3.4 C) compared to the control mice. The early peak of inflammation
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seen at day 1 post airways challenge in the lung sections compared to the sustained 
eosinophilia seen in the BAL fluid suggest that airway and lung inflammation may peak at 
different times. It may also be due to an influx of inflammatory cells such as neutrophils and 
macrophages in the lung section that have not been measured in the BAL fluid.
Antibody and cytokine production
Analysis of serum from the same mice showed that three immunisations and one airway 
challenge could induce an increase in OVA-specific IgE and IgGl (Figure 3.5 A and B). 
These results are consistent with data suggesting that IgE production is important in airways 
inflammation [217], and IgGl production confirming that the model has a Th2 phenotype. 
An increase in IL-5 levels was detected in the BAL fluid (Figure 3.5 C), consistent with data 
showing that IL-5 production is important in airways inflammation and drives eosinophil 
maturation and activation [149].
Detection of antigen specific T cells
Using flow cytometry, transgenic OVA-specific T cells were detected in the draining lymph 
nodes of the lung and in the BAL fluid (Figure 3.6 A and B). To examine the distribution 
and orientation of these cells in situ, laser scanning cytometry (LSC) was employed, using 
the KJI.26 mAb to analyse lung sections (described in chapter 2). Figure 3.6 C shows the 
detection of transgenic T cells in sections of lung tissue. There is no significant difference 
between the groups in the DLN, BAL or lung tissue. Figure 3.6 D shows a flow cytometry 
plot of %KJ1.26 cells in the DLN at day 3 post airways challenge.
;
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will be called the “long model” throughout this thesis, and the protocol using one OVA/alum 
immunisation and one airways challenge ten days later will be called the “short model”.
These experiments define a protocol that can be used to induce allergic airways
inflammation with eosinophilia as part of the outcome measure with the ability to track and 
quantify antigen-specific T cells within lymph nodes, lung and airways throughout this
process, employing LSC as a novel technique, for the first time in this model. The protocol ,
Ausing three OVA/alum immunisations, seven days apart followed by one airways challenge
The literature demonstrates that there are many variations on the murine airways
inflammation model, many using different protocols to reach similar endpoints. To 
investigate whether it was possible to manipulate the initial model of one OVA prime and 
one OVA airway challenge, which did not induce eosinophilia, LPS was added to the OVA 
challenge.
3.2.3 Effect of LPS addition to OVA airways challenge in the short model
The short adoptive transfer model (Figure 3.1 A) did not produce any BAL eosinophilia 
when one OVA immunisation and one airway challenge was administered. This is in 
contrast to the long model where one OVA challenge results in recruitment of eosinophils to 
the airway. Lung inflammation caused by LPS has been used as a model of acute lung 
injury, mirroring some features of acute respiratory distress syndrome in humans [357]. To 
determine if LPS would be enough to induce eosinophilia it was added to OVA and given as 
the airways challenge in the short model (Figure 3.7 A). Only days 0, 1 and 4 were analysed 
as endpoints in the short model, due to an increase in animal numbers per group limited the
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number of days possible to cull. When OVA plus LPS was introduced into this model as the 
airway challenge, instead of OVA alone, a significant BAL eosinophilia was induced by day 
4 after airways challenge (Figure 3.7 B) plus significant neutrophil influx at day one post 
airways challenge (Figure 3.7 C). Analysis of inflammation in lung histological sections 
also showed a trend towards increased inflammation in animals challenged with OVA plus 
LPS although this was not statistically significant (Figure 3.7 D).
Cytokine and antibody production
The addition of LPS to OVA in the airway challenge resulted in a significant increase in 
BAL IL-5 production compared with OVA alone (Figure 3.8 A), as seen previously in the 
long model. The level of IFNy was undetectable in both groups (Figure 3.8 B). The increase 
in IL-5 production with the addition of LPS to OVA in the airways challenge may help to 
induce more eosinophilia in the short model.
The levels of OVA-specific IgE and IgGl were measured in serum. No difference was seen 
between antibody levels when OVA and OVA+LPS were compared. (Figures 3.8 C and D).
LPS-induced BAL eosinophilia in the short model is associated with recruitment of 
antigen-specific T cells in the airway.
Antigen-specific T cells were measured in the DLN and BAL fluid by flow cytometry. No 
difference was observed between groups in the DLN (Figure 3.9 A). When compared with 
the OVA alone treated mice, a significant increase in T cells was seen in the BAL fluid in 
mice treated with OVA+LPS (Figure 3.9 B). This was supported by a similar increase in
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transgenic cells in lung sections analysed by LSC for OVA+LPS compared with OVA i 
(Figure 3.9 C), although this data was not significant.
Overall, these results suggest that the addition of LPS to a model that previously showed no 
airway inflammation or associated pathology has been switched to a model with pathology.
This is associated with an increase in IL-5 production and recruitment of antigen-specific T
The long and the short models produced differing results when OVA immunisation and
II
cells to the BAL. This recruitment of T cells also suggests a role for them in the effector 
phase of the response, after the initial sensitisation. The influence of LPS on airways 
inflammation will be studied in greater detail in chapter four.
I
3.2.4 Investigation into the differences between the two models
As shown above, two different models have been manipulated to produce similar end results.
IOVA airway challenge were administered. Only when OVA+LPS airway challenge was
given in the short model was eosinophilia and associated lung inflammation observed, 
although this was accompanied by a transient neutrophil influx not present in the long 
model. To investigate the differences between the two models, and to determine if we were 
looking at two different routes to the same end point, or different pathologies, an initial 
screening was carried out to assess co-stimulatory molecules, cytokines and chemokines 
(Figure 3.10). Antigen-specific T cells were purified from the draining lymph nodes and 
lung tissue and analysed by quantitative RT-PCR as described in chapter 2.
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IThe RT-PCR analysis showed that there were differences between the two models where 
pathology is present (i.e. long model: OVA immunisation with OVA airway challenge, and 
short model: OVA immunisation and OVA+LPS airway challenge) and where no pathology 
was seen (i.e. long model: OVA immunisation with PBS airway challenge, and short model: 1
OVA immunisation and OVA airway challenge).
Comparison of the two models when pathology was present showed that in the long model
Where no pathology was observed, it was found that in both the short model IFNy showed a 
slight increase in expression in both the lung and the DLN, and an increase was seen in the 
DLN in the long model. IFNy is known to decrease eosinophilia after antigen challenge, and 
inhibits Th2 cells and IgE release [344]. It may be possible that pathology in these models is 
unable to develop due to IFNy skewing the response towards a T hl phenotype. In the DLN 
of the long model the costimulatory molecules were upregulated in the PBS challenged 
group and slightly increased in the OVA treated mice.. This may be due to the three 
immunisations given in the long model compared to the one in the short model, although the 
PBS airway challenge was not sufficient to drive the T cells to produce a response.
i
the lung tissue shows that none of the factors examined are upregulated. In contrast, in the 
short model IL-13 together with all of the costimulatory molecules and chemokines were 
upregulated. When the DLN were analysed from the long model, it was found that IL-5 and 
CCR3 expression were upregulated, as were the costimulatory molecules ICOS, 0X40, and 
CD40L. However, when the antigen-specific T cells from the draining lymph nodes were 
analysed from the short model, nothing was upregulated.
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This suggests that although there are similarities in the end result (increased eosinophilia, 
lung inflammation and increased cytokine and antibody responses) the manner by which 
they were reached is different. Comparison of the two models where no pathology was 
observed shows that the presence of IFNy may be enough to inhibit the development of a 
Th2 response in both models, even though costimulatory molecules are upregulated in the 
DLN of the long model. When pathology has developed the response seen in the long and 
short models differs. In the long model the response is greater on the DLN compared to the
lung tissue, with increased Th2 cytokine IL-5 and CCR3 which have both been shown to be 
important in eosinophil development and activation. However, in the short model the 
response seems to be driven by both costimulatory molecules and chemokines and the Th2 
cytokine IL-13. In contrast to the long model the response is shown to be stronger in the S3
lung tissue compared to the DLN.
This initial screening of a limited number of factors potentially deemed important in the 
pathogenesis of asthma has given an interesting overview into the role of antigen-specific T 
cells in the disease. Although these results imply that the two models have different 
mechanisms that lead to a similar endpoint, this is only a snapshot 72 hours after airways 
challenge (where eosinophilia is at its peak) and may reflect a kinetic difference between the 
models. To obtain a more precise understanding of the role of Ag-specific T cells in the 
long and short model, it would be beneficial to carry out a timecourse across the duration of 
the disease. More rigorous controls are also needed to ensure comparisons between the two
models can be carried out accurately. Although antigen specific T cells are important to
'I
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track responses in this model of airways inflammation, it may also have been beneficial to 
analyse the lymph node as a whole as many other cells are involved in the response that will 
upregulate or express different receptors (e.g. dendritic cells), and this may give a clearer 
indication of what is driving the response.
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3.3 Discussion
The role of the Tli2 cell has been extensively studied in animal models of asthma. However, |
the importance of antigen-specific T cells and the locations of their cellular interactions are 
less well understood. To investigate this, an adoptive transfer model of allergic airways 
inflammation was devised where OVA-specific transgenic T cells (from the D O ll.lO  
mouse) could be identified by use of the K J1.26 monoclonal antibody. The DO 11.10 system 
is well-established in studies of T cell interactions [339, 348] and has also been used in t
models of experimental asthma although in most cases the transgenic cells were used 
principally to investigate the different effects of transferring Thl or Th2 cells rather than to i
examine compartment-specific contributions by these cells [194, 242, 349, 350]. Where Ag- 
specific T cells have been tracked into different tissues following transfer, some studies have 
identified but not quantified the transgenic T cells [121]. The remainder of studies have i
almost exclusively used T cells which have been polarised and activated in vitro to either a 
Thl or Th2 phenotype before transfer [168, 195, 251, 351-354]. Although this gives the
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advantage of a shorter in vivo protocol as the activated cells are able to respond to airways 
challenge without any requirement for further immunisation, the driving of cells in vitro with 
recombinant cytokines and neutralising antibodies prior to transfer is non-physiological.
I
&
The model established here differs in that the development of eosinophilic airways 
inflammation is combined with the transfer of naïve antigen (OVA)-specific T cells. This 
enables in vivo T cell responses to be analysed through the ability both to identify and 
quantify Ag-specific T cells in different anatomical locations (lymph nodes, lungs and BAL
f
i
fluid). To achieve adequate sensitisation to Ag, systemic immunisation with OVA was |
required using aluminium hydroxide as an adjuvant. The immunisation leads to expansion i
of endogenous OVA-specific cells as well as transgenic cells, facilitated by aluminium ;
hydroxide which also biases the development of T cells towards a Th2 phenotype [358]. J
Thus the transition from naïve to memory T cell with consequent maturation and activation i
takes place in vivo, rather than in vitro. The advantage of ‘polarising’ the T cells in this way 
is that the associated response to Ag by the animals’ endogenous immune cells means that 
the Tg T cells are more likely to be representative of the natural immune response, rather 
than causative as in the case of adoptive transfer of previously polarised cells. Thus we have 
established a novel model of allergic airways inflammation where the Ag-specific T cell 
response can be analysed in different cellular compartments.
Many established airways models use aerosol OVA to challenge animals. This method 
allows the dosing of several mice at one time, without the need for anaesthetic and multiple 
doses are safe. However, there are also disadvantages to this protocol. Specialised 
equipment is needed and although a measured dose of antigen is given to each chamber, 
there is no guarantee that each mouse will inhale an equal amount. As nébulisation is 
administered in the air, there is a chance that antigen may be present on the fur and ingested 
by mice during grooming, leading to induction of oral tolerance [336, 337]. The intranasal 
route was chosen in this study due to ease o f administration and through comparison of 
published studies o f airways inflammation.
■Analysis of BAL fluid content allows the evaluation of cell infiltrates in the airways. 
However, it is important to analyse lung inflammation in intact samples of lung. 
Histological analysis of the lungs showed that inflammation was variable over sections, with
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some areas displaying severe inflammation and other areas of the same lung showing no sign 
of inflammation. To overcome this problem, a previously established scoring system was 
adapted [356]. This scoring system allows objective analysis in a number of ways. Ten 
fields per section are scored limiting the impact of heterogeneity of pathology. 
Inflammation is scored in four separate cellular compartments (perivascular, peribronchiolar, 
bronchiole walls and alveolar walls) giving a more accurate assessment of the disease. Other
scoring systems used in lung inflammation models do not look at as many parameters, 
including only peribronchiolar and perivascular infiltrates in the score [359, 360].
iIThese parameters described above allow an objective score of lung pathology to be 
established. The histological score and differential cell counts from the BAL may be used 
together to give a clearer perspective of the inflammatory response. For example, if an 
inflammatory stimulus is not sufficient to induce BAL eosinophilia, it may have produced 
changes in cellular compartments, which should be detected in histological sections. This 
had been proven in clinical trials where IL-5 reduced BAL eosinophilia but had no effect on 
AHR [156]. However, in a subsequent study it was shown that although BAL eosinophilia 
was reduced, there was only a 50% reduction in eosinophilia in the airway wall [157],
highlighting the need to take both measurements into account.
The experiments in this chapter have shown that the adaptation of the well established OVA 
induced airways inflammation model [341] used by many groups to study airways 
inflammation resulted in pathology as previously shown. This model, consisting of three
OVA immunisation followed by an OVA airways challenge produces BAL eosinophilia.
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lung inflammation, increased OVA-specific IgE and IgG l, and increased IL-5 production. 
The response to antigen challenge in this model is similar to the response seen in humans, 
which consists of an IgE-mediated inflammatory cascade in the airways, characterised by the 
influx of Th2 lymphocytes and eosinophils and chronic pulmonary inflammation [361]. The 
pathology in the long model was associated with recruitment of antigen-specific T cells to 
the airways. Several studies have been published that show the importance of T cells in 
asthma, from their ability to migrate to the lung in response to antigen challenge, and their 
role in the development of eosinophils and lL-5 production [362-368].
As well as the long model, a shorter model was also developed consisting of one OVA 
immunisation followed by one airways challenge of OVA plus LPS. This model also 
resulted in BAL eosinophilia, lung pathology and increased BAL IL-5 production 
accompanied by increased antigen-specific T cell recruitment to the lungs. However, this 
model was not associated with an increase in IgE or IgGl antibody production. This data is 
supported by several studies showing that there are at least three pathways that lead to 
airways inflammation in murine models. One is dependent on IgE and MCs, one is 
dependent on eosinophils and IL-5 and the other is dependent on IL-13 (reviewed in [369]). 
The addition of LPS to the short model may contribute to the asthma like response as it has 
been shown that LPS administered at low doses in murine models of airways inflammation 
causes a Th2 type response [370].
The data presented in this chapter have shown that the antigen-specific T cells involved in 
the development of the two models of airways inflammation express different levels of
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cytokines, co-stimulatory molecules and adhesion molecules. The development of several 
models of airways inflammation based upon sensitisation by systemic administration of 
protein antigens such as OVA and subsequent inhalation challenge have gained widespread 
acceptance. In such models, concomitant development of both eosinophil dominated 
inflammation and AHR to cholinergic stimuli have been repeatedly demonstrated [154, 371- 
373]. Although there are many different models in use, it has not been determined why the 
different models give similar results. Many studies in murine models have shown that the 
expression of chemokine receptors on Th2 cells are important for the recruitment of these 
cells to the lungs and in initiating an immune response [236, 345-347, 374]. The role of 
costimulatory molecules and cytokines have also been studied in airways inflammation [344, 
375-378]. However, these factors have not been compared between the different studies.
The two models characterised in this chapter have shown as other studies that there are 
different routes to the same endpoint. This raised the question of whether we were looking 
at two different routes to the same endpoint or whether they had different pathologies. To 
address this question an initial screen of co-stimulatory molecules, cytokine and chemokine 
expression on antigen-specific T cells was carried out by quantitative RT-PCR to phenotype 
the two models.
It was found that when the two models were compared when no pathology was present that 
there was an increase in IFNy expression in the DLN and lung in the short model and in the 
DLN in the long model. IFNy is known to promote a Thl phenotype and has been shown to 
suppress the development of airways inflammation [195, 379, 380]. There was also an
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increase in costimulatory molecules in the long model, although this may be accounted for 
by the three immunisations given, which may stimulate the T cells, but the PBS airway 
challenge may not have been enough of a boost to activate the T cells to mount a response.
Comparison of the two models where pathology was induced showed that both the long and 
short model has increased expression of all costimulatory molecules examined (CD28, 
ICOS, 0X 40 and CD40L). When cytokines were analysed it was found that the long model 
had increased expression of IL-5, which correlates to the BAL IL-5 measured earlier in the 
model. IL-5 production has been shown to be important in the maturation and activation of 
eosinophils in airways inflammation [253, 381-383]. This is in contrast to the results seen in 
the long model when no pathology was present no IL-5 was expressed, suggesting that IL-5 
is important in the induction of airways inflammation. In the short model it was found that 
IL-5 was not needed to induce inflammation but that the expression of IL-13 was 
upregulated. Several studies have shown the importance of IL-13 inducing airways 
inflammation [144, 384-387], Again this is in contrast to the short model where no 
pathology was seen. These results also add to the hypothesis that there are several routes to 
the same endpoint and that many different factors are involved in the induction of airways 
inflammation. In both the long and the short models CCR3 is upregulated. This chemokine 
has been implicated in the accumulation of eosinophils in the airways of asthmatics and for 
the development of AHR [244, 245, 347, 388]. From these results it is clear that although 
the two models have similar outcomes there are major differences in the way in which the 
responses were mounted. These preliminary results emphasize the need for caution when 
comparing different studies from different groups, even if the end results seem comparable.
■i
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The experiments in this chapter have optimised and characterised robust models of murine 
airway inflammation. The use of adoptively transferred OVA-specific T cells allows the 
identification and quantification of antigen-specific cells in the lymph nodes, lungs and BAL 
over a timecourse. Using these models I aim to examine the effects of exogenous 
inflammation (LPS), an anti-inflammatory therapy (anti-TNF alpha) and to track cell 
divisions and interactions in cellular compartments over the course of the disease.
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Figure 3.1: Adoptive transfer model of allergic airways inflammation
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients by i.v. 
injection. Mice received lOOpg OVA and 1% alum by i.p. injection followed by 1 or 3 
intranasal challenges with 50pg OVA 10 days later or on days 10,11 and 12 (A). Control 
mice were immunised with PBS/alum and challenged with intranasal OVA. Mice were 
sacrificed at various timepoints. BAL preparations were sampled and analysed for eosinophil 
content from cytospins (B and C), Draining lymph nodes were stained with fluorescent 
antibodies against CD4 and the transgenic T cell receptor (mAb KJ1.26). Cells were
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analysed by flow cytometry to identify CD4 and KJ1.26 antigen specific T cells (D). Values
Iare represented as mean ± standard error of the mean (SEM), n= 3 per group, n= 2 repeats.
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Figure 3.2; Inflammation in lung sections.
Lung sections were taken for histological analysis and stained with H&E. Perivascular and 
peribronchiolar eosinophilic infiltrates were seen (black and white arrow respectively) in 
OVA challenged mice (A). Panel B shows a different view from the same lung section with 
no inflammation.
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Figure 3.3: Lung inflammation.
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients by i.v. 
injection. Mice were then immunised with lOOpg OVA/alum by i.p. injection 3 times, one 
week apart, followed by 1 intranasal challenge with 50pg OVA one week later. Mice were 
sacrificed at various timepoints thereafter. Lung sections were taken for histological 
analysis and stained with H&E. Figures show peribronchiolar (A), perivascular (B) and 
alveolar wall (C) inflammation. Longitudinal section of perivascular inflammation (D).
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Figure 3.4: 3 immunisations with OVA/alum and 1 airway challenge with OVA induces 
BAL eosinophilia and associated pathology
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients by i.v. 
injection. Mice were then immunised with lOOpg OVA/alum by i.p. injection 3 times, one 
week apart, followed by 1 intranasal challenge with 50^g OVA or PBS one week later (A). 
Mice were sacrificed at various timepoints thereafter. This resulted in a significant increase 
in eosinophilia (B) and lung pathology (C). Values are represented as mean ± SEM, n= 3 per 
groupn= 2 repeats (*p<0.05).
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Figure 3,5: Antibody and cytokine production
3x10*^  OVA-specific T cells were adoptively transferred into naïve Balb/c recipients by i.v. 
injection. Mice were then immunised with lOOpg OVA/alum by i.p. injection 3 times, one 
week apart, followed by 1 intranasal challenge with 50fig OVA or PBS one week later. 
Mice were sacrificed at various timepoints thereafter. This resulted in a significant increase 
in antigen-specific IgE (A), IgGl (B), and BAL IL-5 production (C). Values are represented 
as mean ± SEM, n= 3 per group, n= 2 repeats, (**p<0.01).
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Figure 3.6: Detection of antigen-specific T cells
3x10* OVA-specific T cells were adoptively transferred into naïve Balb/c recipients by i.v. 
injection. Mice were then immunised with lOOpg OVA/alum by i.p. injection 3 times, one 
week apart, followed by 1 intranasal challenge with 50pg OVA or PBS one week later. 
Mice were sacrificed at various timepoints thereafter. Antigen-specific T cells were 
analysed by flow cytometry in the DLN (A) and BAL (B). LSC was used to analyse OVA- 
specific T cell in lung sections (C). Flow cytometry plot shows raw data for %KJ1.26 in 
DLN at day 3 post airways challenge (D). Values are represented as mean ± SEM, n= 3 per 
group, n= 2 repeats.
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Figure 3.7: Addition of LPS to short airway inflammation model causes increased 
eosinophilia and neutrophilia
3x10* naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50p.g OVA 
alone or SOpg OVA plus 2.5pg LPS (A). Mice were sacrificed at various timepoints. This
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resulted in a significant increase in BAL eosinophilia (B) and neutrophilia (C). Lung 
sections were stained for H&E and scored for lung pathology (D). The solid black line 
represents the baseline pathology. Values are represented as mean ± SEM, n=5 per group, n= 
2 repeats (^'*p<0.01).
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Figure 3.8: Cytokine and antibody production
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with 100p,g OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50pig OVA 
alone or 50pg OVA plus 2.5pg LPS. Mice were sacrificed at various timepoints. This 
resulted in a significant increase in BAL IL5 production (A). IFNy was undetectable (B). 
Antigen-specific IgE (C) and IgGl (D) serum levels were measured. Values are represented 
as mean ± SEM, n=5 per group, n= 2 repeats (*x:p<0.01).
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Figure 3.9: Antigen-specific T cells in DLN, BAL and lung tissue
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOjig OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50pg OVA 
alone or 50p.g OVA plus 2.5p,g LPS. Mice were sacrificed at various timepoints. OVA- 
specific T cells were identified in DLN (A). A significant increase in antigen-specific T 
cells was seen in the BAL when challenged with OVA (B). Cells were identified by LSC 
analysis in lung sections (C). Values are represented as mean ± SEM, n=5 per group, n= 2 
repeats (*>Kp<0.01).
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Figure 3.10: Analysis of antigen-specific T cells from the long and short models.
Mice were treated as described in figures in figures 3.5 (long) and 3.6 (short) legends. 72 
hours after airways challenge lung tissues and draining lymph nodes were removed and T 
cells were removed by positive selection for CD4^ T cells and then negative selection for 
antigen specific T cells. RNA was then extracted form the samples and RT-PCR was used to 
quantify specific co-stimulatory molecules, cytokines and chemokines. The table 
summarises the results. (n=10 per group).
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CHAPTER 4 - MICROBIAL PRODUCTS AND THEIR 
EFFECT ON ALLERGIC AIRWAYS INFLAMMATION
137
4.1 Introduction
The relationship between asthma and infection has been known for decades [11]. However, 
details of the interactions and mechanisms involved in this association remain unclear. 
Although the role of viral infections in childhood asthma have been studied quite extensively 
[307, 312, 389], the effect of bacterial infections is poorly understood [390]. Many 
epidemiological studies have shown an inverse relationship between living in rural areas and 
the incidence of atopy and asthma [391-393]. This is thought to be due to the increased level 
of bacterial endotoxin, suggesting that increased exposure to bacterial infection can be 
protective against the development of asthma [391, 394-396]. In contrast, several studies 
have shown that levels of endotoxin in house dust correlate with severity of asthma [397- 
400]. Experimental administration of LPS to asthmatic and healthy subjects results in AHR 
and respiratory symptoms [401, 402], with an exaggerated effect seen in asthmatics [403,
404].
Host defence against microbial pathogens is elicited through the innate immune system by 
means of TLRs. It is reasonable to assume that the effect of infectious agents on the 
development of allergy is closely linked to the activation of TLRs by PAMPs [405]. This is 
supported by studies using MyD88 deficient mice, showing that lack of TLR signalling 
resulted in Th2 responses and increased IgE production [406]. Most epidemiologic studies 
of exposure to TLR ligands and their effects on atopic phenotype have looked at LPS 
(endotoxin). Early studies showed that house dust mite endotoxin levels were lower in 
homes of allergen-sensitised verses non-sensitised infants, showing that indoor endotoxin ' 
exposure in early life may protect against allergen sensitisation [3251. This was further
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supported by a study which identified livestock as a main source of endotoxin in homes and 
confirmed an inverse association between endotoxin exposure and atopy rates on farms 
[391].
The use of animal models to elucidate the mechanisms involved in these complex and 
contradictory studies has also proven inconclusive. The addition of LPS in murine models 
of allergic airways inflammation can result in either exacerbation or amelioration of 
pathology [332, 407, 408]. In animal studies it seems that the timing, route and dose of LPS 
administered are all able to affect the outcome of disease. However, several studies have 
consistently shown that LPS has a suppressive effect on asthma when administered at the
above that the underlying mechanisms of these effects are unclear and that more studies are 
needed to understand the complexities involved to be able to effectively treat airways 
inflammation.
time of antigen sensitisation [409, 410], In contrast, no conclusive results have been reached 
,when LPS is given after antigen sensitisation [407, 408]. It is clear from the studies outlined
I
'To examine the effect of LPS administration on allergen-induced airways inflammation, I
will use the adoptive transfer models described in chapter 3. The aim of this chapter is to 
examine and characterise the effects of exogenous inflammation, given locally or 
systemically, on airways inflammation. Our investigations show that LPS administered at 
the time of airways challenge can produce differing results depending on the route of 
administration. Given locally, LPS resulted in an increased antigen-driven eosinophilic 
inflammation in the airways, which was accompanied by increased antigen-specific T cell
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numbers in the airways. When given systemically, LPS was shown to reduce airways 
inflammation, although no effect on antigen-specific T cells in the airways was found. -1 ■ ■ i | i
There was also no affect on the memory response following subsequent antigen airways i
challenge, suggesting that LPS was affecting the inflammatory response and not the adaptive 
response. The results shown here were also mimicked using BLP, a TLR2 agonist, i 
demonstrating the effects are not TLR4 specific. These results emphasize the many 
underlying factors involved in the immune response, and give an insight into the role 
exogenous factors play in mediating the immune response.
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4.2 Results
4.2.1 Effect of addition of LPS to OVA airways challenge
In chapter 3 a model of allergic airways inflammation was established, in which adoptive 
transfer of Ag-specific T cells was followed by three immunisations, seven days apart and a 
single OVA airways challenge (Figure 3.4A). This model will be referred to as the “long 
model”. This model will be modified to include the addition of LPS to the airways challenge 
to determine the effects of local administration of microbial products (Figure 4.1 A). The 
LPS administered has been tested for impurities by SIGMA and was shown to contain less 
than five percent protein impurity. The airways challenge includes either OVA alone, LPS 
alone or a combination of OVA plus LPS. As expected OVA alone gave significant 
eosinophilia, with OVA plus LPS showing similar results. LPS alone was not sufficient to 
induce BAL eosinophilia (Figure 4 .IB). When neutrophilia was assessed in the BAL, OVA 
alone did not induce neutrophilia. In contrast, the OVA plus LPS and the LPS alone 
treatments resulted in significantly higher levels of neutrophils compared with the OVA 
alone group (Figure 4.1C). These results suggests that the presence of antigen in the airway 
challenge is important in the induction of eosinophilia in this model, even though the mouse 
has been primed. When lung inflammation in histology sections was analysed, all three 
treatment groups induced inflammation higher than the baseline. OVA alone showed a 
constant level of inflammation throughout the timecourse. OVA+ LPS showed the highest 
level of inflammation, peaking at day three post airways challenge. LPS showed an early 
peak at day one post airway challenge, steadily declining over the timecourse (Figure 4 .ID).
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4,2.2 Cytokine and antibody production
IL-5 and IFNy were measured to determine if the ability of LPS to exacerbate allergic airway 
inflammation was due to its capacity to affect cytokine production. BAL fluid was analysed 
by ELISA. OVA alone and OVA+LPS caused a significant increase in IL-5 production 
compared to LPS alone, however, the addition of LPS to Ova airways challenge decreased 
IL-5 compared to OVA alone(Figure 4.2 A). IFNy could not be detected (Figure 4.2 B).
The production of OVA-specific antibodies was also assessed. Serum levels of Th2- 
associated OVA-specific antibodies IgE and IgGl were not increased by the addition of LPS 
to OVA challenge (Figure 4.3 A and B respectively). However, the Th2 associated 
antibodies are not increased when LPS is added to OVA, suggesting that these mechanisms 
may not be involved in the increase in eosinophilia. It may be possible that antibody 
production is already maximal with OVA challenge alone and that the addition of LPS does 
not increase this.
4.2.3 OVA plus LPS enhances recruitment of antigen-specific T cells to the airway but not to the DLN
The recruitment of antigen-specific T cells to the DLN and BAL and was examined by flow 
cytometry. There was no difference in number of transgenic T cells in the DLN when all 
three treatment groups were compared (Figure 4.4 A). However, the numbers of transgenic 
T cells in the BAL fluid were found to be increased when OVA alone or OVA+LPS was 
given compared with LPS alone (Figure 4.4 B). Although the numbers are not significant, a 
similar trend was seen in further experiments. Furthermore, LSC analysis of lung sections
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showed a significant increase in T cell numbers in OVA and OVA+LPS treated mice 
compared with the LPS alone treatment (Figure 4.4 C). This suggests that antigen-specific T 
cells may play a prominent role in the airways in the development of lung eosinophilia.
4.2.4 OVA plus LPS can induce airways eosinophilia in the short model
Initially, when the short model was carried out with one OVA/alum immunisation and a 
single intranasal OVA challenge (as described in chapter 3, Figure 3.5 A) this was 
insufficient to induce eosinophilia. As the addition of LPS increased airway eosinophilia in 
the long model, it was hypothesised that the addition of LPS to OVA airways challenge 
would be able to induce eosinophilia in the short model (Figure 4.5 A). As previously seen 
OVA alone did not induce eosinophilia in this short model. However, the addition of 
OVA+LPS led to a significant increase in BAL eosinophilia, seen at day four post airway 
challenge (Figure 4.5 B). This was accompanied by a significant increase in BAL 
neutrophilia seen at day one post airway challenge, not seen in the OVA alone group (Figure
4.5 C). Analysis of lung inflammation in histological sections showed a trend towards an 
increase in inflammation when OVA+LPS was given compared with OVA alone, although 
this was not significant (Figure 4.5 D).
4.2.5 Effect of LPS on cytokine and antibody production
The addition of LPS to OVA in the airway challenge resulted in a significant increase in 
BAL IL-5 production compared with OVA alone (Figure 4.6 A), as seen previously in the 
long model. The level of IFNy was undetectable in both groups (Figure 4.6 B). The increase
I
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in IL-5 production with the addition of LPS to OVA in the airways challenge may help to 
induce more eosinophilia in the short model.
1
The levels of OVA-specific IgE and IgGl were measured in serum. No difference was seen 
between antibody levels when OVA and OVA+LPS were compared. (Figures 4.6 C and D). 
These results suggest that the levels of Th2-associated antibodies are not responsible for the 
levels of eosinophilia in the airways in this model.
4.2.6 LPS-induced BAL eosinophilia in the short model is associated with 
recruitment of antigen-specific T cells in the airway
Antigen-specific T cells were measured in the DLN and BAL fluid by flow cytometry. No 
difference was observed between groups in the DLN (Figure 4.7 A). When compared with 
the OVA alone treated mice, a significant increase in T cells was seen in the BAL fluid in
:mice treated with OVA+LPS (Figure 4.7 B). This was supported by a similar increase in 
transgenic T cells in lung sections analysed by LSC for OVA+LPS compared with OVA
(Figure 4.7 C), although this data was not significant.
Overall, these results suggest that the addition of LPS to a model that previously showed no
airway inflammation or associated pathology has been switched to a model with pathology. 
. .This is associated with an increase in IL-5 production and recruitment of antigen-specific T 
cells to the BAL. This recruitment of T cells also suggests a role for them in the effector 
phase of the response, after the initial sensitisation.
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4.2.7 Pam3CSK4 (BLP) enhances eosinophilia airways inflammation when 
administered locally with antigen
To determine if the effects seen with LPS were limited to the TLR4 pathway, the 
experiments were repeated using BLP, a TLR2 ligand. When BLP was added to OVA in the 
airway challenge in the short model, a significant increase in BAL eosinophilia was seen 
(Figure 4.8 A) compared with OVA alone. This was accompanied by a significant BAL 
neutrophilia in the OVA plus BLP treated mice compared with OVA alone (Figure 4.8 B), as 
seen with the addition of LPS. As with LPS, BLP did not cause a change in recruitment of 
antigen-specific T cells to the DLN between the two groups (Figure 4.8 C). However, a 
significant increase in transgenic T cell was seen in the BAL when BLP was added to OVA
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(Figure 4.8 D). This is consistent with the results shown with the addition of LPS. These 
results show that it is possible to enhance airway inflammation by recruitment of T cells to 
the airways by a variety of PAMP-dependant pathways.
4.2.8 Effect of systemic LPS and BLP on airway eosinophilia
It has been shown in many studies that the route of administration of microbial products can
affect the disease outcome in murine models [332, 407, 408, 410]. To determine whether the
route of administration of LPS or BLP had any effect on the outcome of the adoptive transfer 
.model of airway inflammation, they were introduced systemically into the long model 
(Figure 4.9 A), two hours after airways challenge. As shown by other groups [411] BAL 
eosinophilia was significantly reduced by both LPS and BLP (Figure 4.9 B).
4.2.9 Systemic effect of LPS and BLP is transient
These results suggest the effects of LPS and BLP may be due to a direct effect on the 
effector mechanisms of inflammation, rather than on the underlying immune response, due 
to the effects being seen after the airway challenge and also very rapid. If the effect is truly 
transient, then it should not affect immunological memory. However, it may be the case that 
LPS and BLP are acting as adjuvants to enhance the response to OVA exposure.
To elucidate how LPS and BLP are working, mice were exposed to the regime described 
earlier (Figure 4.9 A) with an initial OVA airway challenge followed by systemic LPS or 
BLP two hours later. The mice were then left to rest for two weeks before being given a 
second OVA airway challenge (Figure 4.10 A). The inflammatory response to the second 
challenge was then measured. Although LPS and BLP suppressed the BAL eosinophilia 
after the initial airway challenge (as previously seen), there was no difference between the 
groups after the second airway challenge (Figure 4.10 B). This shows that the suppressive 
effects of LPS and BLP are transient but also that they do not have any adjuvant effects. 
There was no difference in recruitment of antigen-specific T cells to the DLN or the BAL 
(Figure 4.10 C and D) or in antigen-specific IgE production (data not shown) between the 
different treatment groups, suggesting that there was no additional priming by the LPS or 
BLP injections. These results show that the effect of LPS and BLP is transient and may 
work directly on the local inflammatory response. The effects of LPS and BLP are also not 
due a change in T cell trafficking. However, it has not been shown that these agents lead to 
increased immunological sensitisation to airway antigens.
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4.2.10 Cells are not sequestered to the peritoneal cavity after i.p. injection
Another possible explanation for the reduction in eosinophilia seen after i.p. injection of LPS 
or BLP, is that the injection causes an acute inflammatory reaction in the abdomen with 
consequent accumulation of inflammatory cells in that location, in turn reducing the cell 
number in the other location (i.e. airways). To examine this possibility, the cellular 
compartment of the peritoneal cavity was examined in the long model at various timepoints 
after the i.p. injection of LPS or BLP. Figure 4.11 A shows that there was no significant 
increase in total cell number in LPS or BLP treated mice compared to the control group. 
The eosinophil numbers were unaffected between the groups (Figure 4.11 B). The 
neutrophil number is increased in the LPS and BLP number (Figure 4.11 C), but decreased 
in the macrophages and lymphocytes (Figure 4.11 D and E). These results show that LPS 
and BLP cause an acute inflammatory response in the abdomen characterised by a neutrophil 
influx. However, this is not accompanied by enhanced recruitment of other inflammatory 
cells, in particular eosinophils. Thus the reduction in BAL eosinophils is not directly due to 
their sequestration to the peritoneal cavity.
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4.3 Discussion
The first part of this chapter focused on the local administration of the TLR agonists LPS 
and BLP in conjunction with OVA airways challenge in previously sensitised mice. It was 
found that administration of the microbial products in addition to OVA in the airway 
exacerbated eosinophilic inflammation in the long model and induced it in the short model. 
This suggests that microbial products may play a role in regulating the severity of existing 
allergic airways inflammation, or that they could promote a switch to an eosinophilic 
response in previously non-allergic lung.
To try and elucidate the mechanisms involved in these responses, a series of experiments 
were carried out to determine if the microbial products were having a direct effect on the 
inflammatory pathway, or if they were altering the adaptive immune response. When LPS 
or BLP is added to the OVA airway challenge there is a significant increase in BAL 
eosinophilia. This is accompanied by a marked increase in BAL neutrophilia. These results 
are consistent with many human studies, who have shown an increase in neutrophil influx 
and AHR after inhalation of endotoxin in both normal [399, 402, 412] and asthmatic [413] 
subjects. The neutrophil influx was found not to be related to a change in lung function 
[402, 414]. This is consistent with the results in the long model, showing that although 
OVA airways challenge does not induce a neutrophil influx, lung inflammation is still 
observed, suggesting that neutrophils may not be necessary for lung pathology. However, 
many studies have shown that neutrophils are associated with clinical forms of asthma [415-
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I418]. The increase in eosinophils seen with addition of LPS to OVA airways challenge is 
comparable to both human and murine studies. When atopic, but not normal, patients were
challenged with LPS an increase in eosinophils was observed in lavage fluid [419], In mice 
previously sensitised to allergen, low doses of LPS resulted in exacerbation of eosinophilia 
[420].
As well as the increase in BAL cell content, other mediators were also measured in response 
to addition of LPS to the airways challenge. The production of cytokines in the BAL 
showed there was an increase in IL-5 production with addition of LPS to OVA, which was 
not present with LPS alone. IFNy was not detectable in any group. Several mechanisms 
have been proposed to explain LPS induction of eosinophilia and proinflammatory 
cytokines. DCs are well recognized to play a central role in inflammatory reactions elicited 
by LPS [421]. When DCs are activated by LPS through TLR4, they become mature and 
acquire an increased ability to prime T cells [422]. A study by Eisenbarth et aL, reported 
that low level inhaled LPS signaling through TLR4 is necessary to induce Th2 responses to 
inhaled antigens in a mouse model of allergic sensitization. The mechanism by which LPS 
signaling results in Th2 sensitization was shown to involve the activation of antigen- 
containing dendritic cells [407]. However, a recent study proposed that LPS-induced MCs 
activation and modulation with increased production of Th2 cytokines, such as IL-5 and IL- 
13, appear to control the severity of eosinophilic airway inflammation [423]. It is known 
that IL-5 and IL-I3 play a crucial role in the induction and the severity of eosinophilic 
infiltrate in airway inflammation in the lung [362]. IL-5 is a key factor for eosinophilia and 
could be responsible for some tissue damage in chronic asthma [424]. The data presented 
here suggests that the addition of LPS to an OVA airways challenge results in the 
exacerbation of eosinophilia..
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It is possible that LPS and BLP may alter the underlying adaptive immune response, via 
different pathways including influence on B cells and IgE production, or by altering T cell 
number or function. An increase in IgE level could lead to an exaggerated response to 
antigen through enhanced cross-linking of IgE receptors on effector cells such as mast cells 
with consequent degranulation and release of inflammatory and bronchospasmogenic 
mediators. IgE has been shown to be important in humans [216, 217, 220-222, 425] and 
animal airways disease [426, 427], however, it may not be critical [224]. Serum levels of
OVA-specific IgE were found to be no different between animals that received LPS or BLP
:with OVA and those that received OVA alone. The same was also true of IgGl and IgG2a 
levels arguing against a shift towards a Thl-type phenotype.
The role of Ag-specific CD4^ T helper cells in this model was explored using the DOII.IO  
transgenic OVA-specific T cell system. The commonly accepted idea of antigen 
presentation in airways inflammation is that antigen is presented to T cell in the draining 
lymph node, which then leads to increased production of Th2 cytokines and inflammation.
But recent studies have shown that there is a population of memory T cells resident in the 
local tissue that are reactivated upon antigen re-stimulation [428-430], most likely by DCs 
[233]. However, antigen presentation in the airways has not been proven. The findings 
reported here concur with these studies. Although the proportion of Ag-specific T cells was 
increased in DLN after airway challenge, there was no difference in the increase between 
animals challenged with OVA plus LPS/BLP and those challenged with OVA alone. 
However, the number of Tg T cells was seen to increase in the BAL fluid when LPS/BLP
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was included in the airway challenge, in both the long and short model. This strongly 
supports a role for T cells in the airways during the effector phase of the response.
These experiments have shown that LPS and BLP given in conjunction with OVA in an 
airways challenge, in previously sensitised mice, leads to an exaggerated airway response, 
predominantly eosinophilic. The underlying mechanism behind this response is still not 
fully understood, although it may be mediated by T cell number in the airways, but not the 
DLN.
The second part of the chapter focuses on the administration of TLR ligands by systemic 
injection at the time of airway challenge. Previous work has shown that the TLR2 agonist, 
BLP, has a suppressive effect on a model of allergic airways inflammation [411]. Work 
presented in this chapter shows that these effects can be mirrored in the long adoptive 
transfer model and is also reproducible using LPS. The work done using the model with 
BLP suggested that BLP may act by skewing the immune response towards a T hl 
phenotype, causing a reduction in Th2 inflammation. However, T hl responses do not 
always reduce or counteract allergic inflammatory responses [164, 167, 431].
In contrast to the results seen when LPS or BLP were administered locally at the time of
challenge, systemic administration of LPS or BLP at the time of challenge resulted in 
amelioration of BAL eosinophilia compared with OVA alone. This data correlates to other 
studies which have also shown a decease in airways inflammation with systemic endotoxin 
treatment in murine models [408, 420, 432, 433]. When other parameters were analysed it
I
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was found that systemic LPS or BLP did not affect the numbers of antigen-specific T cells in 
the DLN or in the BAL. There were also no differences between cytokine or antibody 
production when compared to the control groups, implying that there was not a shift from a 
Th2 phenotype to a T hl phenotype. If the suppressive effect of the TLR agonists were 
acting through the adaptive response, it may be expected that the effect may also be seen in 
the memory response to antigen re-exposure. However, when mice were re-challenged with 
OVA fourteen days after the first airway challenge there was no change in the eosinophil 
response (speed or extent) in mice previously challenged systemically with LPS or BLP. 
Therefore, this data suggests that these agonists do not act via an effect on adaptive 
immunity.
Further experiments carried out were aimed at determining whether systemic injection was 
causing inflammatory cells to be sequestered into the peritoneum. Peritoneal lavage was 
carried out and cell contents compared to the BAL fluid. Both LPS and BAL caused an 
influx of neutrophils into the peritoneum, but there was no effect on eosinophil numbers and 
macrophage and lymphocyte numbers were reduced. Therefore, it seems improbable that 
inflammatory cells are being recruited into the peritoneum instead of the airways.
The experiments in this chapter have looked at the effect of TLR agonists, LPS and BLP, 
administered locally and systemically at the time of airways challenge. In these protocols
model of disease, as most patients will already have been sensitised when they seek
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the mice have already been sensitised to the allergen, which may represent a more clinical
- 
.treatment. This approach differs from many other studies that have looked at TLR
-SIi
administration at the time of sensitisation [401, 407-409, 433-435]. The results presented in 
this chapter suggest that exposure to microbial products lead to the worsening of airways 
inflammation in a murine model of allergic airways inflammation. This is supportive of 
studies done in humans [436-440], which showed that inhalation of LPS by allergic 
asthmatics induced airways inflammation, including increased eosinophilia in the airways. 
The experiments in this chapter imply that this may be due to an accumulation of antigen- 
specific T cells in the airways, which may affect the underlying adaptive immune response. 
This may also lead to increased sensitisation to other allergens, as Th2 cells have been 
shown to facilitate priming of naive T cells to unrelated antigen through IL-4 secretion 
[441]. This has been seen in atopic patients that accumulate allergens over time [442,443].
Systemic treatment at the time of allergen challenge was shown to reduce subsequent 
inflammation, which means that there is a possibility that there may be therapeutic benefits 
of these agents. The ability to reduce inflammation is important but a problem with these 
agents is that LPS may act as an adjuvant on antigen re-exposure. However, my results 
imply that this is not the case, although the effects of LPS and BLP in reducing inflammation 
after a subsequent antigen challenge were diminished. The transient effects of systemic LPS 
and BLP therefore may not be of great therapeutic benefit, although understanding the 
underlying mechanisms may allow the development of ways to prolong their effects.
When compared to other studies, when LPS is given locally during antigen challenge, my 
results are in concurrence, showing exacerbation of airways inflammation [332, 407, 433]. 
However, there are also conflicting studies showing amelioration of the inflammatory
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response [410, 433, 444, 445]. The use of systemic LPS to suppress the allergic response 
agrees with the data presented in this thesis [432, 444]. When LPS has been administered 
during sensitisation either locally or systemically most studies have shown a reduction in 
airways inflammation [423, 432, 446, 447]. In spite of this, caution must be taken when 
comparing these studies as different routes of administration, doses, timing and species have 
been used throughout the publications.
s
Overall, these results have shown that LPS administered at the time of antigen challenge can
produce differing results depending on the route of administration. When LPS was given
locally it resulted in an increased antigen-driven eosinophilic inflammation in the airways,
accompanied by an increase in antigen-specific T cell numbers in the airways. This implies
a role for T cells in the effector phase of the immune response, showing that LPS can
modulate the adaptive immune response. When given systemically, LPS reduced airways
inflammation, although there was no change in T cell numbers in the DLN or the airways.
There was also no affect on the memory response following subsequent antigen challenge,
suggesting that the effect is on the inflammatory response. The results have also been shown
using BLP, a TLR2 agonist, demonstrating that the effects are not TLR4 specific. These
results highlight the many underlying factors involved in the immune response and help our 
.understanding of how exogenous inflammatory mediators can affect airways inflammation.
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Figure 4.1: Adoptive transfer model of allergic airways inflammation with addition of 
LPS.
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OV A/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days
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later with either 50|ig OVA alone, 50pg OVA plus 2.5pg LPS, or 2.5[ig LPS alone (A).
Mice were sacrificed at various timepoints. BAL preparations were sampled and analysed
,for eosinophil (B) and neutrophil (C) content from cytospins. Lung sections were stained for i 
H&E and analysed for lung pathology (D). Baseline pathology represented by solid black 
line. Values are represented as mean ± SEM, n=5 per group, n= 2 repeats (*p<0.05).
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Figure 4.2: Cytokine production
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with 100|xg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with either 50pg OVA alone,50p,g OVA plus 2.5[ig LPS, or 2.5|xg LPS alone. Mice 
were sacrificed at various timepoints. BAL supernatants were analysed for 1L5 (A) and 
IFNy (B). Values are represented as mean ± SEM, n=5 per group, n= 2 repeats (=i'p<0.05).
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Figure 4.3: Antibody production
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with either 50pg OVA alone,50pg OVA plus 2.5pg LPS, or 2.5pg LPS alone. Mice 
were sacrificed at various timepoints. Serum was analysed for IgE (A) and IgGl (B). Values 
are represented as mean ± SEM, n=5 per group, n= 2 repeats.
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Figure 4.4: Identification of antigen-specific T cells in DLN, BAL and lung tissue
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with 100|Lig OVA/alum 1%, 
by i.p. injection,three times, 7 days apart, followed by one intranasal challenge 7 days later 
with either 50p,g OVA alone,50^g OVA plus 2.5|ig LPS, or 2.5|ig LPS alone. Mice were 
sacrificed at various timepoints. Antigen-specific T cells were identified in the DLN (A) and 
BAL fluid (B) by flow cytometry. Lung sections were stained for antigen-specific T cells 
and analysed by LSC (C). Values are represented as mean ± SEM, n=5 per group, n= 2 
repeats.
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Figure 4.5: Addition of LPS to short airway inflammation model causes increased 
eosinophilia and neutrophilia
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOjig OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50pg OVA
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alone or 50|ig OVA plus 2.5p.g LPS (A). Mice were sacrificed at various timepoints. This 
resulted in a significant increase in BAL eosinophilia (B) and neutrophilia (C). Lung 
sections were stained for H&E and scored for lung pathology (D). The solid black line 
represents the baseline pathology. Values are represented as mean ± SEM, n=5 per group, n= 
2 repeats (**p<0.01).
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Figure 4.6: Cytokine and antibody production
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50p,g OVA 
alone or 50pg OVA plus 2.5pg LPS. Mice were sacrificed at various timepoints. This 
resulted in a significant increase in BAL IL5 production (A). IFNy was undetectable (B). 
Antigen-specific IgE (C) and IgGl (D) serum levels were measured. Values are represented 
as mean ± SEM, n=5 per group (**p<0.01).
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Figure 4.7: Antigen-specific T cells in DLN, BAL and lung tissue
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with 100p,g OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50p,g OVA 
alone or 50|ig OVA plus 2.5\xg LPS. Mice were sacrificed at various timepoints. OVA- 
specific T cells were identified in DLN (A). A significant increase in antigen-specific T 
cells was seen in the BAL when challenged with OVA (B). Cells were identified by LSC 
analysis in lung sections (C). Values are represented as mean ± SEM, n=5 per group, n= 2 
repeats (H«*p<0.01).
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Figure 4.8: Short adoptive transfer model with addition of BLP causes BAL 
eosinophilia and neutrophilia
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOfxg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with either 50pg OVA 
alone or 50p,g OVA plus 2.5jig BLP. Mice were sacrificed at various timepoints. This 
resulted in a significant increase in BAL eosinophilia (A) and neutrophilia (B). Antigen 
specific T cells were identified in DLN (C) and BAL (D) by flow cytometry. Values are 
represented as mean ± SEM, n=5 per group, n= 2 repeats (*:i:p<0.01).
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Figure 4.9; Short adoptive transfer model with systemic LPS or BLP re-challenge BAL
suppresses BAL eosinophilia
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOfxg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with 50pg OVA. Mice 
were then challenged with LPS or BLP by i.p. injection two hours later (A). Mice were 
sacrificed at various timepoints. Re-challenge with LPS or BLP resulted in significant 
suppression of BAL eosinophilia (B). Values are represented as mean ± SEM, n=5 per 
group, n= 2 repeats (**p<0.01).
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Figure 4.10: Effect of systemic LPS or BLP on antigen-rechallenge
3x10*^  naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge seven 
days later with SOjxg OVA. Mice were then challenged with LPS or BLP by i.p. injection 
two hours later. Fourteen days later mice received an intranasal challenge with 50pg OVA 
(A). Mice were sacrificed at various timepoints. BAL samples were analysed for
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eosinophilia (B). Antigen-specific T cells wee identified in DLN (C) and BAL fluid (D). 
Values are represented as mean ± SEM, n=5 per group, n= 1 repeat (*M;p<Q.01).
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Figure 4.11: Effect of systemic LPS or BLP on peritoneal washes
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge seven
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days later with 50p.g OVA. Mice were then challenged with LPS or BLP by i.p. injection 
two hours later. Fourteen days later mice received an intranasal challenge with 50p.g OVA 
(A). After sacrifice, peritoneal lavage was performed on each mouse and the cell content 
analysed by cytospin preparation. Graphs show: total cells (A), eosinophils (B), neutrophils 
(C), macrophages (D) and lymphocytes (E). Values are represented as mean ± SEM, n=5 per 
group, n= 1 repeat (*p<0.05).
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CHAPTER 5 EFFECT OF TNFa BLOCKADE ON 
AIRWAYS INFLAMMATION
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5.1 Introduction
Anti-TNFa therapy was the first of a new class of drugs called biologic therapies, mostly 
monoclonal antibodies and soluble receptors, which were designed to target specifically 
critical points in pathways, with the aim of producing potent but precise effects on disease 
pathophysiology. TN Fa blockade was initially directed against the synovial inflammation 
seen in rheumatoid arthritis [448] but has found a role in several other rheumatic diseases as 
well as inflammatory conditions such as inflammatory bowel disease and psoriasis [449,
450]. Despite much research into the immunological mechanisms underlying asthma, 
relatively few biologic therapies have been investigated in asthma: notably, anti-IL-5 and 
anti-CD4 agents have not shown great benefit in clinical trials [141, 142, 156, 157] and anti- 
IgE mAb is only now beginning to enter clinical practice as an adjunct to standard treatment 
in patients with atopic asthma and evidence of sensitisation to perennial allergens [220, 221,
451].
T N F a  is a potent pro-inflammatory cytokine with immunoregulatory activities, and is 
produced by many cell types including monocytes, macrophages, lymphocytes, neutrophils, 
eosinophils, and mast cells [283, 290, 452]. In the lung, TN Fa is synthesised and stored 
mainly in mast cells and alveolar macrophages [300]. It functions as a chemoattractant for 
neutrophils and monocytes, increases microvascular permeability, and activates T cells, 
eosinophils, and mast cells. Furthermore, there is increased expression of TNFa in the 
airway of asthmatic patients compared to normal subjects [300, 301]. Mast cells are unique 
in being the only tissue-resident cells with granules containing preformed T N F a  and 
consequently during the early stages of inflammation or infection they may be the sole
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source of this cytokine [302]. TN Fa is able to stimulate the production of IL-8, regulated on 
activation normal T expressed and secreted (RANTES) and granulocyte macrophage colony 
stimulating factor (GM-CSF) by airway epithelial cells, which increases the expression of 
vascular adhesion molecules such as intercellular cell adhesion molecule l(ICA M -l) and 
vascular adhesion molecule 1 (VCAM-1), which are involved in the recruitment of 
inflammatory cells to the airways [303]. TN Fa is also thought to be involved in airway 
remodelling through its effects on fibroblasts and by inducing eosinophils to release matrix '
metalloproteinase 9 [304]. Furthermore, experimental administration of TNF to the airways t
can induce AHR [453,454].
Data such as these have been sufficient to initiate a number of small trials of anti-TNF 
therapy in human asthmatics. Of these, one has shown no benefit [455], whereas two more 
recent trials, both looking at severe asthmatics, show that there is some improvement in lung 
function with treatment [277]. However, these have been small studies and large-scale
 :
double-blind randomised control trials are awaited.
1:1
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However, despite the trials of these therapies, the mechanisms of action of anti-TNFa 
therapies remain unclear. A novel mode of action is suggested by McLachlan and 
colleagues which emphasises the link between mast cells, TNFa and the regulation of 
inflammation and immunity [305, 456]. They demonstrated in a murine model, that
injection of E. coli into the footpad led to hypertrophy of the popliteal (draining) lymph 
node, attributable to an influx of T and B lymphocytes and associated with mast cell 
degranulation in the footpad. Mast cell deficient mice (W/W3 mice showed significantly
1
reduced lymph node swelling which was reversed by reconstitution of the mice with wild-
I
■
type mast cells, but not with TNFa-deficient mast cells. As lymph nodes are the central 
inductive site of the adaptive immune response, facilitating the interaction of T cells and 
APCs, such effects could be significant in a wide range of conditions including infection, 
autoimmune conditions and allergies where there is immune activation.
To examine the effects of TNFoc blockade on airways inflammation, I will use the adoptive 
transfer model described in chapter 3. The aim of this chapter is to examine the effects of 
anti-TNFa given systemically on airways inflammation and to elucidate the mechanism 
underlying the response. Our investigations show that TNFa blockade during either the 
induction or effector phases caused no reduction in pathology associated with the disease. 
However, blockade during the induction phase prevented lymph node hypertrophy. When
TN Fa blockade was administered throughout the induction and effector phases of disease, 
lymph node hypertrophy and lung pathology were reduced, although the reduction in BAL
eosinophilia was not significant. This was associated with a reduction in BAL IL-5 
.production, showing that anti-TNFa treatment is needed throughout the course of the disease 
to reduce inflammation. When anti-TNFa treatment was administered in a more acute 
model of airways inflammation, the result was more pronounced, showing a reduction in 
BAL eosinophilia, pathology, lymph node hypertrophy, BAL IL-5 production and IgE 
production. When L-selectin expression was assessed on antigen-specific T cells it was 
found that the draining lymph nodes and the lung tissue had increased expression in both 
anti-TNFa and control mice. These data suggest that although anti-TNFa treatment affects
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the accumulation of T cells in draining lymph nodes, it does not mediate its effects via the 
expression of L-selectin. Thus anti-TNFa may be useful in severe and acute asthma.
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5.2 Results
In chapter 3 a model of allergic airways inflammation was established, in which adoptive 
transfer of Ag-specific T cells was followed by three immunisations, seven days apart and a 
single OVA airways challenge (Figure 3.4 A). This model will be referred to as the “long 
model”. In chapter 4 a similar model was adapted, in which adoptive transfer of Ag-specific 
T cells was followed by a single immunisation, followed by a single OVA plus LPS airways 
challenge ten days later (Figure 4.5 A). This model will be referred to as the “short model”. 
These models will be used to investigate the effects of anti-TNFa treatment on airways 
inflammation.
It has been shown that TNFa may regulate hypertrophy of lymph nodes following infection 
via an effect on T cells [305]. If TN Fa is important in the lymph node response, then 
blocking its action during the induction phase would suppress the initial primary immune 
response. However, a later effect of TNFa on T cell effector function cannot be ruled out, 
therefore it is important to assess the effects of TNFa blockade during the effector phase of 
the disease. To determine if TNFa blockade had an effect on the induction or effector phase 
of the long model, anti-TNFa treatment was given at a dose of 50mg/kg (previously 
optimised dose: personal communication by Simon Cruwys, Astra Zeneca) by i.p. injection 
the day before and two days after OVA/ALUM immunisation (Figure 5.1 A).
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5.2.1 Effect on TNFa blockade during induction or effector phase of airway I
inflammation.
To determine if anti-TNFa treatment affected lymph node hypertrophy when given during 
the induction or effector phase of the long model, the draining and non-draining lymph 
nodes were removed and weighed. When TNFa was blocked during the induction phase, 
the draining (mediastinal) lymph node did not increase in weight as was seen in the control 
group (Figure 5.1 B). However, this difference was only seen day seven post airways 
challenge. This difference was not seen when TNFa was blocked during the effector phase 
(Figure 5.1 C). No difference was seen in the non-draining (inguinal) lymph nodes when 
treated with anti-TNFa during the induction or the effector phase (Figure 5.1 D and E). 
When the cellularity of the lymph nodes was determined, no significant differences were 
seen between the two groups after any of the treatment regimes (Figure 5.2). The increase in 
weight of the LN was not accompanied by any changes in cellularity. This may be explained 
by oedema, which would increase the weight of the lymph node but not the cellularity.
When cell infiltrates were analysed in the BAL fluid it was found that there was no 
significant difference in BAL eosinophils or neutrophils when TN Fa was blocked during the 
induction or the effector phase of the model (Figure 5.3 A to D). Consistent with this result, 
there were no significant differences in lung pathology with either treatment regime (Figure 
5.3 E and F).
. .The use of OVA-specific TcR Tg T cells in our airway inflammation model allows the 
kinetic analysis of antigen-specific T cells as the disease progresses. Lymph nodes and BAL
'fluid were analysed by flow cytometry for KJl.26'^ T cells. There were no significant
'
differences in numbers of antigen-specific T cells recruited to the draining or non-draining 
lymph nodes, or to the BAL fluid when TN Fa was blocked during either the induction or 
effector response (data not shown).
These results suggest that TN Fa blockade during the induction phase of OVA-induced 
airway inflammation is able to stop lymph node hypertrophy in the draining lymph node but 
has no other significant effects on inflammation in the induction or effector phase.
5.2.2 Treatment with anti-TNFa causes a significant reduction lung pathology 
and reduction in BAL eosinophilia
As the previous results did not show any effect on the pathology of airway inflammation, the 
experiment was repeated with TN Fa being blocked throughout both the induction and 
effector phase of the long model (Figure 5.4 A).
TN Fa blockade throughout the long model appeared to cause an overall reduction in BAL
eosinophilia compared to control mice (Figure 5.4 B). However, this figure was not
statistically significant. Histological analysis of inflammation in lung sections showed that
anti-TNFa treatment produced a significant reduction in lung pathology compared to the
control group, consistent with the possible decrease in eosinophilia seen in the BAL fluid
(Figure 5.4 C). Decreased cell infiltrate and inflammation in anti-TNFa treated mice can be 
.seen in H&E stained sections, compared to the control group (Figure 5,4 D-G). This
suggests that TNFa blockade can have an effect on inflammation when blocked throughout 
the course of the disease, possibly not solely through an effect on eosinophilia.
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5.2.3 Anti-TNFa treatment prevents hypertrophy of the draining lymph nodes 
of the lung.
The draining lymph nodes are important in adaptive immune responses and are known to 
accumulate large numbers of circulating lymphocytes following infection [457]. This 
increase in lymph node size is important for the interaction of T cells and APCs and further 
induction of immune responses [73]. To determine if TNFa blockade has any effect on 
lymph node hypertrophy the mice were treated as described above and draining and non­
draining lymph nodes were weighed and cellularity determined after airway challenge. After 
anti-TNFa treatment the draining lymph node did not increase in weight, whereas those 
from the control group did show an increase in weight. (Figure 5.5 A). Non-draining lymph 
nodes from both the etanercept and the control group showed an equal increase in weight 
(Figure 5.5 B). The cellularity of the draining lymph nodes and the non-draining lymph 
nodes was determined. In the draining lymph nodes, the increase in cellularity observed in 
control mice was decreased with anti-TNFa treatment (Figure 5.5 C). There was no 
difference in cellularity between the two treatment groups in the non- draining lymph nodes 
(Figure 5.5 D). This suggests that blockade of TNFa may have an effect on cell movement 
to the draining lymph node and this decrease in cell number may account for the draining 
lymph nodes not increasing in weight as seen in the control group. However, analysis of 
antigen-specific T cells by flow cytometry showed no difference in cell number between 
groups (Figure 5.5 E and F).
Î
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5.2.4 BAL cytokine and serum antibody responses after airways challenge.
BAL fluid was collected and analysed for the presence of IL-5 and IFNy. IL-5 was 
significantly reduced in anti-TNFa treated mice compared to the control group, which 
correlates with the reduction in eosinophilia observed in the BAL fluid (Figure 5.6 A). IFNy 
production could not be detected in either of the groups (data not shown). Serum was 
assessed for OVA-specific antibody production. There was no significant difference 
between OVA-specific IgE in the anti-TNFa group and the control group (Figure 5.6 B).
5.2.5 Effect of etanercept in the short model.
A n ti-TN Fa drugs are now being considered as a possible therapy for asthma and recent 
clinical trials have shown beneficial effects in asthmatic patients [458, 459]. These studies 
looked at severe asthmatics, characterised by chronic airways inflammation, and high 
neutrophils numbers in the airways [415, 416, 460]. The short model characterised in 
chapter 4, where one immunisation and one airways challenge with OVA plus LPS may be 
more representative of chronic airways inflammation as the eosinophilia is accompanied by 
a marked neutrophil influx. Furthermore, when OVA-specific T cells were analysed by RT- 
PCR (as described in chapter 3) it was found that they expressed a high level of TN Fa 
compared to any of the other groups in the short or long model. For these reasons, it was 
decided to determine if anti-TNFa would have a more pronounced effect in this model.
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5,2.6 Etanercept treatment in the short model reduced BAL eosinophilia, DLN 
weight and cellularity.
When anti-TNFa treatment was administered throughout the short model (Figure 5.7 A), it 
resulted in a significant decrease in eosinophilia compared to the control group (Figure 5.7 
B). There was no difference observed in neutrophil number between the two groups (Figure 
5.7 C). When DLN were removed and weighed it was found that anti-TNFa treated mice 
did not show an increase in weight as seen in the control group (Figure 5.8 A). There was no 
difference in weight between the two groups in the non-DLN (Figure 5.8 B). The same 
trend was seen when cellularity was determined, showing that there were significantly more 
cells in the control group of the DLN (Figure 5.8 C) and no difference between the two 
groups in the non-DLN (Figure 5.8 D). However, when antigen-specific T cells were 
analysed by flow cytometry, no difference was seen between the groups in the DLN, non- 
DLN or the BAL (Figure 5.9). These results show that etanercept treatment throughout the 
short model is able to reduce eosinophilia, which was not seen in the long model, and DLN 
weight and cellularity, in a T cell-independent manner.
5.2.7 Effect of etanercept on cytokine and antibody production in the short 
model.
BAL fluid was collected and analysed for the presence of IL-5 and IFNy. IL-5 was 
significantly reduced in the etanercept treated group compared with the control group 
(Figure 5.10 A). IFNy could not be detected in either group. Serum was analysed for OVA- 
specific antibody production. There was a significant reduction in IgE production at day
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four post airways challenge in the etanercept treated group compared to the control group
I
(Figure 5.10 B).
Overall, anti-TNFa treatment in the short model caused a significant reduction in BAL
0
eosinophilia, IL-5 production, DLN weight and cellularity and OVA-specific IgE production 
compared with the control group, independent of T cell number. The reduction in 
eosinophilia and IgE production was not seen in the long model. These results are consistent 
with clinical trials in which anti-TNFa had been shown to be more effective in patients with 
severe asthma (short model), than mild to moderate asthma (long model)suggesting that anti- 
TNFa therapy is beneficial in airways inflammation.
Despite these results, it is still unclear as to how anti-TNFa therapies actually work. These 
results suggest that etanercept may be affecting the migration of cells to the DLN, causing a 
reduction in weight and cellularity compared with the control group. Adhesion molecules 
are known to play vital roles in numerous cell processes, including cell transmigration and 
response. T lymphocytes migrate from circulation to the lung to initiate and propagate 
airways inflammation. The adhesion molecules mediating lymphocyte influx into the 
airways during an allergic response have been poorly defined. Thus L-selectin expression, 
which has been shown to be important in access to lymph nodes [461], was measured on 
antigen-specific T cells in the short model after anti-TNFa treatment.
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5.2.8 L-selectin expression on antigen specific T cells.
The short model was run as described previously (Figure 5.7 A), with etanercept treatment 
throughout. Antigen-specific T cells in DLN, non-DLN and lung tissue were assessed by 
flow cytometry for the expression of L-selectin low (effector) and L-selectin high (naïve) 
cells. There was significantly increased KJ1.26 L-selectiiF low cells at day four post 
challenge in both etanercept and control mice in the DLN (Figure 5.11 A). There was no 
difference in L-selectin expression between the anti-TNFa treated mice and the control mice 
in non-DLN (Figure 5.11 B). In the lung tissue there were increases in the number of L- 
selectin low expressing T cells at day one post challenge in anti-TNFa and control groups 
and as seen in the DLN, there was significantly increased KJ1.26 L-selectin^ low cells at 
four post challenge in mice treated with etanercept and the control mice (Figure 5.11 C).
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5.3 Discussion
T N F a  is a major therapeutic target in a range of chronic inflammatory diseases e.g. 
rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease [462-464]. These diseases 
are mostly Thl-type diseases associated with increased TNFa production. Genetic studies 
have also shown an association between TNFa, AHR and asthma [465] and murine studies 
have shown that inhalation of TNFa leads to AHR [466]. Many cells are able to produce 
TNFa, but those most relevant to asthma are T cells, monocytes, macrophages, mast cells,
i t-eosinophils and epithelial cells. These cells are involved in tissue remodelling, epithelial cell 
barrier permeability, recruitment of inflammatory infiltrates to the site of inflammation and 
upregulation of adhesion molecules [467]. Anti-TNFa drugs are now being considered as a 
possible therapy for asthma and recent clinical trials have shown beneficial effects in 
asthmatic patients [458, 459] .
Even though asthma is a Th2 disease characterised by eosinophils, recent interest has been 
shown in TNFa as a therapy for asthma. Studies that have looked at TNFa inhibition in 
animal models have shown a suppressive effect on eosinophils [468-471], however one 
study using TN Fa receptor knockout mice did not [47IJ. The differences in results
.observed might be due to the TNFa inhibition employed or the models used. Most of these 
studies have used TNFa receptor knockout mice or anti-TNF antibodies, unlike etanercept, 
which binds to and functionally inhibits soluble receptors [468-471]. Clinical studies using
differing strategies of TN Fa blockade have shown differential effects in diseases, where 
anti-TNF antibody but not soluble receptor is beneficial in Crohn’s disease [450, 472].
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The experiments in this chapter have investigated a role for TN Fa in the treatment of
Iallergic airways inflammation. The airways model can be considered in two phases: the 
sensitisation phase, where the mouse is immunised with the OVA antigen, developing a 
systemic immunological response, and the effector or challenge phase, where rechallenge 
with the Ag via the airways leads to eosinophilic inflammation. The effect of etanercept 
treatment may depend on the phase in which it is administered. If TNFa were important in 
the lymph node response to antigen then it would seem plausible that blocking its action 
during the sensitisation phase would suppress the primary immune response to OVA. To 
examine this, etanercept was given either in the sensitisation or effector phases.
When anti-TNFa was administered during the induction phase of the model it prevented
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lymph node swelling. However, this was not accompanied by any reduction in eosinophilia 
or pathology. Similarly, in experiments where anti-TNFa was given during the effector 
phase only, no significant effect on lung inflammation, eosinophilia or lymph node size was 
observed. This suggests that although anti-TNFa treatment during induction was able to 
reduce lymph node swelling, the effect may be independent of the mechanisms leading to 
eosinophilic inflammation. Anti-TNFa treatment throughout the long model of airways 
inflammation (possibly representative of mild to moderate asthma) prevented hypertrophy of 
the draining lymph nodes of the lung. This was accompanied by a decrease in BAL 
eosinophilia (although not statistically significant) and IL-5 production, and a reduction in 
lung pathology. This data is representative of several murine and human studies that show 
administration of anti-TNFa leads to the amelioration of BAL eosinophilia and associated 
Th2 cytokines [277,455, 466, 470].
■i
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was accompanied by a decrease in DLN weight and cellularity. This data correlates with the
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However, recent clinical trials have shown beneficial effects of TNF blockade in patients 
with severe asthma, a clinical phenotype which is characterised by chronic airways 
inflammation, relative corticosteroid-resistance and a tendency towards high numbers of
■
neutrophils in the airways [415, 416, 460]. It seems likely that the acute model used here, in 
which inhaled allergen results in a predominantly eosinophilic infiltrate, does not represent 
the pathophysiological changes ongoing in this subgroup of patients. Indeed, in a clinical 
trial of mild-moderate asthmatics, whose disease the murine model is more likely to 
resemble, no improvement in airway eosinophils or AHR was found [455].
In chapter 3 it was demonstrated that the short model, which has an airways challenge of 
OVA plus LPS significantly worsened airways inflammation, not only in terms of 
eosinophils but also neutrophils. Although this does not resemble all aspects of severe 
asthma (the model provides an acute, as opposed to chronic inflammation and the 
neutrophilia is transient) it may provide the basis for further studies to investigate how 
therapeutic agents such as etanercept may work. Furthermore, when OVA-specific T cells 
were analysed by RT-PCR (as described in chapter 3) it was found that they expressed a 
high level of TN Fa compared to any of the other groups in the short or long model. 
Therefore it was hypothesised that anti-TNFa treatment may have a more profound effect in
this model.
As hypothesised, when anti-TNFa was administered throughout the short model it caused a 
significant reduction in BAL eosinophilia, IL-5 and antigen-specific IgE production. This
<
recent studies suggesting that anti-TNFa therapies are more beneficial in severe asthmatics 
compared to patients that exhibit mild or moderate symptoms [415, 416,460].
One mode of action by which TNFa may be exerting its effects is by blocking lymph node 
hypertrophy. It is known that naïve T cells continually enter and exit lymphoid organs in a 
recirculation process that is essential for immune surveillance. During an immune response 
the egress process can be shut down transiently [474]. When this occurs locally it increases 
lymphocyte numbers in the responding lymphoid organ. Several mediators of the innate 
immune system are known to cause shutdown, including TNF a , although the mechanisms 
are still unclear [475-477]. TNFa has also been shown to be capable of altering the number 
and specificity of lymphocytes recirculating through stimulated lymph nodes by selectively 
altering the entry of lymphocytes into the efferent lymphatics of inflamed lymph nodes in 
vivo [478-480]. This would correlate with the decrease in cellularity and weight observed in 
the draining lymph nodes of anti-TNFa treated mice, suggesting that blocking TNFa allows 
cells to leave the lymph node instead of being trapped and initiating a subsequent immune 
response.
Lymphocyte trafficking is not a random event as although naïve T cells appear to circulate 
without preference for any one group of lymph nodes, memory T cells preferentially return 
to the tissues associated with the lymph node groups in which they became sensitised: as 
process known as lymphocyte homing [481]. This process is controlled by adhesion 
receptors on the lymphocyte binding to vascular addressins selectively expressed on the 
endothelium [482, 483]. L-selectin is expressed on most lymphocytes and is the key
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receptor that initiates lymphocyte capture events in high endothelial venules in secondary 
lymphoid organs and at peripheral sites of injury and inflammation [461]. L-selectin has 
been shown to mediate arteriolar and venular rolling on inflamed pulmonary endothelium 
[484-486], and has been shown to be important in lymphocyte migration during an allergic 
inflammatory response [487]. Most studies demonstrate the absence of L-selectin results in 
reduced inflammation [488-491]. However, some studies have shown that L-selectin is 
required for the development of airway hyperresponsiveness but not airway inflammation in 
murine models of asthma [492].
To determine if anti-TNFa treatment was affecting the expression of L-selectin and 
therefore lymphocyte migration, its expression was measured on antigen-specific T cells 
from DLN, non-DLN and lung tissue. When L-selectin expression was measured in the 
DLN and the lung it was found that both the etanercept treated mice and the control mice 
showed increased expression after airways challenge. When L-selectin levels were 
measured in the non-DLN there was no difference between the groups and expression was 
not changed after administration of airways antigen. This data suggests that anti-TNFa may 
be affecting the migration of cells to the DLN in an L-selectin independent manner. It has 
also been observed that 50,000 L-selectin molecules per cell are required for efficient rolling 
in lymph node HEVs [493], therefore the presence of L-selectin on lymphocytes may not 
predict their potential to home to lymph nodes [494].
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Overall, these results have shown that when anti-TNFa treatment was administered during 
the induction phase of the long model it prevented lymph node swelling. However, this was 
not accompanied by any reduction in eosinophilia or pathology. Similarly, in experiments 
where anti-TNFa was given during the effector phase only, no significant effect on lung 
inflammation, eosinophilia or lymph node size was observed. This suggests that although 
anti-TNFa treatment during induction was able to reduce lymph node swelling, the effect 
may be independent of the mechanisms leading to eosinophilic inflammation. Blocking 
TNFa throughout both the induction and effector phases of the long model showed effects of 
anti-TNFa in reducing overall lung inflammation and preventing lymph node hypertrophy in 
an antigen-induced model of airway inflammation, with a less pronounced effect on lung 
eosinophilia. In the short model, TN Fa blockade throughout caused a reduction in BAL 
eosinophilia and associated pathology, and DLN weight and cellularity did not increase 
compared to control mice.
The data presented in this chapter suggests a novel mechanism of action of anti-TNFa 
therapy in immune diseases, by inhibiting lymph node responses in an L-selectin 
independent manner. A more pronounced reduction in lung inflammation and eosinophilia 
was seen in the short model, which may be more representative of a sever asthmatic 
response correlates with recent studies stating that anti-TNFa therapies are more effective in 
this group of asthmatic patients.
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3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by 
intranasal administration of 50pg OVA. Mice were treated during the induction phase with 
50mg/kg etanercept (E on timeline) by i.p. injection one day before and two days after each 
immunisation. In other experiments etanercept were treated with etanercept during the 
effector phase (A). Control mice were given 50mg/kg human IgG instead of etanercept 
during the induction or effector phase. Draining lymph nodes (B and C) and non-draining 
lymph nodes (D and E) were removed and weighed. Results are expressed as mean ± SEM 
(* P<0.05), n=3-4 per group, n~ 1 repeat.
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Figure 5.2: Effect of etanercept on lymph node cellularity
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by 
intranasal administration of 50pg OVA. Mice were treated during the induction phase with 
50mg/kg etanercept by i.p. injection one day before and two days after each immunisation. 
In other experiments etanercept were treated with etanercept during the effector phase. 
Control mice were given 50mg/kg human IgG instead of etanercept during the induction or
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effector phase. Draining lymph nodes (A and B) and non-draining lymph nodes (C and D) 
were removed and cellularity was determined. Results are expressed as mean ± SEM, n=3-4 
per group, n= 1 repeat.
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Figure 5.3: Etanercept treatment does not affect lung inflammation
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by 
intranasal administration of 50pg OVA. Mice were treated during the induction phase with 
50mg/kg etanercept by i.p. injection one day before and two days after each immunisation. 
In other experiments etanercept were treated with etanercept during the effector phase. 
Control mice were given 50mg/kg human IgG instead of etanercept during the induction or 
effector phase. BAL fluid was sampled and eosinophils (A and B), and neutrophils (C and 
D) were analysed by cytospin preparation. Lung sections were harvested and analysed for 
pathology (E and F). Baseline inflammation represented by solid black line. Results are 
expressed as mean ± SEM, n=3-4 per group, n= 1 repeat.
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Figure 5.4: Etanercept treatment throughout reduces lung pathology
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with 100p.g OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by 
intranasal administration of 50pg OVA. Mice were treated throughout with 50mg/kg 
etanercept by s.c. injection every two days. Control mice were given 50mg/kg human IgG 
instead of etanercept (A). BAL fluid was sampled and eosinophil content was analysed by 
cytospin preparation (B), Lung sections were scored for inflammation (C). Lung sections 
were stained with H&E. Sections show anti-TNFa (D,E) and IgG (F,G) treated mice at day 
4 post airways challenge at lOx and 20x magnification. Results are represented as mean ± 
SEM (* p< 0,05), n=3-6 per group, n= 2 repeats.
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Figure 5.5: Etanercept treatment throughout reduces DLN weight and cellularity.
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by
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intranasal administration of 50^ig OVA. Mice were treated throughout with 50mg/kg 
etanercept by s.c. injection every two days. Control mice were given 50mg/kg human IgG 
instead of etanercept. Draining and non-draining lymph nodes were removed and weighed 
(A and B) and cellularity was determined (C and D). OVA-specific T cell numbers were 
determined by flow cytometry (E and F), Results are represented as mean ± SEM (» p< 
0.05), n=6 per group, n= 2 repeats.
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Figure 5.6: Etanercept reduces IL-5 production
3x10^ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOfxg OVA and 1% alum by i.p. injection on three occasions, 
each a week apart. One week after the final immunisation, mice were challenged by 
intranasal administration of 50pg OVA. Mice were treated throughout with 50mg/kg 
etanercept by s.c. injection every two days. Control mice were given 50mg/kg human IgG 
instead of etanercept. BAL fluid was sampled and analysed for IL-5 (A). Serum from the 
same mice was removed and analysed by ELISA for Ag-specific IgE (B). Results are 
represented as mean ± SEM (* p< 0.001), n=3-6 per group, n= 2 repeats.
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Figure 5.7: Etanercept treatment throughout the short model reduces BAL 
eosinophilia.
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection. Ten days later mice 
were challenged by intranasal administration of 50p,g OVA. Mice were treated throughout 
with 50mg/kg etanercept by s.c. injection every two days (A). Control mice were given 
50mg/kg human IgG instead of etanercept. BAL fluid was sampled and eosinophil content 
was analysed by cytospin preparation for eosinophils (B) and neutrophils (C). Results are 
represented as mean ± SEM (* p< 0.05), n=5 per group, n= 2 repeats.
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Figure 5.8: E tanercep t treatm en t throughou t the short model reduces DLN weight and 
cellularity.
3x10'’ OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with 100p.g OVA and 1% alum by i.p. injection. Ten days later mice 
were challenged by intranasal administration of 50p,g OVA. Mice were treated throughout 
with 50mg/kg etanercept by s.c. injection every two days. Control mice were given 50mg/kg 
human IgG instead of etanercept. DLN and non-DLN were removed and weighed (A and B) 
and cellularity calculated (C and D). Results are represented as mean ± SEM (* p< 0.05), 
n=5 per group, n= 2 repeats.
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Figure 5,9: Effect of etanercept on antigen-specific T cells.
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection. Ten days later mice 
were challenged by intranasal administration of 50pg OVA. Mice were treated throughout 
with 50mg/kg etanercept by s.c. injection every two days. Control mice were given 50mg/kg 
human IgG instead of etanercept. Antigen-specific T cells were analysed by flow cytometry 
in DLN (A) non-DLN (B) and BAL fluid (C). Results are represented as mean ± SEM, n=5 
per group, n= 2 repeats.
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Figure 5.10: Etanercept reduces IL-5 and IgE in the short model.
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection. Ten days later mice 
were challenged by intranasal administration of 50pg OVA. Mice were treated throughout 
with 50mg/kg etanercept by s.c. injection every two days. Control mice were given 50mg/kg 
human IgG instead of etanercept. BAL fluid was sampled and analysed for IL-5 (A). Serum 
form the same mice was analysed for antigen-specific IgE (B). Results are represented as 
mean ± SEM, (^p<0.05), n=5 per group, n= 2 repeats.
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Figure 5.11: L-selectin expression on antigen-specific T cells.
3x10® OVA-specific T cells were adoptively transferred into naïve Balb/c recipients, which 
were then immunised with lOOpg OVA and 1% alum by i.p. injection. Ten days later mice 
were challenged by intranasal administration of 50pg OVA. Mice were treated throughout 
with 50mg/kg etanercept by s.c. injection every two days. Control mice were given 50mg/kg 
human IgG instead of etanercept. Antigen-specific T cells were analysed by flow cytometry 
in DLN (A) non-DLN (B) and BAL fluid (C) for L-selectin expression. Results are 
represented as mean ± SEM, (*p<0.05), n=5 per group, n= 2 repeats.
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CHAPTER 6 WHEN AND WHERE DOES T CELL 
DIVISION AND ACTIVATION TAKE PLACE IN 
ALLERGIC AIRWAYS INFLAMMATION?
-iS
6.1 Introduction
The recirculation of T cells through secondary lymphoid organs and peripheral non­
lymphoid tissues is fundamental to the maintenance of immune surveillance. It is believed 
that naïve T cells recirculate randomly through secondary lymphoid sites until they are 
stimulated by antigen conveyed there from tissues by A PCs [495, 496]. During T cell 
activation, naïve T cells are imprinted with a template of the site in which they were initially 
stimulated [497]. These cells then differentiate to acquire a tissue specific homing 
phenotype via expression of different receptor and signalling molecules, which facilitate 
return to that site [498]. Allergic asthma is characterised by chronic eosinophilic airway 
inflammation, believed to be orchestrated by Tli2 lymphocytes specific for inhaled allergen 
[499] and pulmonary immune responses can be generated by the introduction of antigen into 
the airways [500, 501]. The development of specific cell-mediated pulmonary immunity 
requires an afferent phase, during which inhaled antigens are captured, processed and 
presented to T cells in the context of MHCII on APCs [502] and an efferent phase in which 
T cells traffic through lymph nodes to sites of inflammation. Thus T cells are potentially 
involved in two phases of airway inflammation.
Drugs that interfere with the activation of T cells or more selectively Th2-specific signalling 
molecules, and drugs that prevent the selective migration into lung tissue are promising 
novel strategies for the treatment of allergic asthma. Previous studies have shown that 
depletion of CD4^ T cells by administration of antibody clearly inhibited allergen-induced 
airway eosinophilia and AHR [124, 503]. It has also been shown that CD4^T lymphocytes 
are critical for the development of airway epithelial changes and subepithelial fibrosis as
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well as AHR in a murine model of chronic asthma [504]. A study in IL-4 knockout mice, 
using mAh against CD4 in a murine model of allergic airways showed that the drug inhibited 
allergen-induced increases in airways responses, the number of eosinophils in BAL fluid, 
serum antigen-specific IgE levels and IL-13 in BAL fluid [505], suggesting that Th2 
responses play a critical role for the development of allergen induced airway remodelling 
and that inhibition of Th2 responses may be a viable therapeutic approach.
Thus, although T cells play an important role in asthma pathogenesis, it is still unclear as to 
when and where T cell activation and division takes place in allergic airways inflammation. 
An extensive network of dendritic cells line the conducting airways and interstitium of the 
lung and are capable of presenting inhaled antigen to naïve and memory T cells ex vivo [506- 
509]. Maturation and migration of airway dendritic cells to the T cell areas of the lymph 
nodes are poorly understood but are thought to be essential for mature DCs to interact with 
naïve recirculating T cells [502, 510]. Thus understanding the timing and location of T cell 
divisions and activation in airways inflammation should provide insights into the 
pathogenesis and treatment of infectious and allergic diseases of the lung.
The activation and division of naïve T cells in vivo is difficult to detect because of the low 
frequency of high affinity antigen-specific T cells. Although unmanipulated TCR transgenic 
animals make normal high affinity T cell responses to immunogenic and tolerogenic 
antigens, adoptive transfer of CFSE labelled transgenic T cells into a normal recipient offers 
a number of advantages. The main advantage is that the T cell division profile can be
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correlated to in vivo distribution and recirculation of antigen-specific T cells to lymph nodes 
and non-draining lymphoid sites. l i
In this chapter antigen-specific T cells will be used in conjunction with CFSE labelling and 
assessment of proliferating cell nuclear antigen (PCNA) expression to allow identification of 
T cell division after antigen airways challenge. To model the early events during T cell 
activation and division in response to inhaled antigen, adoptive transfer of CFSE labelled 
antigen-specific T cells in an acute lung injury model will be used. This will allow naive T 
cells to be studied in different compartments involved in the response and the kinetics of the 
response assessed. The adoptive transfer model described in chapter 3 will be employed to 
examine PCNA expression by specific-antigen experienced cells as an indication of their
recent division in the DLN, PLN, BAL and lung in the model of airways inflammation.
■IOur investigations show that cell division of antigen-specific T cells after an airways 
challenge of OVA plus LPS to naïve BALB/c mice could be seen by day three post airways 
challenge in the DLN, BAL and lung tissue. There is no cell division seen in the PLN 
throughout the timecourse. Interestingly, when the number of cell divisions was analysed it 
was found that although the three compartments show cell division by day three, T cells in
the BAL and lung have divided more times than those in the DLN. This suggests that the 
response in these tissues is more vigorous than in the DLN or that more differentiated cells 
are remaining in these compartments. When antigen-specific T cell division was quantified 
by LSC in tissue sections of DLN, PLN and lung it was found in the long adoptive transfer 
model that there was an early wave of T cell division at day one post airways challenge in
.o s
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the lung, followed by similar in the DLN. This leads to another wave of recently divided T 
cells in the lung, which corresponds to peak BAL eosinophilia. It is possible that the second 
wave of T cell division may be needed for the chronicity of asthma. In the short model of 
airways inflammation it was found that by day four post airways challenge both the DLN 
and lung showed significant T cell division compared with control groups. As seen in the 
long model there was no T cell division in the PLN. Although the kinetics are not as clear in 
this experiment it still suggests that T cell division in the lung and DLN is important to get 
airways pathology. This data gives an insight into the timing and location of antigen- 
specific T cell division in airways inflammation and will be important for rational design and 
application of therapeutics targeted against leukocyte migration.
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6.2 Results
T cells play a major role in regulating inflammatory responses and have been shown to be 
important in asthma pathogenesis. However, it is still unclear when and where T cells divide 
or are activated in asthma. This chapter will use OVA-specific T cells and the adoptive 
transfer model of airways inflammation characterised in Chapter Three to try and elucidate 
where T cells are dividing after antigen challenge in the DLN, PLN BAL and lung tissue.
6.2.1 T cells divide in the DLN, BAL and lung after airways challenge.
An initial experiment was set up to investigate if we were able to detect antigen-specific T 
cell division. CFSE labelled OVA-specific T cells were adoptively transferred into naïve 
BALB/c mice, which then received an airways challenge of OVA plus LPS. T cell division 
was then tracked in the DLN, PLN, BAL and lung over a timecourse (Figure 6.1).
When T cell division was analysed in the different compartments after airways challenge it 
was found that there was no division in any compartment at day 0 post challenge. By day 3 
after airways challenge the same percentage of T cells in the DLN, BAL and lung have all 
undergone division. No T cell division is seen in the PLN over the timecourse measured. 
Both the DLN and BAL T cells continue to divide at day five and seven. After the peak of T 
cell division in the lung at day three, the percentage of division drops at day five and seven 
(Figure 6.2 A). This may be due to the T cells dying or migrating to another compartment.
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Although this data shows when and where antigen-specific T cells are dividing, it does not 
give any information about the extent of division. To determine if there was any difference 
in the number of cell divisions between the different compartments, the data was analysed to 
show T cells that had divided 1-3 times and T cells that divided 4-6 times.
6.2.2 BAL and lung T cells divide more vigorously than DLN T cells.
When T cells that divided 1-3 times were analysed over the timecourse, at day 3 post 
challenge when previously it looked as though the DLN, BAL and lung T cells were 
dividing at the same rate, the DLN have a greater percentage of T cells that have divided in 
this group. BAL and Lung have the same percentage of T cells dividing 1-3 times at this 
timepoint (Figure 6.2 B). As seen for the total percentage of T cell division, the DLN and 
BAL T cells continue to divide at day five and seven post airways challenge, with the lung T 
cell division declining (Figure 6.2 B).
Interestingly, when T cells that had divided 4-6 times were analysed it was found that BAL 
and lung T cells had a higher percentage of cells dividing than the DLN at day 3 post 
airways challenge (Figure 6.2 C). On days five and seven after antigen challenge DLN T 
cells were dividing more times that the BAL and lung. There was no difference in the 
percentage of T cells dividing 4-6 times in the BAL or lung at days 5 and 7 post challenge. 
This shows that although the overall percentage of T cell division is not different between 
the DLN, BAL and Lung at day 3 post airways challenge, the number of cell divisions is
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greater in the BAL and lung at earlier time points, with the DLN dividing more than the 
BAL and lung T cells at days five and seven post airways challenge.
It is important to remember when analysing this data that the T cells involved were naïve 
and are making a primary response, which may differ from T cells that have previously been 
exposed to antigen. To address this issue the adoptive transfer model of airways 
inflammation was used to track division in T cells already sensitised to OVA. However, due 
to the length of the protocol, CFSE could not be used as the immunisation regime means that 
all the labelled T cells will have divided by the time antigen challenge is administered, 
meaning newly divided cells could not be identified in the compartments. Several studies 
have shown proliferating cell nuclear antigen (PCNA) as a reliable marker of division. Its 
temporal expression and relatively short half-life mean that cells expressing the PCNA are 
likely to be recently divided in the location they are observed in.
6.2.3 Long adoptive transfer model.
To enable the quantification of antigen specific T cell expression of PCNA, tissue samples 
from the long adoptive transfer model, previously described in chapter three, were analysed 
by LSC. The long model consists of the transfer of OVA-specific T cells into naïve BALB/c 
mice, followed by three OV A/alum immunisations seven days apart. Mice then receive an 
intranasal challenge seven days later of OVA, OVA plus LPS or LPS alone (Figure 6.3 A). 
As described previously this model results in significant BAL eosinophilia in the OVA plus 
LPS and the OVA alone groups, but not in the LPS alone group (Figure 6.3 B). When BAL 
was analysed for cell infiltrates it was found that OVA plus LPS and LPS alone resulted in a 
transient influx of neutrophils at day 1 post airways challenge (Figure 6.3 C). As shown in
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clinical and other murine models of airways inflammation, eosinophilia is associated with an 
increase in BAL IL-5 production and increased antigen-specific serum IgE levels (Figure 6 3  
D and E).
6.2.4 PCNA expression.
Lymph node and lung tissue sections from frozen sections stored from the experiment 
described above were stained with fluorescent antibodies against OVA-specific TcR 
transgenic T cells (KJ1.26) and PCNA and lymph nodes were also stained for the B cell 
marker B220 to allow visualisation of the lymph node architecture. LSC was used to allow 
identification of double positive cells in situ as described in chapter 2. Figures 6.4 and 6.5 
show antibody staining in lymph nodes and lung tissue respectively. Green staining in the 
lymph node represents B cell follicles and autofluorescent structure in lung tissue, PCNA 
expressing cells are blue and KJ1.26 transgenic T cells are red. Antigen-specific T cells 
expressing PCNA, i.e. recently divided cells, are coloured pink.
When cells were quantified in DLN sections it was apparent that there were no KJl.26^ 
PCNA^ cells at day one post airways challenge. However, by day three after challenge 
antigen specific T cells in the OVA plus LPS and OVA alone groups had undergone 
division. The LPS alone challenged animals showed little evidence of cell division (Figure 
6.6 A). The percentage of double positive (KJl.26^ PCNA^) cells declined after the peak at 
day three post airways challenge through days five and seven. In lung sections an initial 
burst of T cell division was seen at day one post airways challenge in the OVA plus LPS and 
OVA alone groups, again very little division was seen in the LPS alone group (Figure 6.6 B). 
The T cell division increases in the OVA plus LPS and OVA groups through day three and
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peaks at day five post airways challenge, dropping by day seven. There was no difference 
between any of the treatment groups in the PLN (Figure 6.6 C), and the division that was 
seen was very low, as might be expected, suggesting that the low levels of division seen in 
the LPS groups in the OVA plus LPS and OVA alone groups in the DLN and the lungs may 
be non-specific staining.
When the data from the DLN and the lung sections are analysed in parallel (Figure 6.7) it 
can be seen that there is an initial wave of T cell division, presumably driven by local 
antigen presentation after airways challenge seen in the lung followed by similar in the DLN, 
probably driven by migrating dendritic cells. This leads to another wave of recently divided 
T cells accumulating in the lung. When compared with the data shown in figure 6.3 A and B 
it can be seen that the initial division of T cells in the lung corresponds to the transient 
neutrophil influx seen in the BAL. It is also of note that the peak T cell division in the lung 
corresponds to the peak of BAL eosinophilia ( Figure 6.8).
6.2.5 Short adoptive transfer model.
As well as the long adoptive transfer model described above, PCNA expression was also 
assessed in the short model, previously described in chapter three, to determine if there was a 
difference in timing or location of T cell division between the models. The short model 
consists of the adoptive transfer of naïve OVA-specific T cells into naïve BALB/c mice 
followed by one immunisation with OV A/alum. Ten days later mice received an intranasal 
challenge with OVA plus LPS or OVA alone (Figure 6.9 A). As described in chapter three, 
airways challenge with OVA plus LPS in this model results in significant BAL eosinophilia
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at day four post challenge compared with the OVA alone group (Figure 6.9 B). The OVA 
plus LPS group induces an influx of neutrophils at day one post challenge as previously 
seen. This was not seen in the OVA alone group (Figure 6.9 C). This protocol also induces 
significant BAL IL-5 production in the OVA plus LPS group compared with the OVA along 
group (Figure 6.9 D) and an increase in serum IgE levels at day 4 post airways challenge in 
both OVA and OVA plus LPS treated mice (Figure 6.9 E).
6.2.6 Cell division in the short model.
As in the long model, lymph node and lung sections were stained for antigen-specific T cells 
and PCNA expression and analysed by LSC. In the DLN there is no T cell division at day 
one post airways challenge, but by day four post challenge there is significantly more 
division in the OVA plus LPS group compared with the OVA alone group (Figure 6.10 A). 
The lung mirrors the division seen in the DLN, with no division at day one post challenge 
and significant division in the OVA plus LPS group compared with the OVA alone group by 
day four after airways challenge (Figure 6.10 B). As seen in the long model there was no 
difference in the groups in the PLN (Figure 6.10 C), and the level of division was very low 
again suggesting that it might be non-specific staining.
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6.3 Discussion
The CD4^Th2 cell is a critical mediator of the asthma phenotype. Adoptive transfer of Th2 
cells into naïve mice followed by aerosol challenge has clearly demonstrated that Th2 cells 
are recruited into the lung and are critical for inducing the characteristic hallmarks of 
asthma, including AHR, eosinophilia and mucus production [353]. Although it is know that 
T cells are present in the airways and the draining lymph nodes [511] it has been difficult to 
determine where, how and when they interact with the rest of immune system. Many studies 
have looked at the migration of lymphocytes between lymph nodes and airways [242, 512- 
515] and the subsequent interaction between T cells and DCs [351, 516-518]. However, it is 
not known if T cells are activated and divide in the lung itself or the lymph nodes.
The experiments in this chapter have investigated the timing and location of antigen-specific 
T cell division after antigen airways challenge. Naïve T cells have been studied after 
transfer of CFSE labelled cells into BALB/c mice followed by intranasal challenge. When 
the division of naïve T cells was analysed in the DLN, PLN, BAL and lung tissue it was 
found that there was division by day three post airways challenge in the DLN, BAL and 
lung. There was no division seen in the PLN throughout the timecourse. Although the three 
locations showed division at the same timepoint, the magnitude of the response was 
different. In the BAL and lung tissue it was shown that the T cells had divided more in these 
compartments than the T cells in the DLN. This data correlates with data showing that naïve 
T cells are recruited to the airways after antigen challenge [516, 519], and similar studies 
using fluorescent beads as a model of inhaled antigen have been detected in lung and BAL 
after intranasal administration [351].
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The majority of studies looking at T cell activation and division in airways inflammation 
have looked in murine models where dendritic cells primed for a specific antigen are 
transferred into naïve mice, which receive a subsequent airways challenge, and the response 
analysed [513, 516, 517, 520]. The adoptive transfer model used in this chapter allows the 
identification of naïve T cells transferred into mice and given an airways challenge to induce 
airways pathology. The use of laser scanning cytometry allows the quantification of recently 
divided antigen-specific T cells in situ providing a novel model to study these parameters. 
When T cell division was quantified by LSC in the long model it was found that there was 
an early wave of T cell division seen in the lung at day one post airways challenge, followed 
by similar in the DLN at day three post challenge. At day five post challenge there was 
another wave of antigen-specific T cell division seen in the lung tissue. The early T cell 
division may have been caused by uptake and presentation of antigen by resident dendritic 
cells, which have been shown to be present in the lung [518]. The location of these dendritic 
cells allows them to have direct contact with incoming antigens. It is known that there is a 
dendritic cell network situated immediately above and beneath the basement membrane of 
the upper and lower airways enabling these cells to sample the epithelium for inhaled 
antigens [225, 509, 521]. It has also been shown in experimental models of respiratory virus 
infection that a population of memory T cells are established in the lung parenchyma and the 
lung airways [522, 523]. Airway resident memory cells contribute significantly to recall 
responses by providing immediate effector activity at the site of antigen entry [524]. A 
population of resident memory T cells may account for the early T cell division seen day one 
post airways challenge in the lung.
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Previous studies depleting CD4^ T cells in a murine model of airways inflammation before 
antigen challenge have shown reduction in AHR response to acetylcholine challenge and 
reduced eosinophilia, IgE and IL-13 production [505]. A study using A/J mice in an OVA 
induced model of airways inflammation with administration of anti-CD4 mAh before 
airways challenge caused reduction in AHR and lung eosinophilia [124] and lung 
eosinophilia was also prevented in a murine model of airways inflammation in CD4 deficient 
mice [363]. These studies suggest an important role for T cells in the induction and 
maintenance of immune responses to antigen. Gaining and insight into the location and 
timing of T cell division and activation will enable more accurate therapeutic intervention in 
airways inflammation.
To determine the site of T cell division in airway inflammation, antigen-specific T cells were 
tracked in different compartments throughout the course of the disease and proliferating cell 
nuclear antigen (PCNA) expression was measured on antigen-experienced T cells as an 
indication of their recent division. When T cell division was quantified by LSC in the long 
model it was found that there was an early wave of T cell division seen in the lung at day 
one post airways challenge, followed by similar in the DLN at day three post challenge. At 
day five post challenge there was another wave of antigen-specific T cell division seen in the 
lung tissue. The early T cell division may have been caused by uptake and presentation of 
antigen by resident dendritic cells, which have been shown to be present in the lung [518]. 
The location of these dendritic cells allows them to have direct contact with incoming 
antigens. It is known that there is a dendritic cell network situated immediately above and 
beneath the basement membrane of the upper and lower airways enabling these cells to 
sample the epithelium for inhaled antigens [225, 509, 521]. It has also been shown in
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experimental models of respiratory infection that a population of memory T cells are 
established in the lung parenchyma and the lung airways [522, 523]. Airway resident
memory cells contribute significantly to recall responses by providing immediate effector 
activity at the site of antigen entry [524], showing that there is local antigen presentation in 
the lung [525].
Upon antigen encounter, respiratory tract DCs migrate to the draining mediastinal lymph 
nodes where they control the activation and differentiation of antigen-specific T cells [526]. 
Activated effector T cells will migrate back to the site of inflammation and will be 
(re)stimulated locally by activated DCs [525]. It has been shown that different subsets of 
DCs are responsible for antigen transportation in response to different types of antigen [527]. 
A study by De heer et al., showed both myeloid and plasmacytoid DCs take up antigen 
within the draining lymph node in response to OVA inhalation, but only the myeloid subset 
was shown to present antigen to naïve CD4^ T cells [231]. As well as DCs, macrophages are 
able to uptake and process antigen to T cells and may be the first cell to encounter antigen in 
the airways (REF). Alveolar macrophages play a key role in the maintenance of 
immunological homeostasis in the respiratory tract and represent the most abundant cells in 
the conducting airways (REF). Macrophage numbers are increased in the lung and alveolar
*
space of patients with asthma and COPD and are localised to sites of alveolar destruction 
(REF). This movement and activation of T cells corresponds to the peak of antigen-specific 
T cell division seen in the DLN at day three post airways challenge. The subsequent wave 
of T cell expansion seen in the lung may be due to T cells returning to the site of 
inflammation where they initially encountered antigen after being imprinted in the DLN. It
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has been hypothesised that during activation naïve T cells are imprinted with a template of 
the site in which they were initially stimulated [497]. These cells then differentiate to 
acquire a tissue-specific homing phenotype which facilitates there return to that site [481, " I
498]. The idea that antigen-specific T cells can home back to the site of initial antigen 
encounter parallels the data shown in this study in which there is a second wave of T cell 
division seen in the lung tissue at day five post airways challenge. The two stages of T cell 
division in the lung mimics the data shown by Catron et a l,  who showed that as well as an 
initial T cell response to antigen, a population of “late-arriving” T cells are present after 
antigen challenge that may be central memory cells and were shown to proliferate more 
extensively than the resident T cells [513]. These cells may be critical for the chronic 
pathology that is seen in asthma patients. This data gives an insight into the timing and 
location of Ag-specific T cell division in airways inflammation and will be important for 
rational design and application of therapeutics.
shown to be crucial in the development of asthma pathogenesis [2]. The presence of 
neutrophils have been shown to be associated with severe asthmatics [416, 528] and are 
known to be chemotactic for T cells [529], suggesting that there presence in the BAL early 
in the response may cause the recruitment of activated T cells to the site of inflammation and 
ensuing pathology. T cells are crucial in the development of eosinophilia in airways
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When all the data form the experiment was analysed in parallel it was seen that the initial T 
cell division seen in the lung corresponded to the influx of neutrophils in the BAL, and the
second wave of T cell division in the lung coincided with the peak of BAL eosinophilia. 
Allergic asthma is associated with Th2 responses and the presence of T cells have been
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inflammation [2, 190, 235, 363, 364, 530] and the peak of T cell division in this model is 
consistent with the peak of BAL eosinophilia.
When T cell division was measured in the short model, no division was seen at day one post 
challenge in the DLN or the lung. This is in contrast to the data seen in the long model 
where T cell division was seen in the lung at this timepoint. This may be due to the T cells 
in this model only being primed once as apposed to three times. By day four after airways 
challenge, there was division seen in both the DLN and the lung. No division was observed 
in the PLN over the timecourse. The peak of T cell division in both the DLN and the lung 
corresponds to the peak BAL eosinophilia seen in this model. Although the data from this 
timecourse is not as detailed as the long adoptive transfer model, it still implies that T cell 
division in the DLN and lung is associated with BAL eosinophilia and lung pathology.
The migration of T cells between lymph nodes and the site of inflammation is crucial to the 
resulting immune response. Inhibiting T cell trafficking has been shown to be an effective 
strategy for treating a host of inflammatory diseases such as multiple sclerosis and Crohns’ 
disease [461], thus the increasing knowledge being gathered on the involvement of T cells in 
diseases such as asthma will enable therapies to be targeted more effectively. Recently there 
has been increased interest in the use of FTY720 as a therapeutic drug in models of 
transplantation and auto immunity and has recently been shown to be important in kidney 
transplantation [531-534]. FTY720 selectively and reversibly sequesters lymphocytes, via 
the sphingosine 1-phosphate receptor, but not monocytes or granulocytes from blood and 
spleen in to secondary lymphoid organs, preventing their migration towards sites of
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inflammation [535-537]. More recently a study using FTY720 in a murine model of allergic 
airways inflammation showed administration of the drug before antigen airways challenge 
abrogated airways inflammation by inhibition of the migration of dendritic cells to draining 
lymph nodes, which in turn inhibited the formation of allergen-specific Th2 cells in lymph 
nodes [538]. This study again highlights the importance of using systems such as the 
adoptive transfer system, where tracking of cells of known specificity allows identification 
of both T cells and dendritic cells and their possible interactions in diseases.
Overall these results have shown that antigen administration to naïve antigen-specific T 
cells results in cell division in the DLN, lung and BAL all at day three post challenge. 
However, it was found that the T cells in the BAL and lung divided more in these 
compartments. This suggests that the response seen in the BAL and lung was more vigorous 
than in the DLN. When memory T cells divisions were quantified in the long adoptive 
transfer model by LSC it was found that an early wave of T cell division, presumably driven 
by local Ag presentation after airways challenge, was seen in the lung followed by similar in 
the DLN, probably driven by migrating dendritic cells. This leads to another wave of 
recently-divided T cells accumulating in the lung. Peak T cell division in the lung 
corresponded to BAL eosinophilia, which is mimicked in the short adoptive transfer model 
where peak T cell division at day four post airways challenge mirrors peak BAL 
eosinophilia. This data gives an insight into the timing and location of Ag-specific T cell 
division in airways inflammation and will be important for rational design and application of 
therapeutics.
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Figure 6.1: CFSE Timeline
3x10* naïve CFSE labelled transgenic OVA-specific T cells were adoptively transferred by 
intravenous injection into BALB/c recipients which were given an intranasal challenge one 
day later with 50^g OVA plus 2.5|ig EPS. Mice were sacrificed at various time points.
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Figure 6.2: CFSE division in DLN, PLN, BAL and lung
3x10® naïve CFSE labelled transgenic OVA-specific T cells were adoptively transferred by 
intravenous injection into BALB/c recipients which were given an intranasal challenge one 
day later with 50p.g OVA plus 2.5pg LPS. Mice were sacrificed at various time points. 
OVA-specific CFSE labelled T cells were analysed for number of cell divisions in DLN, 
PLN, BAL and lung tissue (A). Data was analysed by the number of cell divisions: graph B
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shows 1-3 division, graph C shows 4-6 divisions. Values are represented as mean ± SEM, 
11=3 per group, n= 1 repeat.
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Figure 6.3: Long adoptive transfer model (Discussed in chapter 3)
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OV A/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days
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later with 50pg OVA, 50fxg OVA plus 2.5pg LPS or 2.5pg LPS alone (A). Mice were 
sacrificed at various timepoints. BAL fluid was sampled and cytospins preparations were 
analysed for the presence of eosinophils (B) and neutrophils (C). BAL IL-5 production (D) 
and serum IgE levels (E) were measured in the same mice. Values are represented as mean 
± SEM, n=3 per group , n= 2 repeats C^p<0.05).
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Figure 6.4: KJ and PCNA staining in lymph nodes
3x10* naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OV A/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with 50pg OVA plus 2.5pg LPS. Mice were sacrificed at various timepoints. LN 
sections from day five post airways challenge were stained with fluorescent antibodies for 
OVA-specific T cells (KJ), PCNA and B220 and analysed by laser scanning cytometry.
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Figure 6.5: KJ and PCNA staining in lung tissue
3x10* naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OV A/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with 50pg OVA plus 2.5pg LPS. Mice were sacrificed at various timepoints. Lung 
sections from day five post airways challenge were stained with fluorescent antibodies for 
OVA-specific T cells (KJ) and PCNA and analysed by laser scanning cytometry.
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Figure 6.6: Quantification of KJ+ve/PCNA+ve cells by LSC
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with 100p,g OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with 50pg OVA, 50(ig OVA plus 2.5[ig LPS or 2.5[ig LPS alone. Mice were sacrificed 
at various timepoints. LN and lung sections were stained for OVA-specific T cells and 
PCNA. Double positive cells were quantified by LSC. Values are represented as mean ± 
SEM, n=3 per group, n= 2 repeats.
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Figure 6.7: DLN and Lung overlay
3x10* naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with 50pg OVA, 50pg OVA plus 2.5pg LPS or 2.5[jig LPS alone. Mice were sacrificed 
at various timepoints. LN and lung sections were stained for OVA-specific T cells and 
PCNA. Double positive cells were quantified by LSC. Values are represented as mean ± 
SEM, n=3 per group, n= 2 repeats.
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Figure 6.8: DLN and Lung and BAL overlay
3x10* naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, three times, seven days apart, followed by one intranasal challenge 7 days 
later with 50pg OVA, 50pg OVA plus 2.5pg LPS or 2.5pg LPS alone. Mice were sacrificed 
at various timepoints. LN and lung sections were stained for OVA-specific T cells and 
PCNA. Double positive cells were quantified by LSC. BAL fluid was sampled and 
cytospins analysed for neutrophil and eosinophil content. Values are represented as mean ± 
SEM, n=3 per group, n= 2 repeats.
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Figure 6.9: Short adoptive transfer model (Discussed in chapter 3)
3x10® naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with 50pg OVA or 50pg 
OVA plus 2.5pg LPS. Mice were sacrificed at various timepoints. BAL fluid was sampled
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and cytospins preparations were analysed for the presence of eosinophils (B) and neutrophils 
(C). BAL IL-5 production (D) and serum IgE levels (E) were measured in the same mice. 
Values are represented as mean ± SEM, n=5 per group, (''“"p<0.01), n= 2 repeats.
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Figure 6.10: Quantification of KJ+ve/PCNA+ve cells
3x10^ naïve transgenic OVA-specific T cells were adoptively transferred by intravenous 
injection into BALB/c recipients, which were then immunised with lOOpg OVA/alum 1%, 
by i.p. injection, followed by one intranasal challenge 10 days later with 50p.g OVA or 50jj,g 
OVA plus 2.5[ig LPS. Mice were sacrificed at various timepoints. LN and lung sections 
were stained for OVA-specific T cells and PCNA. Double positive cells were quantified by 
LSC. Values are represented as mean ± SEM, n=5 per group p''p<0.05), n= 2 repeats.
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CHAPTER 7 - GENERAL DISCUSSION
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7.1 Introduction
Asthma is a complex chronic inflammatory disease of the lung characterised by airflow 
obstruction, airway hyperresponsiveness, and airway inflammation [539]. The inflammatory 
response is characterised by infiltration of the airway wall by mast cells, lymphocytes and 
eosinophils, together with the elevation of antigen-specific IgE. Several studies have shown 
a critical role for Th2 cytokines such as IL-4, IL-5 and IL-13 in the disease process [136, 
154, 385]. Furthermore, abundant clinical and experimental evidence suggests that T helper 
cells initiate and maintain inflammation in allergic asthma [105, 124, 353]. Through the 
cytokines they secrete, Th2 lymphocytes drive the production of allergen-specific IgE and 
orchestrate the recruitment and activation of the primary effector cells, such as mast cells, 
and eosinophils. Despite recent advances in understanding of the pathology of asthma, there 
are still gaps in our knowledge regarding the mechanisms initiating, maintaining and 
regulating airway inflammation resulting in the disease.
Though antigen-specific T cells are widely accepted to be critical in allergic airways 
inflammation it has proved difficult to study where, when and how they interact with the rest 
of the immune system due to their low precursor frequency [355]. While the presence of 
isotype switched antibodies (e.g. IgE) indicate that antigen-specific T cells play a crucial role 
in allergic airways inflammation these cells could potentially make contributions in a variety 
of ways [540, 541]. For example, they may have indirect effects on other cells (e.g. 
eosinophils) via their production of cytokines (IL-5) and/or direct effects via production on 
cytokines and/or surface molecules [344, 542, 543]. As such in this thesis I developed 
model systems to allow me to track antigen-specific T cells in the context of allergic airways
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inflammation. Using these models I have been able to describe where and when T cell 
activation and division likely occurs in allergic airways inflammation, the impact of non­
specific inflammatory events (e.g. equivalent to infection) on this condition and how 
therapeutic intervention may be working.
7.2 Development of novel models of airways inflammation
The D Oll.lO  adoptive transfer system is well-established in studies of T cell interactions 
[339, 348] and has also been used in models of experimental asthma although in most cases 
the transgenic cells were used principally to investigate the different effects of transferring 
Thl or Th2 cells rather than to examine compartment-specific contributions by initially 
naïve T cells [194, 242, 349, 350]. Where Ag-specific T cells have been tracked into 
different tissues following transfer, some studies have identified, but not quantified, 
transgenic T cells [121]. The remainder of studies have almost exclusively used T cells 
which have been polarised and activated in vitro to either a Thl or Th2 phenotype before 
transfer [168, 195, 251, 351-354]. The model established here differs in that the 
development of eosinophilic airways inflammation is combined with the transfer of naïve 
antigen (OVA)-specific T cells. This enables the developing T cell responses to be analysed 
in vivo via the ability both to identify and quantify Ag-specific T cells in different 
anatomical locations (lymph nodes, lungs and BAL fluid) through every stage from initiation 
of activation, through differentiation to effector function.
The adaptation of the well established OVA induced airways inflammation model [341] used 
by many groups to study airways inflammation resulted in pathology as previously shown.
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This model, consisting of three OVA immunisation followed by an OVA airways challenge
(long model), produces BAL eosinophilia, lung inflammation, increased OVA-specific IgE
and IgGl, and increased IL-5 production. The response to antigen challenge in this model is
similar to that seen in humans, which consists of an IgB-mediated inflammatory cascade in
the airways, characterised by the influx of Th2 lymphocytes and eosinophils and chronic
pulmonary inflammation [361]. Several studies have shown the importance of T cells in the
effector phase of asthma, from their ability to migrate to the lung in response to antigen
challenge, and their role in the development of eosinophils and IL-5 production [362-368].
Previous work carried out in this lab has shown that the depletion of CD4^ T cells in the
models described above, results in loss of airway inflammation and associated pathology
[544]. Indeed, the pathology in this “long model” described above was associated with 
.recruitment of antigen-specific T cells to the airways.
A variation of the long airways model where one OVA immunisation and one OVA airways 
challenge is administered, the “short model”, did not induce any BAL eosinophilia. This is 
in contrast to the long model where one OVA challenge results in recruitment of eosinophils 
to the airway.
I
I
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Lung inflammation caused by LPS has been used as a model of acute lung injury, mirroring 
some features of acute respiratory distress syndrome in humans [357]. To determine if LPS 
would be sufficient to induce eosinophilia it was added to OVA and given as the airways 
challenge in the short model. When OVA plus LPS was introduced into this model as the
-4:?'
airway challenge, instead of OVA alone, a significant BAL eosinophilia was induced.
I
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Analysis of inflammation in lung histological sections also showed a trend towards increased 
inflammation in animals challenged with OVA plus LPS. This was accompanied by a 
significant increase in BAL IL-5 production compared with OVA alone as seen previously in 
the long model. No difference was seen between antibody levels when OVA and OVA+LPS 
were compared. The increase in IL-5 production with the addition of LPS to OVA in the
airways challenge may help to induce more eosinophilia in the short model. Antigen-specific 
T cells were measured in the DLN and BAL fluid by flow cytometry and OVA+LPS 
treatment resulted in accumulation of T cells in the BAL and lung sections.
I
Î
Overall, these results suggest that the addition of LPS to a model that previously showed no 
airway inflammation or associated pathology has been switched to a model with pathology. 
This is associated with an increase in IL-5 production and recruitment of antigen-specific T 
cells to the BAL. This recruitment of T cells also suggests a role for them in the effector 
phase of the response, after the initial sensitisation.
The use of LPS allowed the development of a shorter model that produced the same end 
result as the long model with only an OVA airways challenge. This raised the question of 
whether we were looking at two different routes to the same endpoint or whether they had 
different pathologies. To address this question an initial screen of co-stimulatory molecules,
cytokine and chemokine expression on OVA-specific T cells, was performed by quantitative 
RT-PCR to phenotype the two models. It was found that although the two different models
.
produced the same results, the route by which it was reached was different. These 
preliminary results emphasize the need for caution when comparing different studies from 
different groups, even if the end results seem comparable.
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These experiments have optimised and characterised robust models of murine airway 
inflammation. The use of adoptively transferred OVA-specific T cells allows the 
identification and quantification of antigen-specific cells in the lymph nodes, lungs and BAL 
over a timecourse, without obviously affecting the disease outcome. These models will 
enable investigation into the effects of exogenous inflammation (LPS), an anti-inflammatory 
therapy (anti-TNF alpha) and to track cell divisions and interactions in cellular 
compartments over the course of the disease.
7.3 Using novel models to investigate the location of T cell division
We next went on to use these models to examine the location and timing of T cell division in 
the lung, DLN and PLN in the airways model. The recirculation of T cells through 
secondary lymphoid organs and peripheral and non-lymphoid tissues is fundamental to the 
maintenance of immune surveillance. It is believed that naïve T cells recirculate randomly 
through secondary lymphoid sites until they are stimulated by antigen conveyed there from 
tissues by antigen presenting cells [495, 496], During the ensuing T cell activation, naive T 
cells are imprinted with a template of the site in which they were initially stimulated [497]. 
These cells then differentiate to acquire a tissue specific homing phenotype via the 
expression of different receptor and signalling molecules, which facilitate return to that site 
[498]. The development of specific cell-mediated pulmonary immunity requires an afferent 
phase, during which inhaled antigens are captured, processed and presented to T cells in the 
context of MHCII on antigen presenting cells [502] and an efferent phase in which T cells 
are trafficked through lymph nodes to sites of inflammation [545]. Thus, T cells are 
potentially involved in two phases of airway inflammation.
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Previous studies depleting CDA T cells in a murine model of airways inflammation before 
antigen challenge have shown reduction in AHR response to acetylcholine challenge and 
reduced eosinophilia, IgE and IL-13 production [505]. A study using A/J mice in an OVA 
induced model of airways inflammation with administration of anti-CD4 mAb prior to 
airways challenge caused reduction in AHR and lung eosinophilia [124] and lung 
eosinophilia was also prevented in a murine model of airways inflammation in CD4 deficient 
mice [363]. These studies suggest an important role for T cells in the induction and 
maintenance of immune responses to antigen. Gaining an insight into the location and 
timing of T cell division and activation will enable more accurate therapeutic intervention in 
airways inflammation. The information obtained in these experiments may allow T cells to 
be targeted before they become activated or to stop cell migration to lymph nodes and 
subsequent reduce the ensuing immune response to encountered antigen.
To determine the site of T cell division in airway inflammation, antigen-specific T cells were 
tracked in different compartments throughout the course of the disease and proliferating cell 
nuclear antigen (PCNA) expression was measured on antigen-experienced T cells as an 
indication of their recent division. When T cell division was quantified by LSC in the long 
model it was found that there was an early wave of T cell division in the lung at day one post 
airways challenge, followed by similar in the DLN at day three post challenge. At day five 
post challenge there was another wave of antigen-specific T cell division seen in the lung 
tissue. The early T cell division may have been caused by uptake and presentation of 
antigen by resident dendritic cells, which have been shown to be present in the lung [518]. 
The location of these dendritic cells allows them to have direct contact with incoming 
antigens. It is known that there is a dendritic cell network situated immediately above and
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beneath the basement membrane of the upper and lower airways enabling these cells to 
sample the epithelium for inhaled antigens [225, 509, 521]. It has a[so been shown in 
experimental models of respiratory infection that a population of memory T cells are 
established in the lung parenchyma and the lung airways [522, 523]. Airway resident 
memory cells contribute significantly to recall responses by providing immediate effector 
activity at the site of antigen entry [524], showing that there is local antigen presentation in 
the lung [525].
Upon antigen encounter, respiratory tract DCs migrate to the draining mediastinal lymph 
nodes where they control the activation and differentiation of antigen-specific T cells [526]. 
Activated effector T cells will migrate back to the site of inflammation and will be 
(re)stimulated locally by activated DCs [525]. It has been shown that different subsets of 
DCs are responsible for antigen transportation in response to different types of antigen [527]. 
A study by De heer et a i, showed both myeloid and plasmacytoid DCs take up antigen 
within the draining lymph node in response to OVA inhalation, but only the myeloid subset 
was shown to present antigen to naïve CD4^ T cells [231]. This movement and activation 
of T cells corresponds to the peak of antigen-specific T cell division seen in the DLN at day 
three post airways challenge. The subsequent wave of T cell expansion seen in the lung may 
be due to T cells returning to the site of inflammation where they initially encountered 
antigen after being imprinted in the DLN. It has been hypothesised that during activation 
naïve T cells are imprinted with a template of the site in which they were initially stimulated 
[497]. These cells then differentiate to acquire a tissue-specific homing phenotype which 
facilitates there return to that site [481, 498]. The idea that antigen-specific T cells can home 
back to the site of initial antigen encounter parallels the data shown in this study in which
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there is a second wave of T cell division seen in the lung tissue at day five post airways 
challenge. The two stages of T cell division in the lung mimics the data shown by Catron et 
al., who showed that as well as an initial T cell response to antigen, a population of “late- 
arriving” T cells are present after antigen challenge that may be central memory cells and 
were shown to proliferate more extensively than the resident T cells [513]. These cells may 
be critical for the chronic pathology that is seen in asthma patients. This data gives an 
insight into the timing and location of Ag-specific T cell division in airways inflammation 
and will be important for rational design and application of therapeutics.
7.4 Using novel models to assess the impact of TLR ligands on allergic 
airways inflammation
The adoptive transfer models developed enabled investigation into the effects of exogenous 
sources of inflammation on allergic airways inflammation. Epidemiological studies have 
suggested that overall prevalence of atopy and asthma in a population is inversely related to 
the level of endotoxin in the environment [391, 395, 396] but in patients known to have 
asthma, the level of endotoxin in house dust is positively related to disease severity [394, 
397, 399, 400]. The data presented here show conc[usively that in a murine model of 
eosinophilic airways inflammation, concurrent administration of LPS or BLP with antigen- 
challenge exacerbates the subsequent inflammation in previously sensitised mice. 
Importantly, these data also show that where the protocol is suboptimal for inducing airway 
eosinophilia, the addition of TLR ligands can promote an inflammatory outcome. 
Furthermore the route of administration of TLR agonist is critical as systemic injection of 
the same agents lead to suppression of airway inflammation. Comparing the data presented
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here, with those of other studies suggests that not only is route of administration important 
but also dose and timing, going some way to explain the conflicting results seen in animal 
and human studies [332, 407].
The effect of TLR agonists, LPS and BLP, administered locally and systemically at the time 
of airways challenge was investigated. The protocols used for these studies use mice 
previously sensitised to the allergen, which may represent a more clinically relevant model 
of disease, as most patients will already have been sensitised when they seek treatment. This 
approach differs from many other studies that have looked at TLR administration at the time 
of sensitisation [401, 407-409, 433-435]. The results suggest that exposure to microbial 
products lead to the worsening of airways inflammation in the model. This is supportive of 
studies done in humans [436-440], which showed that inhalation of LPS by allergic 
asthmatics induced airways inflammation, including increased eosinophilia in the airways. 
The experiments imply that this may be due to an accumulation of antigen-specific T cells in 
the airways, which may affect the underlying adaptive immune response. This may also lead 
to increased sensitisation to other allergens, as Th2 cells have been shown to facilitate 
priming of naïve T cells to unrelated antigen through IL-4 secretion [441]. This has been 
seen in atopic patients that accumulate allergens over time [442,443].
Throughout this study LPS has been used in conjunction with OVA and ALUM which are 
known to induce a Th2 phenotype. LPS was shown to exacerbate this response. It has been 
shown that innate immune responses to LPS can modulate adaptive immune responses to 
allergens, and that low doses of LPS can induce Thl type responses and high doses of LPS
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can induce Th2 responses [576] It is also known that signalling through TLR is required for 
adaptive Thl responses and unclear if it is needed for Tli2 priming [577[. This suggests that 
although the addition of LPS in the adoptive transfer model used in this study exacerbated 
the Th2 response, it is possible that if OVA was given with a Thl antigen that Thl responses 
would be augmented as well as LPS is not classically a Th2 inducer.
When compared to other studies, when LPS is given locally during antigen challenge, my 
results are in concurrence, showing exacerbation of airways inflammation [332, 407, 433]. 
However, there are also conflicting studies showing amelioration of the inflammatory 
response [410, 433, 444, 445]. The use of systemic LPS to suppress the allergic response 
agrees with the data presented in this thesis [432, 444]. When LPS has been administered 
during sensitisation either locally or systemically most studies have shown a reduction in 
airways inflammation [423, 432, 446, 447]. In spite of this, caution must be taken when 
comparing these studies as different routes of administration, doses, timing and species have 
been used throughout the publications.
Several mechanisms have been proposed to explain LPS induction of eosinophilia and 
proinflammatory cytokines. DCs are well recognized to play a central role in inflammatory 
reactions elicited by LPS [421]. When DCs are activated by LPS through TLR4, they 
become mature and acquire an increased ability to prime T cells [422]. A study by 
Eisenbarth et al., reported that low level inhaled LPS signaling through TLR4 is necessary to 
induce Th2 responses to inhaled antigens in a mouse model of allergic sensitization. The 
meehanism by which LPS signaling results in Th2 sensitization was shown to involve the
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activation of antigen-containing dendritic ceils [407]. However, a recent study proposed 
that LPS-induced MCs activation and modulation with increased production of Th2 
cytokines, such as IL-5 and IL-13, appear to control the severity of eosinophilic airway 
inflammation [423]. It is known that lL-5 and IL-13 play a crucial role in the induction and 
the severity of eosinophilic infiltrate in airway inflammation in the lung [362]. IL-5 is a key 
factor for eosinophilia and could be responsible for some tissue damage in chronic asthma 
[424].
In the context of clinical disease, these results suggest that exposure to bacterial products 
would be detrimental to patients with asthma, a conclusion that may seem self-evident. 
There are however two further important interpretations that can be made from these results. 
Firstly, the suggestion that microbial products and TLR ligands could be used in a 
therapeutic capacity in asthma [408, 546] should be considered carefully. Although some 
studies have shown promising results, whether the outcome after administration of these 
agents is suppression or exacerbation of inflammation is clearly dependent on a number of 
factors and requires further clarification before any therapeutic potential can be realised. 
Moreover the results reported here show that the suppressive effect following systemic 
administration was transient reducing the possible utility of these agents as long-term 
treatments. The second conclusion from these experiments is that the pro-inflammatory 
effect of local administration of LPS or BLP was associated with the accumulation of Ag- 
specific T cells in the airway.
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7.5 Using novel models to examine mode of action of potential 
therapeutics
The use of the antagonist etanercept in the airways model allowed investigation into the 
mode of action of this therapy. It was found that TNFa blockade caused reduction in 
airways inflammation and associated pathology possibly via its ability to inhibit draining 
lymph node hyperplasia, suggesting a possible novel mode of action for anti-TNFa 
therapies.
Information on the critical locations of cells and cellular interactions should provide new 
ways of targeting the pathways involved. Recent studies have shown that MC-derived TNFa 
may regulate local lymph node enlargement in response to infection [305]. Given the 
importance of MCs in asthma [113, 205, 207] and recent interest in TNFa in airways disease 
[277, 459, 547], the effect of TNFa blockade in the role of lymph node hypertrophy in 
airways inflammation was investigated. When lymph node hypertrophy was inhibited by 
TNFa blockade in the airways model, it was associated with a reduction in draining lymph 
node cellularity, BAL eosinophilia and IL-5, and antigen-specific IgE production. This 
supported the notion that suppression of the lymph node response may be a novel route by 
which anti-TNF agents may act [305]. This hypothesis could also be applied to other 
diseases where TNFa blockade has been proposed [456].
One means by which TNFa may be exerting its effects is by blocking lymph node 
hypertrophy. It is known that naïve T cells continually enter and exit lymphoid organs in a 
recirculation process that is essential for immune surveillance. During an immune response
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the egress process can be shut down transiently [474]. When this occurs locally it increases 
lymphocyte numbers in the responding lymphoid organ. Several mediators of the innate 
immune system are known to cause shutdown, including TNF a , although the mechanisms 
are still unclear [475-477]. TNFa has also been shown to be capable of altering the number 
and specificity of lymphocytes recirculating through stimulated lymph nodes by selectively 
altering the entry of lymphocytes into the efferent lymphatics of inflamed lymph nodes in 
vivo [478-480].
As noted earlier, lymphocyte trafficking is not a random event as although naïve T cells 
appear to circulate without preference for any one group of lymph nodes, memory T cells 
preferentially return to the tissues associated with the lymph node groups in which they 
became sensitised: as process known as lymphocyte homing [481]. This process is 
controlled by adhesion receptors on the lymphocyte binding to vascular addressins 
selectively expressed on the endothelium [482, 483]. In this thesis the role of L-selectin, 
which is expressed on most lymphocytes, and is the key receptor that initiates lymphocyte 
capture events in high endothelial venules in secondary lymphoid organs, and has been 
shown to be important in airways inflammation, was examined in anti-TNFa experiments. 
It was found that cell there was no difference in L-selectin expression on antigen-specific T 
cells between the anti-TNFa treated and control mice, suggesting that inhibition of lymph 
node hypertrophy was not mediated by L-selectin in these experiments.
7.6 Future studies
The study of cell trafficking is fascinating not just because of its obvious relevance to the 
treatment of diseases, but also because an increasing number of technological advances are
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allowing us to visualise processes as never before [355]. Identifying and quantifying cells in 
different anatomical locations, as has been carried out here, will become the most basic of 
information obtained.
Host immunity and immunopathology are mediated largely by cytokines which are short­
lived effector molecules rapidly secreted by different cell types in many different tissue 
compartments. Analysis of cytokine activities in vivo has been extrapolated from in vitro 
studies using isolated cells and through generation of cytokine knockout and transgenic 
overexpressing mice. Although many insights have been gained by these approaches, 
disadvantages are also apparent. In vitro analysis of cells removes them from their in situ 
environment and from potentially critical signals present in tissues, and exogenous cytokines 
are often provided in amounts that might not be physiological. Furthermore, knock out or 
reporter knock in mice preclude the ability to judge the contributions of the cytokine that has 
been deleted since it can no longer contribute to the immune response[548]. The 
development of fluorescent reporter genes allows cells that are activated, or producing 
specific cytokines, to be identified. Thus, cells from mice expressing the enhanced green 
fluorescent protein gene linked to IL-4 become fluorescent when IL-4 is produced, allowing 
the visualisation of a Th2-type response [548, 549]. Cross-breeding these mice with strains 
expressing transgenic T cell receptors would produce cells that allow an antigen-specific 
Th2 response to be monitored in real time in distinct compartments in vivo. The adoptive 
transfer techniques used in this thesis have recently been refined so that fewer cells can be 
transferred and as few as ten antigen-specific cells can be recovered and identified allowing 
a more physiological level of response to be tracked. Furthermore, not only can Ag-specific
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T cells be tracked as demonstrated here but antigen processing and presentation can now be 
demonstrated [550].
Data on antigen presentation have come primarily from in vitro studies or examination of the 
late in vivo consequences of presentation, analyses that do not reveal the details of the early 
steps in this process in a physiological setting. Recently, however, new methods of static 
and dynamic imaging have begun to overcome the barriers to understanding these events, 
providing new insights into when and where antigen acquisition and processing takes place, 
as well as where T cells and APCs interact and for how long. Measurements of the rate and 
directionality of lymphocyte movement are emerging from the application of four­
dimensional imaging techniques to isolated lymphoid tissues and even tissues in living 
animals.
Furthermore, the journey of antigen, from uptake to processing, and finally to presentation 
and activation of T cells can now he visualised [550]. Using the Ea-RFP system a 
fluorescently-labelled antigen can be identified (either free or within cells) until its 
fluorescence is lost through antigen processing. Presentation of the processed peptide (p 
Earl-A* )^ in the context of MHC class II can then be detected by the use of a specific 
monoclonal Ab labelled with a second fluorochrome (Y-Ae) [551]. The picture is 
completed by the use of transgenic T cells (Tea T cells) with TCRs specific for the peptide- 
MHC complex [552]. The ability to identify every step in the sequence from antigen 
exposure through processing and presentation to T cell recognition provides a unique 
opportunity to study the cellular interactions that take place in antigen-induced allergic 
airways disease. Work from this thesis has demonstrated that CD4^ T cells are essential
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during the effector phase of the allergic airways response and suggest that they play an 
important role in the airways. Using the system described above, it should be possible to 
demonstrate antigen uptake and presentation ongoing in the airways during this response and 
possibly to detect effects on antigen presentation mediated by changes in the experimental 
conditions.
The use of the Ea-RFP allows the location and timing of antigen uptake and presentation to 
be tracked in vivo in disease models and has shown the importance of the interaction 
between T cells and DCs. Other studies have also shown an important role for dendritic 
cells in the airways, the implication being that antigen presentation by DCs to T cells takes 
place in the airways, rather than in secondary lymphoid organs, and is important during the 
effector arm of the response [230, 233, 553, 554]. Recently, a novel diptheria toxin (DT) 
based system was developed, which allows the short term inducible ablation of DC in vivo 
[555]. This system has been used to show that depletion of DCs results in a complete 
inability to cross-prime CD8^  T cell responses against Listeria monocytogenes and 
Plasmodium yoelii [555] and to prime LCMV-specific CD8^  T cell responses [556]. 
Analysis of the structure of lymphoid organs after CDllc^ depletion by DT also resulted in 
complete and protracted depletion of marginal zone and matailophillic macrophages [557]. 
These mice will allow the contribution of DCs in diseases to be investigated.
Many chemokmes have been implicated in allergic airways inflammation and strategies to 
inhibit T cell migration to the lung are directed to T cell adhesion or chemoattraction. 
Inhibiting the interaction between adhesion molecules and their ligands can target T cell 
adhesion. In this respect, the use of VLA-4 inhibitors may be relevant in asthma, as 
demonstrated by their effects in allergen-induced inflammatory responses in sheep [558].
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OVA-sensitised and challenged ICAM-1 deficient mice have a dramatically reduced 
inflammatory influx into the airways plus attenuation of AHR compared to wild type mice 
[559]. However, no clinical data on blocking integrins or antibodies to ICAM-1 or VCAM-1 
are available for asthma. Treatment with specific antagonists to chemokine receptors is in 
development for asthma. Pertussis toxin-treated Th2 cells have been described to be unable 
to traffic into the airways and to induce eosinophilic airway inflammation following OVA 
challenge in a mouse model of asthma [242]. Thus, chemokine receptor antagonism may 
become an important approach in the treatment of asthma. Therefore, although in the 
etanercept experiments L-selectin was not shown to be involved in the inhibition of lymph 
node hyperplasia, there are clearly many other chemokines involved in airways 
inflammation and migration of cells between lymph nodes and lungs that could be targeted 
as therapies for asthma. Further investigation of these molecules in the airways 
inflammation model used throughout this thesis would give valuable insight into the 
mechanisms involved in airways inflammation and possible therapeutic targets.
The experiments described using PCNA as a marker of recent cell division showed that there 
may be more than one phase of T cell division in different compartments that are potentially 
important in driving the subsequent immune responses. In order to effectively target 
therapies in diseases such as allergic airways inflammation it is important to understand the 
relevance of the T cell divisions at these timepoints and whether the T cells are functionally 
important in the draining lymph node or the lung. In recent years there has been increased 
interest in the use of FTY720 as a therapeutic drug in models of transplantation and 
autoimmunity and it has recently been shown to be efficacious in kidney transplantation 
[531-534]. FTY720 selectively and reversibly sequesters lymphocytes via the sphingosine
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1-phosphate receptor, but not monocytes or granulocytes, from blood and spleen into 
secondary lymphoid organs, preventing their migration towards sites of inflammation [535- 
537]. More recently a study using FTY720 in a murine model of allergic airways 
inflammation showed administration of the drug before antigen airways challenge abrogated 
airways inflammation by inhibition of the migration of dendritic cells to draining lymph 
nodes, which in turn inhibited the formation of allergen-specific Th2 cells in lymph nodes 
[538]. This study again highlights the importance of using systems such as the adoptive 
transfer system, where tracking of cells of known specificity allows identification of both T 
cells and dendritic cells and their possible interactions in diseases.
Although the techniques described above will allow kinetic analysis of T cell and antigen- 
presenting cell interactions in disease models such as the adoptive transfer model described 
in this thesis, the emergence of new imaging techniques has allowed the behaviour of 
specific cells to be studied in vivo in real time [355, 513, 560-563]. The use of 2-photon 
microscopy has allowed the behaviour of cells with differing phenotypes to be characterised 
for the first time in intact organs.
There are many factors that are likely to shape the magnitude, character and functional 
output of the resulting immune response including the Ag dose, the type and availability of 
APCs bearing Ag, the presence and nature of costimulatory signals and the migratory 
behaviour of T cells and APC. The use of 2-photon microscopy can be used to determine 
many of these factors in real time, in vivo.
Two photon laser microscopy is based on the fact that the fluorophore is excited by near- 
simultaneous adsorption of two higher wavelength photons instead of a single low light
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photon. These effects enable imaging at a depth of up to 300 microns and has improved 
biocompatibility compared to confocal imaging [564]. Since the first demonstration of 
multiphoton in vivo dynamic imaging of lymphocytes these approaches have given valuable 
insight into the mechanisms involved in immune responses [565].
Multiphoton microscopy on exposed or explanted LN has allowed imaging analysis of 
individual cellular interactions over several hours. The behaviour of individual T cells and T 
cell-DC interactions with and without antigen encounter has been studied. It was found that 
naïve T cells are incredibly motile, covering up to 25pm per minute, following a random 
walk rather than directed migration [563] and contacting multiple DCs per hour [560]. Once 
T cells encounter antigen they cluster around the APC inducing activation of the T cell and 
upregulation of CD69 [563, 566]. Subsequently, the T cells become motile again and make 
contact with further antigen-presenting DCs, enhancing their activation and allowing 
upregulation of the IL-2 receptor and production of IFNy [567].
The involvement of chemokines and cytokines in the regulation and induction of the immune 
response has also been studied using multiphoton microscopy. Okada et ah, demonstrated 
that B cells upregulate CCR.7 and migrate to the boundary of the follicle following activation 
[568]. Upon encountering the appropriate T cell, the B cell-T cell interaction can last for 
over 1 hour. Recently, this information has allowed researchers to investigate circumstances 
in which this normal immune response is altered, especially in the regulation of immune 
responses. Schneider et al. demonstrated that CTLA-4 increases T cell motility and 
prevents the formation of stable contacts between T cells and APC, providing a potential 
mechanism by which CTLA-4 may modulate the activation of T cells [569]. Thus, use of
255
'1
. ' i
multiphoton microscopy has recently allowed the detailed examination of cellular migration 
and interactions within the LN.
Multiphoton microscopy may be beneficial in studying the characteristics of cells in disease 
models, giving information on when and where cells interact and whether their 
characteristics affects the outcome of the disease. This method may give an insight into 
whether drugs are able to affect cell movement and speed. For example, studying the cells 
in draining lymph nodes in mice treated with etanercept could determine if anti-TNFa 
blockade affects the migration of cells from lymph nodes.
presentation in the lung may be important in driving the subsequent immune responses. The
I7.7 SummaryIn summary, the data presented here has utilised a robust model of airways inflammation,using the transfer of naïve antigen-specific T cells which can be tracked and quantified in
different anatomical locations (BAL, lung DLN and PLN) in vivo. It was found that T cell
division occurs early in the lung after antigen inhalation, which may drive the division of T 
,cells in the DLN resulting in eosinophilic inflammation. The data suggests that local antigen
role of TLR2 and TLR4 in airways inflammation was investigated and it was found that
bacterial products, such as BLP and LPS, could exacerbate eosinophilic inflammation in
■ ■previously sensitised mice. It was also shown that the timing and route of administration of
LPS/BLP could affect the outcome of the subsequent response. The model was also used to 
investigate the mechanism action of potential therapeutics. It was found that TNFa blockade 
caused a reduction in airways inflammation and associated pathology, possibly by blocking 
lymph node hypertrophy, suggesting a novel mode of action for anti-TNFa therapies.
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